

MFT TRUST FORMULARY**Manchester University**
NHS Foundation Trust

	BNF Chapter
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

Version 9.1 (February 2024)

Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

Formulary status definitions

Formulary (OK to be prescribed - but after any 1st or 2nd line options)

1st line formulary (when there are few formulary options, this is the 1st choice)

2nd line formulary (when there are few formulary options, this is the 2nd choice)

Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.

1st line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



PCT Red/Amber/Green classifications



Adult RAG, DNP & Grey list Paediatric RAG, DNP & Grey list

Red

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

Amber

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP). [See here for a list of GMMMG approved SCPs.](#)

Green

Drugs that are suitable for initiation and ongoing prescribing within primary care.

Green

specialist initiation

Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

Green

following specialist recommendation

Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

Do Not Prescribe: DNP

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

Grey: Grey

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

Unlicensed: U

Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be highlighted in the template as follows: drug name^U

MMC Medicines Management Committee decision tables

Summary of Product Characteristics

Blueteq Enabled Forms

British National Formulary (BNF)

Controlled Drug

British National Formulary for Children (BNFC)

High Cost Medicine

NICE guidance

Payment by Results high cost excluded drug

NOT STOCKED Not routinely stocked, can be ordered if existing patient supply is exhausted

PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY



GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (**No password required**)

British National Formulary for Children (**No password required**)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

Section 1: Gastro-Intestinal System

Supported by the
formulary ([click here](#))



1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

1.2 Anti-spasmodics & other drugs altering gut motility

- Antimuscarinics
- Other Antispasmodics
- Motility Stimulants

1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H₂-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

1.4 Acute diarrhoea

- 1.4.2 Antimotility Drugs

1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response
 - Cytokine Modulators

1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

1.10 Miscellaneous preparations

Trust Guidelines









GASTRO / ENDOSCOPY - medicine & prescribing policies / guidelines (MFT Policy Hub)
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)
















NICE Guidance


Biosimilar Medicines (KTT15)
 Faecal Incontinence (CG49)
 Irritable Bowel Syndrome (CG61)
 Diarrhoea and vomiting in children under 5 (CG84)
 Constipation in children and young people (CG99)
 Acute upper GI bleeding (CG141)
 Dyspepsia and gastro-oesophageal reflux disease (CG184)
 Coeliac disease: recognition, assessment and management (NG20)
 Crohn's disease: management (NG129)
 Ulcerative colitis: management (NG130)
 Ulcerative colitis (acute exacerbations) - infliximab (TA163)
 Crohn's disease - infliximab & adalimumab (TA187)
 Constipation (women) - prucalopride (TA211)
 Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)
 Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
 Naloxegol for treating opioid induced constipation (TA345)
 Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
 Obeticholic acid for treating primary biliary cholangitis (TA443)
 Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)
 Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
 Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
 Naldemedine for treating opioid-induced constipation (TA651)
 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
 Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
 Teduglutide for treating short bowel syndrome (TA804)
 Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
 Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
 Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
 Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
 Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

GMMM Formulary















Formulary Homepage
 Chapter 1: Gastro-Intestinal system (Complete)
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMM Paediatric [Red/Amber/Green](#) Drug List
































































1.1 Dyspepsia & gastro-oesophageal reflux disease		GMMMG
1.1.1 Antacids & Simeticone		
Aluminium & Magnesium Containing Antacids		
Co-magaldrox	 	1st line use
195/220 suspension ^{SF}		
Magnesium Trisilicate	 	
suspension		
Simeticone alone (activated dimeticone)		
Simeticone	 	RESTRICTED Paediatric use only
Infacol® 40mg/mL liquid		
1.1.2 Compound Alginates & Proprietary Indigestion Preparations		
Alginate raft-forming oral suspensions^{SF}	 	
suspension		





































































1.2 Anti-spasmodics & other drugs altering gut motility		GMMMG
Antimuscarinics		
Hyoscine Butylbromide		
tablets; injection	 	
MHRA Drug Safety Update (Feb-17): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease		
Glycopyrronium Bromide (Glycopyrrolate)		
	  	
(Robinul®, Sialanar®) tablets; injection; oral solution; cream		
Other Antispasmodics		
Mebeverine Hydrochloride		
135mg tablets	 	1st line use
Peppermint oil		
capsules	 	
Motility Stimulants		
Metoclopramide		
10mg tablets (see also section 4.6)	 	1st line use
MHRA (Aug-13): Metoclopramide: risk of neurological adverse effects		
Domperidone		
	 	Use where 1st line unsuitable
10mg tablets (see also section 4.6)		
MHRA Drug Safety Update (Dec19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents		
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects		
MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects		











































1.3 Antisecretory drugs & mucosal protectants		GMMMG
1.3.1 H₂-receptor antagonists		
Famotidine Green		
20mg; 40mg tablets	MMC BNF emc	
Ranitidine		
150mg; 300mg tablets	BNF emc	
1.3.3 Chelates & Complexes		
Sucralfate Green		
1g tablets; oral suspension	MMC BNF emc	
Bismuth Subsalicylate (Pepto-Bismol®)		RESTRICTED Adults, H. Pylori eradication regime
262.5mg chewable tablets	MMC BNF emc	
1.3.5 Proton Pump Inhibitors		
Omeprazole		
10mg; 20mg; 40mg capsules; 40mg infusion	NICE BNF emc	
Lansoprazole		RESTRICTED tablets - enteral feeding tubes / dysphagia
15mg & 30mg capsules; 15mg & 30mg orodispersible tablets	NICE MMC BNF emc	
Esomeprazole		RESTRICTED PPI indicated / enteral route not available/appropriate
40mg infusion	MMC BNF emc	
MHRA (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice		
MHRA Drug Safety Update (Sep-15): Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus		

Other PPIs are not available at this Trust

1.4 Acute diarrhoea		
1.4.2 Antimotility Drugs		
Loperamide hydrochloride 2mg capsules; 1mg/5mL syrup ^{SF}	  	1st line use
Codeine Phosphate 15mg; 30mg & 60mg tablets	 	RESTRICTED Adults - high output stomas
Teduglutide   Revestive® injection	     	RESTRICTED Gastro. Consultants only in line with NICE TA804

1.5 Chronic bowel disorders		GMMMG
1.5.1 Aminosalicylates		
Mesalazine  tablets; M/R tablets; M/R granules; enema; foam enema; suppositories	 	PRESCRIBE BY BRAND NAME
Balsalazide Sodium 750mg capsules	  	
1.5.2 Corticosteroids & Enemas		
Prednisolone 5mg tablets	 	1st line use
Budesonide (Budenofalk®) 3mg capsules; rectal foam	  	
Budesonide (Jorveza®)  1mg orodispersible tablets	   	RESTRICTED Adults - eosinophilic esophagitis
Budesonide  3mg CR capsules	  	RESTRICTED Adults - Gastro. Consultants only
Hydrocortisone foam enema	 	
Short chain fatty acid enema  Nutricol® enema	  	RESTRICTED Adults - Gastro. Consultants only
1.5.3 Drugs Affecting the Immune Response		
Azathioprine  tablets; oral solution (see also sections 8.2.1; 10.1.3 & 13.5.3)	 	1st line use
Ciclosporin (oral and I.V. preparations)  capsules; infusion; oral solution (see also section 8.2.2)	  	
Mercaptopurine  tablets; oral suspension (see also section 8.1.3)	 	
Methotrexate (s/c and oral preparations)  tablets; injection; oral solution (see also section 10.1.3)	  	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing		
Mirikizumab   Omvoh® injection; infusion	    	RESTRICTED Gastro. Consultants in line with NICE TA925
Ozanimod   Zeposia® capsules	     	RESTRICTED Gastro. Consultants in line with NICE TA828
Vedolizumab   infusion	     	RESTRICTED Gastro. Consultants in line with NICE TA342 & TA352

Cytokine Modulators		
Adalimumab  	     	RESTRICTED Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE
injection (see also sections 10.1.3, 11.4.2 & 13.5.3) MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
Infliximab  	     	RESTRICTED Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE
infusion (see also sections 10.1.3 & 13.5.3) MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
Filgotinib  	     	RESTRICTED Gastro. Consultants for Ulcerative colitis as per NICE
100mg; 200mg tablets (see also section 10.1.3) MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
Golimumab  	     	RESTRICTED Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE
injection (see also section 10.1.3) MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
Risankizumab  	     	RESTRICTED Specialist use only in line with NICE TA888
75mg; 150mg injection MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of VTE and of serious and fatal infections MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing		
Tofacitinib  	     	RESTRICTED Consultants only in line with NICE
tablets (see also section 10.1.3)		
Upadacitinib  	     	RESTRICTED Consultants only in line with NICE TA856 / TA905
MR tablet (see also section 10.1.3) MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
Ustekinumab  	     	RESTRICTED Gastro. Consultants as per NICE
injection (see also sections 10.1.3)		
ICAM-1 Inhibitor		
Alicaforsen 	  	RESTRICTED Gastro. Consultants only - pouchitis
enema		

1.6 Laxatives		GMMMG
1.6.1 Bulk-forming Laxatives		
Ispaghula husk		1st line use
3.5g sachets	 	
1.6.2 Stimulant Laxatives		
Docusate Sodium		1st line use
capsules; oral solution	 	
Senna		1st line use
tablets; oral solution	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
Bisacodyl		
tablets; suppositories	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
Glycerol		
suppositories	 	
Sodium Picosulfate		
oral solution	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
Co-Danthramer		RESTRICTED Adults, Palliative Care only
oral suspension	 	
Co-Danthrusate		RESTRICTED Adults, Palliative Care only
oral suspension	 	
1.6.3 Faecal Softeners		
Arachis oil		
enema	 	
1.6.4 Osmotic Laxatives		
Lactulose		1st line use
oral solution	 	
Macrogols (Polyethylene glycols)		2nd / 3rd line use Rehab patients / paediatrics
sachets	  	
Phosphates (Rectal)		
128mL enema	 	
Sodium Citrate (Rectal)		
450mg micro-enema	 	
1.6.5 Bowel Cleansing Preparations		
NPSA RRR (Feb-09): Reducing risk of harm from oral bowel cleansing solutions		
Sodium Picosulfate with Magnesium Citrate		1st line use
Picolax® oral powder	 	
Macrogols (Klean-Prep® & Moviprep®) oral powder		
oral powder	 	
1.6.6 Peripheral opioid-receptor antagonists		
Methylnaltrexone Bromide		RESTRICTED Adults, Palliative Care only
injection	 	
Naldemedine		RESTRICTED Adults only in line with TA651
 200 microgram tablets	   	
Naloxegol		RESTRICTED Adults only in line with TA345
 12.5mg; 25mg tablets	   	

1.6.7 Other drugs used in constipation**Prucalopride**

Green

1mg; 2mg tablets

NICE MMC BNF emc














**RESTRICTED - Adult women, Gastro.
Consultants only****Linaclootide**






















Green

290 micrograms capsules

MMC BNF emc

**RESTRICTED - 3rd line use Adults
Gastro. Consultants only**

1.7 Local preparations for anal & rectal disorders		GMMMG
1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids		
Anusol®		
ointment	 	
Proctosedyl®		
ointment	 	
Scheriproct®		
ointment; suppositories	 	
1.7.4 Management of anal fissures		
Glyceryl Trinitrate		1st line for anal fissure
<i>Rectogesic</i> ® 0.4% ointment	  	
Diltiazem Hydrochloride		
 		
2% cream; ointment	 	

1.9 Drugs affecting intestinal secretions		GMMMG
1.9.1 Drugs affecting biliary composition & flow		
Ursodeoxycholic acid 150mg tablets 	  	1st line use
Obeticholic acid  Ocaliva® 5mg; 10mg tablets	     	RESTRICTED Hepatology Consultants only 2 nd line per TA443
1.9.2 Bile acid sequestrants		
Colestyramine 	 	1st line use
Colesevelam Hydrochloride  625mg tablets (see also section 2.12)	  	RESTRICTED adults. Gastro & Lipid Clinic Consultants only
1.9.4 Pancreatin		
Pancreatin 	 	NOT STOCKED

1.10 Miscellaneous preparations



Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 8.4, 10.4 & 13.14)



RESTRICTED
2nd line rescue therapy



Section 2: Cardiovascular System

Supported by the
formulary ([click here](#))



2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

2.3 Anti-arrhythmic drugs

- 2.3.2 Drugs for Arrhythmias

2.4 Beta-adrenoceptor blocking drugs

2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
 - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
 - 2.5.5.2 Angiotensin-II Receptor Antagonists
 - 2.5.5.3 Renin Inhibitors
 - 2.5.5.4 Heart Failure

2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

2.9 Antiplatelet drugs

2.10 Stable angina, acute coronary syndromes & fibrinolysis

- 2.10.2 Fibrinolytic Drugs

2.11 Antifibrinolytic drugs & haemostatics

2.12 Lipid-regulating drugs

2.13 Local sclerosants

2.14 Miscellaneous preparations

Trust Guidelines















CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)
 CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)


























NICE Guidance































Prophylaxis against infective endocarditis (CG64)
 Familial hypercholesterolaemia (CG71)
 Chest pain of recent onset (CG95)
 Stable angina (CG126)
 Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)
 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)
 Chronic heart failure in adults: diagnosis and management (NG106)
 Hypertension in pregnancy: diagnosis and management (NG133)
 Hypertension in adults: diagnosis and management (NG136)
 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
 Acute coronary syndromes (NG185)
 Atrial fibrillation: diagnosis and management (NG196)
 Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)
 Myocardial infarction - thrombolysis (TA52)
 Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)
 Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated by TA95 & TA126)
 Hypercholesterolaemia - Ezetimibe (TA132)
 Coronary artery disease - drug eluting stents (TA152)
 Venous thromboembolism - dabigatran (TA157)
 Rivaroxaban for the prevention of VTE (TA170)
 Atrial Fibrillation - dronedarone (TA197)
 Vascular disease - clopidogrel and dipyridamole (TA210)
 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)
 Acute coronary syndromes - ticagrelor (TA236)
 Venous thromboembolism - apixaban (hip and knee surgery) (TA245)
 Atrial fibrillation - dabigatran etexilate (TA249)
 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)
 Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)
 Stroke (acute, ischaemic) - alteplase (TA264)
 Chronic heart failure - ivabradine (TA267)
 Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)
 Prasugrel with PCI for treating ACS (review of TA182) (TA317)
 Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)
 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)
 Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)
 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
 Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)
 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)
 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
 Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)
 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)
 Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
 Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)
 Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)
 Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)
























GMMMG Formulary
































































Formulary Homepage
 Chapter 2: Cardiovascular system (Complete)
 GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List
 GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List




















2.1 Positive inotropic drugs		GMMMG
2.1.1 Cardiac Glycosides		
Digoxin tablets; elixir; injection  	1st line use	
Digoxin-specific antibody   infusion  		
2.1.2 Phosphodiesterase Inhibitors		
Enoximone <i>Perfan</i> ® 5mg/1mL injection  		
Milrinone <i>Primacor</i> ® 10mg/10mL injection   	1st line use Paediatrics	
Levosimendan <i>Simdax</i> ® 12.5mg/5mL Injection   	RESTRICTED adults. Cardiology ITU Consultant only	


































2.2 Diuretics		GMMMG
2.2.1 Thiazides & Related Diuretics		
Bendroflumethiazide		1st line use
tablets	 	
Chlortalidone		
tablets	 	
Metolazone		2nd line use with loop diuretic
 tablets	MMC  	
MHRA Drug Safety Update (Jan-23): Xaqu (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations		
2.2.2 Loop Diuretics		
Furosemide		1st line use
tablets; liquid; injection	 	
Bumetanide		2nd line use
tablets; oral solution	 	
2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists		
Amiloride hydrochloride		1st line use
tablets; oral solution	 	
Spirolactone		1st line use
tablets	 	
MHRA Drug Safety Update (Feb-16): Spirolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
Eplerenone		RESTRICTED adults. Cardiology Consultant only
 tablets	MMC  	
Finerenone		RESTRICTED adults. Diabetes / Renal Consultant only
 <i>Kerendia</i> ® tablets	NICE MMC  	
2.2.4 Potassium-sparing Diuretics with other Diuretics		
Co-amilofruse		1st line use
tablets	 	
2.2.5 Osmotic Diuretics		
Mannitol		
infusion	 	
























2.3 Anti-arrhythmic drugs		GMMMG
2.3.2 Drugs for Arrhythmias		
Adenosine		
injection	 	
Amiodarone Hydrochloride		
 	tablets; injection	 
MHRA Drug Safety Update (Mar-22): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision		
Disopyramide		
capsules; tablets	 	
Flecainide Acetate		
 Paeds - until stabilised then 	tablets; injection	 
Lidocaine (Lignocaine) Hydrochloride		
injection	 	
Mexiletine		
	<i>NaMuscla</i> ® 167mg capsules	   
Mexiletine Hydrochloride		
	<i>Mexitil</i> ® 50mg; 100mg; 200mg capsules	  
Propafenone Hydrochloride		
tablets	 	
Dronedaron		
	tablets	   
MHRA Drug Safety Update (Oct-11): Dronedaron (Multaq ▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements		
		RESTRICTED Neurology only
		RESTRICTED Cardiology / Neurology only
		RESTRICTED adults. Cardiology Consultant only, in line with TA197

2.4 Beta-adrenoceptor blocking drugs		GMMMG
		NICE NG106
		NICE NG136
		NICE NG196
2.4 Beta-Adrenoceptor Blocking Drugs		
Atenolol tablets; liquid; injection	 	
Bisoprolol Fumarate tablets	MMC  	RESTRICTED adults. Cardiology Consultant only
Carvedilol tablets	MMC  	RESTRICTED adults. Cardiology Consultant only ALSO 2ND LINE FOR VARICEAL BLEED
Esmolol Hydrochloride injection	 	RESTRICTED I.V. only
Etilefrine Hydrochloride  tablets	MMC  	RESTRICTED Haematology Consultants - SCD
Labetalol Hydrochloride tablets; injection	 	RESTRICTED oral preps in pregnancy
Metoprolol Tartrate tablets; injection	 	
Nadolol tablets	MMC  	RESTRICTED paed. ventricular arrhythmias in long QT syndrome
Nebivolol tablets	 	
Propranolol Hydrochloride tablets; capsules; oral solution; injection	 	RESTRICTED not in Cardiology
Sotalol Hydrochloride tablets	 	


2.5 Hypertension & heart failure		GMMMG
		NICE NG106
		NICE NG136
		NICE NG196
2.5.1 Vasodilator Antihypertensive Drugs		NHSE PAH
Hydralazine Hydrochloride		1st line use
tablets; injection	 	
Minoxidil		
tablets	 	
Ambrisentan		RESTRICTED PAH in line with NHSE
 	   	
tablets		
Bosentan		RESTRICTED PAH in line with NHSE
 	   	
tablets		
Sildenafil		RESTRICTED PAH in line with NHSE
 	  	
Revatio® tablets; injection (see also section 7.4.5)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio and Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
Macitentan		RESTRICTED PAH in line with NHSE
 	   	
Opsumit® tablets		
Tadalafil		RESTRICTED PAH in line with NHSE
 	   	
Adcirca® tablets (see also section 7.4.5)		
2.5.2 Centrally Acting Antihypertensive Drugs		
Clonidine Hydrochloride		
tablets; oral solution; injection; patches	 	
Methyldopa		
tablets	 	
Moxonidine		RESTRICTED 3rd line use after other treatments fail
	  	
tablets		
2.5.4 Alpha-Adrenoceptor Blocking Drugs		
Doxazosin		1st line use
	 	
1mg; 2mg & 4mg tablets		
Phenoxybenzamine Hydrochloride		RESTRICTED adults. Specialist initiation only
10mg capsules	 	
Phentolamine Mesilate		RESTRICTED adults. Specialist use, theatres only
injection	 	
2.5.5 Drugs Affecting the Renin-Angiotensin System		
2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
Ramipril		
1.25mg; 2.5mg; 5mg & 10mg capsules	 	
Captopril		RESTRICTED Paediatrics only
12.5mg; 25mg & 50mg tablets	 	
Lisinopril		1st line use
2.5mg; 5mg; 10mg & 20mg tablets	  	GMMMG
Perindopril		
	 	
2mg; 4mg & 8mg tablets		

2.5.5.2 Angiotensin-II Receptor Antagonists		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
Candesartan Cilexetil Green 2mg; 4mg; 8mg; 16mg & 32mg tablets MMC BNF emc	 	1st line use hypertension GMMMG
Losartan Potassium 12.5mg; 25mg; 50mg & 100mg tablets BNF emc	 	2nd line use hypertension
Irbesartan 75mg; 150mg & 300mg tablets MMC BNF emc	 	2nd line use hypertension
Valsartan 40mg; 80mg & 160mg capsules MMC BNF emc	 	2nd line use hypertension
Sacubitril / Valsartan Green 24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets NICE MMC BNF emc	  	RESTRICTED use in line with NICE TA388
2.5.5.3 Renin inhibitors		
Aliskiren DNP 150mg; 300mg tablets MMC BNF emc	 	RESTRICTED adults. Specialist initiation only
MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascular and renal adverse reactions		
2.5.5.4 Heart Failure		
Dapagliflozin Green Forxiga ® tablets NICE MMC BNF emc	  	RESTRICTED adults. Specialist initiation in line with TA679
Empagliflozin Green Jardiance ® tablets NICE MMC BNF emc	  	RESTRICTED adults. Specialist initiation in line with TA773

2.6 Nitrates, calcium-channel blockers & other antianginals		GMMMG
2.6.1 Nitrates		
Glyceryl Trinitrate		
S/L tablets; S/L spray; patches; Injection; ointment	 	
Isosorbide Mononitrate		
tablets; capsules	 	
2.6.2 Calcium-channel Blockers		
Amlodipine		1st choice dihydropyridine
tablets; oral solution	 	GMMMG
Diltiazem		1st choice non-dihydropyridine
tablets; capsules; ointment	 	PRESCRIBE BY BRAND NAME
Nifedipine		2nd choice dihydropyridine
tablets; capsules; oral drops	 	PRESCRIBE BY BRAND NAME
Verapamil Hydrochloride		2nd choice non-dihydropyridine
tablets; injection; oral solution	 	
Nimodipine		RESTRICTED subarachnoid haemorrhage / I.V. then oral
tablets; infusion	 	
2.6.3 Other Antianginal Drugs		
Nicorandil		1st line use
tablets	 	
MHRA Drug Safety Update (Jan-16): Nicorandil (Ikorel): now 2nd-line treatment for angina - risk of ulcer complications		
Ivabradine		RESTRICTED adults 2nd line. Cardiology Consultant only
Green tablets	   	
MHRA Drug Safety Update (Dec-14): Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects		
Ranolazine		RESTRICTED adults 3rd line angina patients not suitable for surgery
Green M/R tablets	  	
2.6.4 Peripheral Vasodilators & Related Drugs		
Naftidrofuryl Oxalate		
capsules	  	
Defibrotide		RESTRICTED Specialist use only in line with NHSE
Red  infusion	    	





























2.7 Sympathomimetics		GMMMG
2.7.1 Inotropic Sympathomimetics		
Dobutamine		RESTRICTED / V. Specialist use only
infusion	 	
Dopamine Hydrochloride		RESTRICTED / V. Specialist use only
infusion	 	
Dopexamine		RESTRICTED / V. Specialist use only
infusion	 	
Isoprenaline		RESTRICTED / V. Specialist use only
injection	 	
2.7.2 Vasoconstrictor Sympathomimetics		
Ephedrine Hydrochloride		RESTRICTED / V. Specialist use only
injection	 	
Metaraminol		
 injection	 	
Midodrine		Specialist use Cardiology / Healthcare of the elderly
 tablets	  	
Noradrenaline acid tartrate		RESTRICTED / V. Specialist use only
infusion	 	
Phenylephrine Hydrochloride		RESTRICTED / V. Specialist use only
injection	 	
2.7.3 Cardiopulmonary Resuscitation		
Adrenaline / Epinephrine		
injection	 	



















2.8 Anticoagulants & protamine		GMMMG
2.8.1 Parenteral Anticoagulants		NICE NG89
ACD-A Anticoagulant Citrate Dextrose		RESTRICTED Specialist use only CRRT
solution	MMC BNF emc	
Dalteparin Sodium		1st line LMWH
injection	MMC BNF emc	
Epoprostenol		RESTRICTED / V. Specialist use only
infusion	PbR X BNF emc	
MHRA Drug Safety Update (Dec-14): Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices		
Heparin		
injection; infusion	BNF emc	
Bivalirudin		RESTRICTED adults. Cardiac Catheter Lab only.
infusion	NICE MMC BNF emc	
Fondaparinux Sodium		RESTRICTED adults. Haematology Consultants only.
injection	MMC BNF emc	
Tinzaparin Sodium		RESTRICTED Obs & Gynae; ACS & VTE in Renal impairment only. Paeds: haemodialysis
injection	MMC BNF emc	
Enoxaparin Sodium		RESTRICTED ACS & VTE in Renal impairment only.
injection	MMC BNF emc	
Argatroban monohydrate		RESTRICTED adults. Treatment of HIT
infusion	MMC BNF emc	
2.8.2 Oral Anticoagulants		
Acenocoumarol		RESTRICTED warfarin intolerant patients only.
tablets	BNF emc	
Phenindione		
tablets	BNF emc	
Warfarin Sodium		
tablets	BNF emc	
MHRA Drug Safety Update (Oct-20): Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic		
MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
MHRA Drug Safety Update (Jul-16): Warfarin: reports of calciphylaxis		
Apixaban		RESTRICTED in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
Dabigatran Etexilate		RESTRICTED in line with NICE
capsules	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
MHRA Drug Safety Update (Jul-12): Dabigatran (Pradaxa ▼): risk of serious haemorrhage		
Edoxaban		RESTRICTED in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
Rivaroxaban		RESTRICTED in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
MHRA Drug Safety Update (Jul-19): Rivaroxaban (Xarelto ▼): reminder that 15 mg and 20 mg tablets should be taken with food		
MHRA Drug Safety Update (Oct-18): Rivaroxaban (Xarelto ▼) after TAVR: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial		
Antidotes		
Andexanet Alfa		RESTRICTED in line with NICE
infusion	NICE MMC BNF emc	





















<p>Idarucizumab Red </p> <p>Praxbind® infusion</p>	<p>RESTRICTED reversal of dabigatran in emergency surgery</p>
<p>2.8.3 Protamine Sulfate</p>	
<p>Protamine Sulfate</p> <p>injection</p>	

MMC BNF emc


BNF emc

2.9 Antiplatelet drugs		GMMMG
		NICE NG185
<p>Aspirin</p> <p>tablets (dispersible & E/C); suppositories</p>	 	
<p>Clopidogrel</p> <p>tablets</p> <p>MHRA Drug Safety Update (Dec-13): Clopidogrel: risk of acquired haemophilia MHRA Drug Safety Update (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice</p>	    	<p>For ACS patients; stroke patients intolerant of aspirin; high-risk patients who've stroked on aspirin</p>
<p>Ticagrelor</p> <p>Green</p> <p>tablets; orodispersible tablets</p>	   	<p>In combination with aspirin for primary PCI in ACS patients & in line with NICE TA420</p>
<p>Prasugrel</p> <p>Green</p> <p>tablets</p> <p>MHRA Drug Safety Update (Jan-14): Prasugrel (Efient): increased risk of bleeding MHRA Drug Safety Update (May-11): Prasugrel (Efient ▼): rare but serious hypersensitivity reactions</p>	    	<p>RESTRICTED adults. Cardiac Catheter Lab as per NICE</p>
<p>Dipyridamole</p> <p>M/R capsules; oral suspension; tablets; injection</p>	   	<p>2^{RY} prevention of stroke in patients already on aspirin</p>
<p>Tirofiban</p> <p>infusion</p>	   	<p>RESTRICTED adults. Cardiac Catheter Lab only (1st line)</p>
<p>Eptifibatide</p> <p>injection; infusion</p>	   	<p>RESTRICTED adult patients admitted on this or tirofiban</p>

2.10 Stable angina, ACS & fibrinolysis		
<ul style="list-style-type: none"> Stable angina (BNF treatment summary) Acute coronary syndromes (BNF treatment summary) Fibrinolytic Drugs (BNF treatment summary) 		
2.10.2 Fibrinolytic Drugs		NICE CG126 NICE NG128
Tenecteplase  injection	   	
Streptokinase  infusion	  	
Urokinase  injection	 	
Alteplase  injection; infusion	   	RESTRICTED

2.11 Antifibrinolytic drugs & haemostatics		GMMMG
2.11 Antifibrinolytic Drugs & Haemostatics		
Etamsylate		
tablets	 	
Tranexamic acid		
injection; tablets	 	
Aprotinin		RESTRICTED
infusion	 	
Aminocaproic acid		RESTRICTED
sachets	  	
Emicizumab		RESTRICTED Haematology as per NHSE
 Hemlibra ® injection	   	 
Vonicog alfa		RESTRICTED Haematology as per NHSE
Veyvondi® injection	  	

2.12 Lipid-regulating drugs		GMMMG
Statins		
Simvastatin		
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Atorvastatin		1 st line use
DNP		
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Rosuvastatin		RESTRICTED Not stocked
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Pravastatin Sodium		RESTRICTED MSH for cases with potential drug interactions
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Bile Acid Sequestrants		
Colestyramine		
Green		
sachets (see also section 1.9.2)	BNF emc	
Colesevelam Hydrochloride		RESTRICTED adults. Gastro & Lipid Clinic Consultants only
DNP		
tablets (see also section 1.9.2)	MMC BNF emc	
Fibrates		
Bezafibrate		
M/R tablets; tablets	BNF emc	1 st line use
Fenofibrate		
67mg / 200mg / 267mg capsules; 160mg tablets	MMC BNF emc	2 nd line use
Omega-3 fatty acid compounds		
Omega-3-acid ethyl esters		
Green		2 ^{RY} prevention post MI / Prevention of preterm birth
capsules	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (Jan-24): Omega-3-acid ethyl ester (1000mg caps): dose-dependent increased risk of AF in patients with established CV diseases or CV risk factors		
Ezetimibe		
Ezetimibe		
10mg tablets	NICE MMC BNF emc	RESTRICTED adults. Lipid Clinic Consultants only
Lipid-regulating drugs		
Alirocumab		
Red		RESTRICTED adults. Lipid Clinic Consultants in line with TA393
Praluent® injection	PbR X NICE MMC BNF emc	
Bempedoic acid (see also Nustendi®)		
Green		RESTRICTED adults. Consultants in line with TA694
Nilemdo® tablets	PbR X NICE MMC BNF emc	
Bempedoic acid (see also Nilemdo®)		
Green		RESTRICTED adults. Consultants in line with TA694
Nustendi® tablets	PbR X NICE MMC BNF emc	
Evolocumab		
Red		RESTRICTED. Lipid Clinic Consultants for HoFH / & NICE TA394
Repatha® injection	PbR X NICE MMC BNF emc blueaq	
Icosapent Ethyl		
Green		RESTRICTED adults in line with NICE TA805
Vazkepa® capsules	PbR X NICE MMC BNF emc	
Inclisiran		
Green		RESTRICTED adults. Lipid Clinic Consultants in line with TA733 for Primary Care Referral
Leqvio® injection	PbR X MMC BNF emc	
Lomitapide		
Red ££		RESTRICTED adults. Lipid Clinic Consultants in line with NHSE 170059P
Lojuxta® capsules	PbR X MMC BNF emc blueaq	
Volanesorsen		
Red ££		RESTRICTED adults. Lipid Clinic Consultants in line with HST13
Waylivra® injection	PbR X NICE MMC BNF emc blueaq	

2.13 Local sclerosants



Local Sclerosants

Ethanolamine Oleate

injection



Sodium Tetradecyl Sulfate

injection



2.14 Miscellaneous preparations



Ajmaline



Gilurytmal® 50mg/10mL injection



RESTRICTED adults.
Cardiology Consultant only

Dapagliflozin

Green

tablets



RESTRICTED
in line with NICE TA679 / TA902

MHRA Drug Safety Update (Dec-21): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus

Empagliflozin

Green

tablets



RESTRICTED
in line with NICE TA929

Regadenoson



Rapiscan® 400micrograms/5mL injection



RESTRICTED adults.
Myocardial perfusion scans

Section 3: Respiratory System

Supported by the
formulary (click here)



3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers
 - Inhaler Devices
 - Nebuliser Diluent

3.2 Corticosteroids

- Compound preparations

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants

3.6 Oxygen (refer to oxygen guidelines)

3.7 Mucolytics

3.8 Aromatic inhalations

3.9 Cough preparations

- 3.9.1 Cough Suppressants
 - Cough Suppressants (Palliative Care ONLY)
- 3.9.2 Demulcent & expectorant cough preparations

3.10 Systemic Nasal Decongestants

3.11 Antifibrotics

Trust Guidelines


















ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)
























NICE Guidance

Idiopathic pulmonary fibrosis (CG163)
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
Inhaler devices for children under 5 (TA10)
Asthma (older children) - inhaler devices (TA38)
Asthma (in children) - corticosteroids (TA131)
Asthma (in adults) - corticosteroids (TA138)
Venom anaphylaxis - immunotherapy pharmlagen (TA246)
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)
Reslizumab for treating severe eosinophilic asthma (TA479)
Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)
Benralizumab for treating severe eosinophilic asthma (TA565)
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Palforzia for treating peanut allergy in children and young people (TA769)
Tezepelumab for treating severe asthma (TA880)












GMMMG Formulary





























































Formulary Homepage
Chapter 3: Respiratory system (Complete)
GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List























































































3.1 Bronchodilators		GMMMG
Asthma		
Methacholine Chloride  Provocholine® nebuliser solution	MMC emc	RESTRICTED detection test for bronchial airway hyperreactivity
3.1.1 Adrenoceptor agonists		GMMMG GMMMG GMMMG
3.1.1.1 Selective beta₂ agonists		
Salbutamol  injection	MMC  emc	
Terbutaline Sulfate  injection	 emc	
Salmeterol	 emc	
Formoterol Fumarate	MMC  emc	Asthma BTS step 3 add-on therapy
3.1.1.2 Other Adrenoceptor Agonists		
Ephedrine Hydrochloride	 emc	
3.1.2 Antimuscarinic Bronchodilators		GMMMG GMMMG GMMMG
Ipratropium Bromide	 emc	1st line use
Tiotropium	MMC  emc	2nd line use COPD maintenance
MHRA Drug Safety Update (Feb-15): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial		
Aclidinium Bromide Eklira Genuair®	MMC  emc	2nd line use COPD maintenance
Glycopyrronium Bromide Seebri Breezhaler®	MMC  emc	2nd line use COPD maintenance
Umeclidinium Bromide Incruse Ellipta®	MMC  emc	2nd line use COPD maintenance
Compound Preparations		
Aclidinium Bromide / Formoterol Fumarate Dihydrate Duaklir Genuair®	MMC  emc	3rd line use COPD maintenance
3.1.3 Theophylline		
Theophylline M/R tablets; M/R capsules	 emc	1st line use PRESCRIBE BY BRAND NAME
Aminophylline  injection M/R tablets; injection	 emc	PRESCRIBE BY BRAND NAME










3.1.4 Compound Bronchodilator Preparations		GMMMG		
Ipratropium Bromide / Salbutamol				
<i>Combivent®</i>	 			
Glycopyrronium Bromide / Formoterol Fumarate		3rd line use COPD maintenance		
<i>Bevespi Aerosphere®</i>	  			
Glycopyrronium Bromide / Indacaterol Maleate		3rd line use COPD maintenance		
<i>Ultibro®</i>	  			
Tiotropium Bromide Monohydrate / Olodaterol Hydrochloride		3rd line use COPD maintenance		
<i>Spolto Respimat®</i>	  			
Umeclidinium Bromide / Vilanterol Trifenatate		3rd line use COPD maintenance		
<i>Anoro Ellipta®</i>	  			
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GMMMG GMMMG GMMMG		
Inhaler Devices				
Volumatic® (spacer inhaler)				
	 			
Aerochamber® Plus (spacer device)				
	 			
Able Spacer® (spacer device)				
	  			
Nebuliser Diluent				
Sodium Chloride				
0.9% nebuliser diluent	 			

3.2 Corticosteroids		GMMMG
Corticosteroids		GMMMG GMMMG GMMMG
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
Beclometasone Dipropionate		
MDI (Clenil Modulite® 50, 100, 200, 250)	NICE MMC BNF emc	
Beclometasone Dipropionate CFC-free		PRESCRIBE BY BRAND NAME
MDI (Qvar Easi-Breathe® or Qvar Autohaler® 50, 100)	NICE MMC BNF emc	
Budesonide		
DPI (Easyhaler®; Pulmicort® Turbohaler® 100, 200, 400) 500micrograms/2mL & 1mg/2mL nebuliser liquid	NICE MMC BNF emc	
Fluticasone Propionate		
MDI (FlixotideEvohaler®) 50, 125, 250; DPI (FlixotideAccuhaler® 50,100, 250, 500)	BNF emc	
Compound preparations		
Budesonide / Formoterol fumarate		Asthma BTS step 3 management
DPI (Fobumix Easyhaler® 80/4.5, 160/4.5, 320/9); DPI (Symbicort Turbohaler® 100/6, 200/6, 400/12); DPI (Duoresp Spiromax® 160/4.5, 320/9)	NICE MMC BNF emc	GMMMG GMMMG
Beclometasone Dipropionate / Formoterol fumarate		Asthma BTS step 3 management
MDI (Fostair®100/6, 200/6); DPI (Fostair NEXThaler® 100/6, 200/6)	MMC BNF emc	
Fluticasone Furoate / Vilanterol Trifenatate		Asthma BTS step 3 management
DPI (Relvar Ellipta® 92/22 asthma or COPD; 184/22 asthma)	MMC BNF emc	
Fluticasone Propionate / Salmeterol		Asthma BTS step 3 management
MDI (Sirdupla® 125, 250)	MMC BNF emc	
Fluticasone Propionate / Salmeterol		Asthma BTS step 3 management
MDI (SeretideEvohaler® 50, 125, 250)	NICE MMC BNF emc	
Fluticasone Propionate / Formoterol Fumarate		Asthma BTS step 3 management
MDI (Flutiform® 50/5, 125/5, 250/10)	MMC BNF emc	
Beclometasone dipropionate / Formoterol fumarate / Glycopyrronium bromide		RESTRICTED - COPD patients who require triple therapy
MDI (Trimbow 87/5/9® & 172/5/9®) DPI (Trimbow NEXThaler 88/5/9®)	MMC BNF emc	GMMMG COPD GMMMG Asthma
Fluticasone Furoate / Vilanterol Trifenatate / Umeclidinium Bromide		RESTRICTED - COPD patients who require triple therapy
DPI (Trelegy Ellipta® 92/55/22 micrograms)	MMC BNF emc	
Formoterol fumarate / Glycopyrronium Bromide / Budesonide		RESTRICTED - COPD patients who require triple therapy
DPI (Trixeo Aerosphere® 5/7.2/160 micrograms)	MMC BNF emc	
Indacaterol / Mometasone Furoate		GMMMG Asthma Guideline 2022
DPI (Ateectura® Breezhaler®)	MMC BNF emc	
Mometasone Furoate / Glycopyrronium Bromide / Indacaterol		GMMMG Asthma Guideline 2022
DPI (Enerzair® Breezhaler®)	MMC BNF emc	
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists		
3.3.1 Cromoglicate & Related Therapy		
Sodium Cromoglicate		
	 	
3.3.2 Leukotriene Receptor Antagonists		
Montelukast		BTS step 2 or 3 in paediatrics
tablets; chewable tablets; sachets	  	
MHRA Drug Safety Update (Sep-19): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions		
3.3.3 Phosphodiesterase type-4 inhibitors		
Roflumilast		RESTRICTED as per NICE TA461
	   	
tablets		



















































3.4 Antihistamines, hyposensitisation & allergic emergencies		GMMMG
3.4.1 Antihistamines		
Non-sedating antihistamines		
Cetirizine Hydrochloride		
tablets; oral solution	 	
Loratadine		
tablets; oral solution	 	
Desloratadine		RESTRICTED children 1-2 years old
tablets; oral solution	  	
Fexofenadine Hydrochloride		
tablets	  	
Sedating antihistamines		
Chlorphenamine Maleate		
tablets; oral solution; injection	  	
Hydroxyzine Hydrochloride		
tablets; oral solution	 	
MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes		
Promethazine Hydrochloride		
tablets; oral solution	  	
Alimemazine Tartrate		
DNP tablets; oral solution	 	
3.4.2 Allergen Immunotherapy		
Allergoid immunotherapy tablets		RESTRICTED Immunology Consultants only
 Lofarma Lais®	  	
Bee venom extract		RESTRICTED Immunology Consultants only
Red injection	  	
Wasp venom extract		RESTRICTED Immunology Consultants only
Red injection	   	
Grass & Rye or tree pollen extract		RESTRICTED Immunology Consultants only
Red Pollinex®	  	
Grass Pollen extract		RESTRICTED Immunology Consultants only
DNP Grazax® oral lyophilisates	   	
House Dust Mite extract		RESTRICTED Immunology Consultants only
Red Acarizax 12-SQ HDM oral lyophilisates®	   	
Peanut Protein powder		RESTRICTED Immunology Consultants only
Red  Palforzia® oral powder in capsules; sachet	   	
Wasp venom extract		RESTRICTED Immunology Consultants only
Red injection	   	
White birch (<i>Betula verrucosa</i>) Pollen extract		RESTRICTED Immunology Consultants only
Red Itulazax 12-SQ Bet oral lyophilisates®	 	
Omalizumab		
Omalizumab		RESTRICTED as per NICE
Red DNP  injection	     	

Anti-interleukin-5 (IL-5) antibody		
Benralizumab   <i>Fasenra</i> ® injection      		RESTRICTED as per NICE TA565
Dupilumab    <i>Dupilumab</i> ® injection (see also section 13.5.3)      		RESTRICTED as per NICE TA751
MHRA Drug Safety Update (Nov-22): Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management		
Mepolizumab   <i>Nucala</i> ® injection      		RESTRICTED as per NICE
Reslizumab   <i>Cinqaero</i> ® infusion      		RESTRICTED as per NICE TA479 NOT STOCKED
Tezepelumab   <i>Tezspire</i> ® injection      		RESTRICTED as per NICE TA880
3.4.3 Allergic Emergencies		
Adrenaline / Epinephrine injection  		PRESCRIBE BY BRAND NAME
MHRA Drug Safety Update (Jun-23): Adrenaline auto-injectors (AAIs): new guidance and resources for safe use		
MHRA Drug Safety Update (Nov-21): Adrenaline auto-injectors: reminder for prescribers to support safe and effective use		
MHRA Drug Safety Update (Aug-17): Adrenaline auto-injectors: updated advice after European review		
Berotrastat   <i>Orladeyo</i> ® capsules     		RESTRICTED specialist use only as per NICE TA738
C1 esterase inhibitor   <i>Beriner</i> ®; <i>Cinryze</i> ® injection      		RESTRICTED acute attacks of HAE 
Conestat Alfa   <i>Ruconest</i> ® injection     		RESTRICTED adults acute attacks of HAE
Icatibant   <i>Firazyr</i> ® injection      		RESTRICTED adults acute attacks of HAE
Lanadelumab   <i>Takhzyro</i> ® injection      		RESTRICTED in line with NICE TA606
Oxandrolone  tablets   		RESTRICTED adults acute attacks of HAE

3.5 Respiratory stimulants & pulmonary surfactants		GMMMG
3.5.1 Respiratory Stimulants		
Doxapram Hydrochloride		
injection	 	
Caffeine Citrate		
injection	  	RESTRICTED apnoea in premature babies
3.5.2 Pulmonary Surfactants		
Poractant Alfa		
 Curosurf® liquid	  	

3.6 Oxygen (refer to oxygen guidelines)



3.7 Mucolytics		GMMMG
Mucolytics		
Sodium Chloride (hypertonic)		
<i>Nebusal</i> ® 7% nebulules	 	
Mannitol inhalation powder 		RESTRICTED Respiratory only in line with NICE
<i>Bronchitol</i> ® capsules	    	
Mannitol diagnostic kit 		RESTRICTED Respiratory only
<i>Osmohale</i> ® capsules	   	
Carbocisteine		RESTRICTED COPD Consultant / referral only
capsules; oral solution; sachets	  	
Dornase Alfa  		RESTRICTED Respiratory only
<i>Pulmozyme</i> ® nebulules	   	
Elexacaftor with Tezacaftor and Ivacaftor  		RESTRICTED Specialist use only
<i>Kaftrio</i> ® tablets	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
Ivacaftor  		RESTRICTED Paediatric Consultants only
<i>Kalydeco</i> ® tablets; granules	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
Lumacaftor with Ivacaftor  		RESTRICTED Specialist use only
<i>Orkambi</i> ® tablets; granules	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
Tezacaftor with Ivacaftor  		RESTRICTED Specialist use only
<i>Symkevi</i> ® tablets	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		

3.8 Aromatic inhalations



Aromatic Inhalations

Benzoin Tincture, Compound, BP













Friars' Balsam liquid



Menthol and Eucalyptus Inhalation, BP 1980

inhalation vapour



3.9 Cough preparations		GMMMG
3.9.1 Cough Suppressants		
Codeine Phosphate		
oral solution	 	
MHRA Drug Safety Update (Feb-24): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine MHRA Drug Safety Update (Jul-23): Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine		
Pholcodine		Withdrawn from UK market as per MHRA alert March 2023
oral solution	 	
MHRA Drug Safety Update (Mar-23): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure		
Dextromethorphan hydrobromide		RESTRICTED non-ketotic hyperglycinaemia
oral solution	MMC  	
Cough Suppressants (Palliative Care ONLY)		
Methadone Hydrochloride		
liquid	 	
Morphine Hydrochloride		
oral solution	 	
3.9.2 Demulcent & expectorant cough preparations		
Simple Linctus		
liquid	 	

3.10 Systemic nasal decongestants



Systemic Nasal Decongestants

NO DRUGS ARE RECOMMENDED FROM THIS GROUP

PbR X

NICE



NHSE: OTC prescribing reduction

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)

3.11 Antifibrotics



Antifibrotics

Pirfenidone



capsules; tablets



RESTRICTED
Respiratory Consultants only
NOT STOCKED

MHRA Drug Safety Update (Nov-20): Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing

Chapter 4: Central Nervous System

Supported by the
formulary ([click here](#))



4.1 Hypnotics & anxiolytics

- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.1.4 Other hypnotics and anxiolytics

4.2 Drugs used in psychoses & related disorders

- 4.2.1 Antipsychotic Drugs
- 4.2.2 Antipsychotic Depot Injections
- 4.2.3 Drugs used for mania and hypomania

4.3 Antidepressant drugs

- 4.3.1 Tricyclic & Related Antidepressant Drugs
- 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
- 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
- 4.3.4 Other Antidepressant Drugs

4.4 CNS stimulants & drugs used for ADHD

4.5 Drugs used in the treatment of obesity

4.6 Drugs used in nausea & vertigo

4.7 Analgesics

- 4.7.1 Non-Opioid Analgesics
- 4.7.2 Opioid Analgesics
- 4.7.3 Neuropathic Pain
- 4.7.4 Antimigraine Drugs

4.8 Antiepileptic drugs

- 4.8.1 Control of the Epilepsies
- 4.8.2 Drugs Used in Status Epilepticus

4.9 Drugs used in Parkinsonism & related disorders

- 4.9.1 Dopaminergic Drugs Used in Parkinsonism
- 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
- 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders

4.10 Drugs used in substance dependence

4.11 Drugs for dementia

Trust Guidelines














































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

NICE Guidance





Obsessive compulsive disorder (OCD) & body dysmorphic disorder (BDD) (CG31)
 Management of Obesity (CG43) (replaces TA22, TA31 & TA46)
 Drug misuse: opioid detoxification (CG52)
 Depression with a chronic physical health problem (CG91)
 Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
 Anxiety (CG113) (replaces CG22)
 Neuropathic pain - pharmacological management (CG173)
 Psychosis and schizophrenia in adults (CG178)
 Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)
 Eating Disorders: recognition and treatment (NG69)
 Parkinson's disease in adults (NG71)
 Attention deficit hyperactivity disorder: diagnosis and management (NG87)
 Stop smoking interventions and services (NG92)
 Dementia: supporting people with dementia and their carers in health and social care (NG97)
 Post-traumatic stress disorder (NG116)
 Depression in children and young people: identification and management (NG134)
 Epilepsies in children, young people and adults (NG217)
 Depression in adults: treatment and management (NG222)
 Motor Neurone Disease: Riluzole (TA20)
 Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)
 Drug Misuse: Methadone & Buprenorphine (TA114)
 Drug Misuse: Naltrexone (TA115)
 Smoking Cessation: Varenicline (TA123)
 Schizophrenia - aripiprazole (TA213)
 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)
 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
 Bipolar disorder (children) - aripiprazole (TA292)
 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
 Vortioxetine for treating major depressive episodes (TA367)
 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
 Galcanezumab for preventing migraine (TA659)
 Cenobamate for treating focal onset seizures in epilepsy (TA753)
 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
 Fremanezumab for preventing migraine (replacing TA631) (TA764)
 Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
 Eptinezumab for preventing migraine (TA871)
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)
 Rimegepant for preventing migraine (TA906)
 Rimegepant for treating migraine (TA919)
 Daridorexant for treating long-term insomnia (TA922)
 Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)





































GMMM Formulary
























Formulary Homepage
 Chapter 4: Central Nervous system (Complete)
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

4.1 Hypnotics & anxiolytics		GMMMG
4.1.1 Hypnotics		NICE CG112
Benzodiazepines		
Temazepam		
 tablets; oral solution	 	
Nitrazepam		
tablets; oral suspension	 	
Zaleplon, Zolpidem & Zopiclone		
Zopiclone		
tablets	  	
Chloral & Derivatives		
Chloral Hydrate		
oral solution; suppositories	 	
MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication		
Clomethiazole		
192mg capsules	 	
Sodium Oxybate		
Sodium Oxybate		
   oral solution	    	RESTRICTED 2 nd line narcolepsy with cataplexy
Melatonin		
Melatonin		
capsules; tablets; oral solution	  	RESTRICTED GMMMG
Melatonin (licensed product 1 st line) - Paediatric patients, e.g. sleep disorders, ADHD		Amber
Melatonin (licensed product only) - Adult patients over 55yrs of age		Green
Melatonin - management of jet lag		DNP
4.1.2 Anxiolytics		NICE CG113
Benzodiazepines		
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression		
Chlordiazepoxide hydrochloride		
 capsules	 	Symptomatic relief of acute alcohol withdrawal
Diazepam		
tablets; liquid; injection; rectal tube	 	
Lorazepam		
tablets; injection	 	
Oxazepam		
tablets	 	
Busiprone		
Busiprone Hydrochloride		
tablets	 	
Others		
Pregabalin		
  capsules; oral solution	  	RESTRICTED generalised anxiety disorder after standard treatment following NICE has failed.
4.1.3 Barbiturates		
NO DRUGS ARE RECOMMENDED FROM THIS GROUP		
4.1.4 Other hypnotics and anxiolytics		
Daridorexant		
 Quviviq® tablets	   	RESTRICTED in line with NICE TA922 NOT STOCKED






4.2 Drugs used in psychoses & related disorders		GMMMG
4.2.1 Antipsychotic Drugs		NICE CG178
MHRA Drug Safety Update (May-12): Antipsychotics: initiative to reduce prescribing to older people with dementia		
Chlorpromazine Hydrochloride Green tablets; oral solution; injection MMC BNF emc		
Haloperidol Green tablets; capsules; oral solution BNF emc		
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
Levomepromazine Green tablets BNF emc		
Promazine Hydrochloride tablets; oral solution BNF emc		
Sulpiride tablets; oral solution BNF emc		
Trifluoperazine tablets; oral solution BNF emc		
Zuclophenthixol tablets BNF emc		
Atypical Antipsychotic Drugs		
Amisulpride Amber Red tablets; oral solution MMC BNF emc		RESTRICTED adults. Consultant Psychiatrist only
Aripiprazole Amber Red tablets; oral solution NICE MMC BNF emc		RESTRICTED paediatrics. Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-23): Aripiprazole (Ablify and generic brands): risk of pathological gambling		
Clozapine Red tablets BNF emc		
MHRA Drug Safety Update (Aug-20): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity		
MHRA Drug Safety Update (Oct-17): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus		
Olanzapine Amber Red tablets; orodispersible tablets; oral solution BNF emc		
Quetiapine Amber Red tablets; M/R tablets MMC BNF emc		RESTRICTED - Consultant initiation - schizophrenia patients
Risperidone Amber Red tablets; orodispersible tablets; oral solution BNF emc		
4.2.2 Antipsychotic Depot Injections		
Flupentixol Decanoate Amber injection BNF emc		RESTRICTED Consultant Psychiatrist only
Fluphenazine Decanoate Amber injection BNF emc		RESTRICTED Consultant Psychiatrist only
Haloperidol Decanoate Amber injection BNF emc		RESTRICTED Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
Risperidone Amber injection BNF emc		RESTRICTED Consultant Psychiatrist only
Zuclophenthixol Decanoate Amber injection BNF emc		RESTRICTED Consultant Psychiatrist only
































4.2.3 Drugs used for mania and hypomania		
Lithium Carbonate Amber tablets; M/R tablets	 	PRESCRIBE BY BRAND NAME
Lithium Citrate Amber oral solution	 	
Valproic Acid Green Gastro-resistant tablets	 	
MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended		

4.3 Antidepressant drugs		GMMMG
		NICE CG31
		NICE CG91
4.3.1 Tricyclic & Related Antidepressant Drugs		NICE NG134
Tricyclic antidepressants		NICE NG222
Amitriptyline Hydrochloride (standard release preparations only)		
tablets; oral solution	 	
Clomipramine Hydrochloride (standard release preparations only)		
capsules	 	
Doxepin Hydrochloride		
capsules	 	
Imipramine Hydrochloride		
tablets	 	
Lofepramine		
tablets; oral suspension	 	1 st line use
Nortriptyline		
tablets	 	
Trimipramine		
DNP tablets; capsules	 	
Tricyclic-related antidepressants		
Mianserin Hydrochloride		
tablets	 	RESTRICTED initiation by Psychiatrist
Trazodone Hydrochloride		
capsules; tablets; oral solution	 	RESTRICTED initiation by Psychiatrist
4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)		
Isocarboxazid		
Red tablets	 	RESTRICTED initiation by Psychiatrist
Phenelzine		
Red 15mg tablets	 	RESTRICTED initiation by Psychiatrist
Tranlycypromine		
Red 10mg tablets	 	RESTRICTED initiation by Psychiatrist
Reversible Monoamine-Oxidase Inhibitors (MAOIs)		
Moclobemide		
Green 150mg; 300mg tablets	 	RESTRICTED 2nd line initiation by Psychiatrist
4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)		
MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery		
Fluoxetine		
capsules; tablets; dispersible tablets; oral solution	 	
Citalopram		
tablets; oral drops	 	
MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
Sertraline		
tablets; oral suspension	 	
Fluvoxamine maleate		
tablets	 	
Paroxetine		
tablets; oral suspension	 	


























































Escitalopram tablets  	RESTRICTED Mental Health Trust initiation only
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation	
4.3.4 Other Antidepressant Drugs	
Venlafaxine  M/R capsules; tablets; M/R tablets  	RESTRICTED initiation by Psychiatrist
Mirtazapine tablets; orodispersible tablets; oral solution   	RESTRICTED initiation by Psychiatrist
Duloxetine  gastro-resistant tablets  	RESTRICTED initiation by Psychiatrist
Flupentixol tablets  	RESTRICTED initiation by Psychiatrist
Reboxetine tablets   	RESTRICTED initiation by Psychiatrist
Tryptophan capsules  	RESTRICTED initiation by Psychiatrist
Vortioxetine  tablets    	RESTRICTED initiation by Psychiatrist









































4.4 CNS stimulants & drugs used for ADHD		GMMMG
4.4 CNS stimulants & drugs used for ADHD GMMMG		NICE NG87
Atomoxetine Amber capsules NICE MMC BNF emc		RESTRICTED on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Jan-12): Atomoxetine (Strattera ▼): increases in blood pressure and heart rate MHRA Drug Safety Update (Mar-09): Atomoxetine: risk of psychotic or manic symptoms in children and adolescents		
Dexamfetamine Amber Red tablets NICE BNF emc		RESTRICTED on Paediatric / Psychiatric advice
Guanfacine Amber Prolonged release tablets NICE MMC BNF emc		RESTRICTED 2 nd line use for ADHD
Lisdexamfetamine Amber CT capsules NICE MMC BNF emc GMMMG		RESTRICTED 2 nd line use for ADHD
Methylphenidate Amber CT tablets; M/R tablets; capsules; M/R capsules NICE MMC BNF emc		RESTRICTED on Paediatric / Psychiatric advice PRESCRIBE BY BRAND NAME
MHRA Drug Safety Update (Sep-22): Methylphenidate long-acting (MR) preparations: caution if switching between products due to differences in formulations MHRA Drug Safety Update (Mar-09): Methylphenidate: safe and effective use to treat ADHD		
Modafinil Green DNP Red tablets BNF emc		RESTRICTED on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Nov-20): Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy MHRA Drug Safety Update (Mar-11): Modafinil (Provigil): now restricted to narcolepsy		
Solriamfetol hydrochloride Red ££ Sunosi® tablets NICE MMC BNF emc		RESTRICTED Sleep Centre only in line with NICE

































































4.5 Drugs used in the treatment of obesity	
4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract	NICE CG43
Orlistat capsules    	RESTRICTED Consultant initiation - Paeds. only
MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines	

4.6 Drugs used in nausea & vertigo		GMMMG
Antihistamines		
Cyclizine		1st line use
tablets; injection	 	
Promethazine Hydrochloride		
tablets; oral solution (see also section 3.4.1)	 	
Promethazine Teoclate		
tablets	 	
Phenothiazines & Related Drugs		
Prochlorperazine		
tablets; buccal tablet; injection	 	
Droperidol		RESTRICTED Consultant initiation only for PONV
injection	  	
Domperidone & Metoclopramide		
Domperidone		
tablets; oral suspension (see also section 1.2)	 	
MHRA Drug Safety Update (Dec-19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents		
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects		
MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects		
Metoclopramide Hydrochloride		
tablets; oral suspension; injection (see also section 1.2)	 	
MHRA Drug Safety Update (Aug-13): Metoclopramide: risk of neurological adverse effects		
5HT₃-receptor antagonists		
Ondansetron		RESTRICTED - Chemotherapy induced & post-op vomiting
 	 	
tablets; orodispersible tablets; injection; oral solution; orodispersible film		
MHRA Drug Safety Update (Jul-13): Ondansetron for intravenous use: dose-dependent QT interval prolongation		
MHRA Drug Safety Update (Aug-12): Ondansetron (Zofran): important new intravenous dose restriction		
Neurokinin 1-receptor antagonist		
Aprepitant		RESTRICTED highly / moderately emetogenic CINV
80mg; 125mg capsules; 25mg/mL oral suspension	  	
Cannabinoids		
Nabilone		RESTRICTED highly emetogenic CINV
	  	
0.25mg; 1mg capsules		
Hyoscine		
Hyoscine Hydrobromide		
patches; tablets (for Hyoscine Butylbromide see section 1.2)	  	
MHRA Drug Safety Update (Jul-23): Hyoscine hydrobromide patches: risk of anticholinergic side effects, including hyperthermia		
Other Drugs for Ménière's Disease		
Betahistine Dihydrochloride		
tablets	 	























4.7 Analgesics		GMMMG
4.7.1 Non-Opioid Analgesics		(see also Chapter 10 for NSAIDs)
Paracetamol		1st line use
tablets; soluble tablets; infusion; injection; oral suspension; suppositories	MMC BNF emc	
Sucrose 24% solution		RESTRICTED Pain relief in neonates
Sweet-Ease® oral solution	MMC BNF emc	
Compound Analgesic Preparations		
Paracetamol and codeine (Co-codamol®)		
tablets; effervescent tablets	BNF emc	
Paracetamol and dihydrocodeine (Co-dydramol®)		
tablets	BNF emc	
4.7.2 Opioid Analgesics		
MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction		
Buprenorphine		RESTRICTED
NOT patch	NICE BNF emc	
Codeine Phosphate		
tablets; syrup; injection	BNF emc	
MHRA Drug Safety Update (Jul-13): Codeine for analgesia: restricted use in children because of reports of morphine toxicity		
MHRA Drug Safety Update (Jun-13): Codeine: restricted use as analgesic in children and adolescents after European safety review		
Diamorphine Hydrochloride		
injection	BNF emc	
Difelikefalin		RESTRICTED Renal Consultants in line with NICE
Kaprvia® injection	PbR X NICE MMC BNF bluefeg emc	
Dihydrocodeine Tartrate standard release preparations only		
tablets	BNF emc	
Fentanyl		Spray RESTRICTED palliative care & haematology initiation (Wd44)
NOT lozenge	MMC BNF emc	
MHRA Drug Safety Update (Oct-18): Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children		
MHRA Drug Safety Update (Sep-08): Serious and fatal overdose of fentanyl patches		
Methadone Hydrochloride		RESTRICTED palliative care & substance misuse
oral solution	NICE BNF emc	
Morphine Sulphate		
tablets; M/R tablets; capsules; M/R capsules; oral solution; injection	BNF emc	
Morphine Sulphate		RESTRICTED palliative care / GMMMG
Actimorph® orodispersible tablets	MMC BNF emc	
Oxycodone Hydrochloride		RESTRICTED 2 nd line for morphine intolerance
capsules; liquid; tablets; M/R tablets; injection	MMC BNF emc	
Pethidine Hydrochloride		
injection; tablets	BNF emc	
Tapentadol Hydrochloride MR		RESTRICTED 3 rd line - Pain Team Consultants only
tablets	MMC BNF emc	
MHRA Drug Safety Update (Jan-19): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines		
Tramadol Hydrochloride		
capsules; M/R capsules; tablets; M/R tablets; soluble tablets; injection	BNF emc	



























4.7.3 Neuropathic Pain		
Amitriptyline		
tablets; oral solution	 	
Carbamazepine		
 tablets; M/R tablets; oral solution; suppositories	 	
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Gabapentin		
  capsules; oral suspension	 	
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April		
MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression		
Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
Pregabalin		3rd / 4th line use if gabapentin contraindicated or not tolerated
  capsules; oral solution	  	
MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression		
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April		
Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
4.7.4 Antimigraine Drugs		
4.7.4.1 Treatment Of Acute Migraine		
Analgesics		
Aspirin		
tablets; dispersible tablets; E/C tablets; suppositories	 	
Paracetamol		
tablets; soluble tablets; oral suspension; infusion; suppositories	 	
Ibuprofen		
tablets; M/R tablets; oral suspension; sachets	 	
5HT₁ receptor agonists		
Sumatriptan		
tablets; nasal spray; injection	 	
4.7.4.2 Prophylaxis of Migraine		
Botulinum Toxin Type A		RESTRICTED Specialist use only in line with NICE
 Botox® injection	    	
Clonidine Hydrochloride		
tablets	 	
Erenumab		RESTRICTED Specialist use only NOT STOCKED
  injection	   	
Eptinezumab		RESTRICTED Specialist use only NOT STOCKED
  injection	   	
Fremanezumab		RESTRICTED Specialist use only NOT STOCKED
  injection	    	
Galcanezumab		RESTRICTED Specialist use only NOT STOCKED
  injection	   	
Pizotifen		
tablets	 	
















4.8 Antiepileptic drugs Green		GMMMG
4.8.1 Control of the Epilepsies		NICE NG217
Carbamazepine Green tablets; M/R tablets; oral solution; suppositories NICE  		
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Phenobarbital Green  tablets; oral solution; injection NICE  		
Phenytoin Sodium Green capsules; oral suspension; injection NICE  		
Sodium Valproate Green tablets; M/R tablets; oral solution; M/R granules; injection NICE  		
MHRA Drug Safety Update (Jan-24): Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age MHRA Drug Safety Update (Oct-23): Valproate: dispense full packs of valproate-containing medicines MHRA Drug Safety Update (Aug-23): Valproate: re-analysis of study on risks in children of men taking valproate MHRA Drug Safety Update (Dec-22): Valproate: reminder of current Pregnancy Prevention Programme requirements... MHRA Drug Safety Update (Jan-20): Valproate (Epilim ▼, Depakote ▼) pregnancy prevention programme: updated educational materials MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance... MHRA Drug Safety Update (Apr-18): Valproate medicines (Epilim ▼, Depakote ▼): contraindicated in women & girls of childbearing potential unless conditions of PPP met MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended		
cenobamate Green Ontozry® tablets NICE   		RESTRICTED Specialist use only in line with NICE
Clobazam Green tablets; oral suspension NICE  		RESTRICTED Specialist use only
Clonazepam Green tablets; oral solution; injection NICE  		RESTRICTED Specialist use only
Eslicarbazepine Green tablets; oral suspension NICE   		RESTRICTED Specialist use only in line with NICE
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Ethosuximide Green capsules; oral solution NICE  		RESTRICTED Paediatrics only
Fenfluramine Hydrochloride Red Fintepla® oral solution NICE   		RESTRICTED Specialist use only in line with NICE
Gabapentin Green  capsules; oral suspension NICE  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
Lacosamide Green tablets; oral solution; infusion NICE   		RESTRICTED Specialist use only
Lamotrigine Green tablets; dispersible tablets NICE  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review		
Levetiracetam Green tablets; oral solution; infusion; granules NICE   		RESTRICTED Specialist use only
MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review		
Oxcarbazepine Green tablets; oral suspension NICE  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Perampanel Green tablets; oral suspension   		RESTRICTED Specialist use only

Pregabalin   capsules; oral solution    	RESTRICTED Specialist use only
MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin	
Primidone  tablets  	RESTRICTED Specialist use only
Rufinamide  tablets    	RESTRICTED Specialist use only Lennox-Gastaut Syndrome
Stiripentol  capsules; sachets    	RESTRICTED Specialist use only
Tiagabine  tablets    	RESTRICTED Specialist use only
Topiramate  tablets; capsules    	RESTRICTED Specialist use only
Vigabatrin  tablets; sachets   	RESTRICTED Specialist use only
Zonisamide  capsules    	RESTRICTED Specialist use only
Cannabidiol (CBD)   Epidyolex®    	RESTRICTED Specialist use only in line with NICE TA614 / 615
4.8.2 Drugs Used in Status Epilepticus	
Lorazepam tablets; injection  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
Diazepam tablets; liquid; injection; rectal tube  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
Clonazepam  tablets; oral solution; injection  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
Midazolam   oromucosal solution; injection; infusion  	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
Paraldehyde injection; rectal solution  	
Phenytoin Sodium  capsules; oral suspension; injection  	
Sulthiame  Ospolot® 50mg tablets   	RESTRICTED Consultant Neurologist use only

4.9 Drugs used in Parkinsonism & related disorders		GMMMG
4.9.1 Dopaminergic Drugs Used in Parkinsonism		NICE NG71
Amantadine Hydrochloride Green capsules; oral solution NICE BNF emc	RESTRICTED Specialist use only	
Apomorphine Hydrochloride Amber injection; infusion NICE MMC BNF emc MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects	RESTRICTED Specialist use only	
Cabergoline Green tablets NICE MMC BNF emc	RESTRICTED Specialist use only	
Co-beneldopa Green capsules; M/R capsules; dispersible tablets NICE BNF emc	RESTRICTED Specialist use only	
Co-careldopa Green tablets; M/R tablets PbR X NICE BNF emc	RESTRICTED Specialist use only	
Entacapone Green tablets MMC BNF emc	RESTRICTED Specialist use only	
Foscarbidopa / Foslevodopa Red Produodopa® infusion NICE MMC BNF emc	RESTRICTED Specialist use in line with NICE	
Opicapone Green capsules MMC BNF emc	RESTRICTED 2nd line Specialist use only	
Pramipexole Green tablets; M/R tablets MMC BNF emc	RESTRICTED 3rd line add-on use Specialist use only	
Rasagiline Green tablets MMC BNF emc	RESTRICTED patients with end of dose fluctuations	
Ropinirole Green tablets; M/R tablets BNF emc	RESTRICTED Specialist use only	
Rotigotine Green transdermal patches NICE MMC BNF emc	RESTRICTED Specialist use only. NBM patients	
Safinamide Green tablets MMC BNF emc	RESTRICTED Specialist use only	
Selegiline Green tablets BNF emc	RESTRICTED Specialist use only	
4.9.2 Antimuscarinic Drugs Used in Parkinsonism		
Orphenadrine Hydrochloride oral solution BNF emc		
Procyclidine (Oral & IM) tablets; oral solution; injection BNF emc		
Trihexyphenidyl Hydrochloride (Benzhexol Hydrochloride) tablet; syrup MMC BNF emc		

4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders		
Propranolol tablets; M/R capsules; oral solution; injection  		
Haloperidol Green tablets; capsules; oral solution MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium  		RESTRICTED Specialist use only
Piracetam tablets; oral solution  		RESTRICTED Specialist use only
Tetrabenazine tablets  		RESTRICTED Specialist use only
Torsion Dystonias & Other Involuntary Movements		
The dose of botulinum toxin is specific to each individual preparation and is NOT interchangeable. The doses for different indications vary - consult product literature & specialist guidance		
Botulinum Toxin Type A Red Botox® injection     		RESTRICTED Specialist use only see decision tables
Botulinum Toxin Type A Red Dysport® injection    		RESTRICTED Specialist use only
Botulinum Toxin Type A Red Xeomin® injection     		RESTRICTED Specialist use only see decision tables

4.10 Drugs used in substance dependence		GMMMG
4.10.1 Alcohol dependence		
Nalmefene Green	   	RESTRICTED - Specialist use only in line with NICE TA325 NOT STOCKED
4.10.2 Nicotine dependence		
Nicotine Replacement Therapy patches, lozenges, inhalator, microtabs	 	NICE NG92 1st line use
Bupropion Hydrochloride tablets	  	
MHRA Drug Safety Update (Nov-20): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs		
Varenicline tablets	   	
4.10.3 Opioid Dependence		
MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction		
Buprenorphine Green 	  	RESTRICTED Initiation by substance misuse specialist
Methadone Hydrochloride 	  	RESTRICTED Initiation by substance misuse specialist
Naltrexone Hydrochloride Red 	   	RESTRICTED Gastro Consultant - cholestatic itch

4.11 Drugs for dementia		GMMMG
4.11 Drugs for Dementia		NICE NG97
Donepezil Hydrochloride Green tablets; orodispersible tablets	   	RESTRICTED Specialist use only
Galantamine Green M/R capsules; tablets	  	RESTRICTED Specialist use only
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
Memantine Hydrochloride Green tablets; oral solution	   	RESTRICTED Specialist use only
Rivastigmine Green capsules; oral solution; transdermal patches	   	RESTRICTED Specialist use only
Dementia - as per NICE TA217 & NG97 Green (following specialist initiation)		Green

Section 5: Infections

Supported by the
formulary ([click here](#))



5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulphonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antileprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, *Enterobius vermicularis*)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

Trust Guidelines

MFT Adult Antimicrobial guidelines
 MFT Paediatric Antimicrobial guidelines
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

NICE Guidance

Prophylaxis against infective endocarditis (CG64)
 Bacterial meningitis and meningococcal septicaemia (CG102)
 Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)
 Hepatitis B (Chronic) (CG165)
 Tuberculosis (NG33)
 Sinusitis (acute): antimicrobial prescribing (NG79)
 Sore throat (acute): antimicrobial prescribing (NG84)
 Otitis media (acute): antimicrobial prescribing (NG91)
 Cough (acute): antimicrobial prescribing (NG120)
 Surgical site infections: prevention and treatment (NG125)
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)
 Hepatitis B: Chronic (TA96) (partially updated by CG165)
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)
 Hepatitis B: Entecavir (TA153)
 Hepatitis B: Telbivudine (TA154)
 Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)
 Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)
 Hepatitis B: Tenofovir disoproxil (TA173)
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)
 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)
 Sofosbuvir for treating chronic hepatitis C (TA330)
 Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
 Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
 Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)
 Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)
 Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)
 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
 Letemovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)
 Cabotegravir with rilpivirine for treating HIV-1 (TA757)
 Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
 Bulevirtide for treating chronic hepatitis D (TA896)

GMMM Formulary

Formulary Homepage
 Chapter 5: Infections (Complete)
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMM Paediatric [Red/Amber/Green](#) Drug List

RESTRICTED USE ANTIBIOTICS

1. Must be recommended / approved for use by consultant medical microbiologist
2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
3. Only available from Pharmacy

RESERVED USE ANTIBIOTICS

1. Can be used only in accordance with the restrictions outlined below.
2. Indication must be clearly documented on the prescription chart.
3. If being used outside of guidelines Microbiology approval must be sought as above.

UNRESTRICTED USE ANTIBIOTICS

1. Can be used according to CMFT Trust guidelines, (those drugs not marked Restricted or Reserved)

5.1 Antibacterial drugs**5.1.1 Penicillins****5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin****Benzylpenicillin Sodium (Penicillin G)**

600mg injection

**Phenoxymethylpenicillin (Penicillin V)**

tablets

**Benzathine Benzylpenicillin**

injection

**RESTRICTED**
unlicensed treatment for syphilis**5.1.1.2 Penicillinase-Resistant Penicillins****Flucloxacillin**

capsules; injection; oral solution

**Temocillin**

1g injection

**RESTRICTED** infection caused by
multi-resistant coliforms.
Micro only**5.1.1.3 Broad Spectrum Penicillins****Amoxicillin**

capsules; oral suspension; injection

**Co-amoxiclav**

tablets; oral suspension; injection

**5.1.1.4 Antipseudomonal Penicillins****Piperacillin with Tazobactam**

injection

**RESERVED**
serious / resistant infections**Ticarcillin with Clavulanic Acid**

Timentin® 3.2g injection

**RESERVED**
serious / resistant infections**5.1.1.5 Mecillinams****Pivmecillinam Hydrochloride**

200mg tablets

**RESTRICTED** UTIs caused by resistant
coliforms**5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams****5.1.2.1 Cephalosporins****Cefalexin**

capsules; tablets; oral suspension

**Cefazolin**

injection

**RESTRICTED**
on Micro. advice only**Cefotaxime**

injection





























































**RESERVED**
as per guidelines for children**Ceftriaxone**

injection















































































**RESERVED**
as per guidelines for children**Cefuroxime**















































injection

**RESERVED**
as per guidelines for children

Cefixime		RESERVED GU infections only
tablets	  	
Ceftazidime		RESERVED pseudomonas infection in CF
injection	  	
Ceftazidime / Avibactam		RESERVED for gram negative organisms Micro. Consultant only
Zavicefta® infusion	  	
Ceftolozane sulfate / Tazobactam sodium		RESERVED for gram negative organisms Micro. Consultant only
Zerbaxa® infusion	  	
Ceftaroline Fosamil		RESERVED CAP & cSSTI treatment. Micro. Consultant only
Zinforo® infusion	  	
Cefoxitin		RESERVED for treatment of mycobacterium abscessus in CF. Micro. Consultant only
injection	  	
Cefiderocol		RESERVED for gram negative organisms Micro. Consultant only
Fetroja® infusion	  	
5.1.2.2 Carbapenems		
Ertapenem		RESTRICTED Outpatient therapy only
infusion	  	
Imipenem with Cilastatin		RESTRICTED Non-Tuberculous Mycobacteria in CF
infusion	  	
Imipenem / Cilastatin / Relebactam		RESTRICTED Micro. Consultant only
 Recarbrio® infusion	  	
Meropenem		RESERVED as per guidelines
injection	  	
Meropenem with Vaboractam		RESTRICTED Micro. Consultant only
Vaborem® infusion	  	
5.1.2.3 Other Beta-Lactam antibiotics		
Aztreonam		RESTRICTED gram negative organisms
injection	 	
Aztreonam lysine		RESTRICTED 3rd line CF patients with chronic pulmonary infection
  Cayston® nebuliser solution	  	
5.1.3 Tetracyclines		
Doxycycline		
capsules; tablets; dispersible tablets	  	
Oxytetracycline		
tablets	 	
Demeclocycline Hydrochloride		RESTRICTED SIADH only
capsules	  	
Lymecycline		RESTRICTED Non-Formulary MMC approved for GP referral
capsules	  	
Minocycline		
capsules; tablets	  	
Tigecycline		RESERVED as per guidelines
infusion	  	

5.1.4 Aminoglycosides		
MHRA Drug Safety Update (Jan-21): Aminoglycosides (gentamicin, amikacin, tobramycin & neomycin): increased risk of deafness in patients with mitochondrial mutations		
Amikacin		RESERVED as per guidelines
injection	PbR X MMC BNF emc	
Gentamicin		
injection	BNF emc	
Tobramycin		RESERVED as per guidelines
Amber Red ££		
injection; inhalation powder; nebuliser liquid	NICE MMC BNF emc	
Neomycin Sulfate		RESTRICTED Gastro team only - op prep
oral solution	BNF emc	
5.1.5 Macrolides		
Clarithromycin		
tablets; oral suspension; infusion	BNF emc	
Azithromycin		RESERVED GU only or specialist use
tablets; oral suspension	BNF emc	
Erythromycin		RESERVED in pregnancy or neonates
tablets; oral suspension; injection	BNF emc	
MHRA Drug Safety Update (Dec-20): Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban		
MHRA Drug Safety Update (Dec-20): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis		
5.1.6 Clindamycin		
Clindamycin		RESERVED as per guidelines
capsules; oral suspension; injection; 2% vaginal cream	BNF emc	
5.1.7 Some other Antibacterials		
Chloramphenicol		RESERVED as per guidelines
capsules; injection	BNF emc	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
Dalbavancin		
Dalbavancin		RESTRICTED Consultant only Micro. approval required
500mg infusion	MMC BNF emc	
Fidaxomicin		
Fidaxomicin		RESTRICTED <i>clostridium difficile</i> associated diarrhoea Micro. only
Green ££		
200mg tablets; 40mg/mL granules for oral suspension	MMC BNF emc	
Fusidic Acid		
Sodium Fusidate		RESERVED as per guidelines
Green		
tablets; oral suspension; 2% cream	BNF emc	
MHRA Drug Safety Update (Sep-11): Systemic fusidic acid and interaction with statins		
Glycopeptides		
Vancomycin		
Green		
injection; capsules; oral suspension	MMC BNF emc	
Teicoplanin		RESERVED as per guidelines
injection	BNF emc	
Daptomycin		
Daptomycin		RESTRICTED as per guidelines
Red		
infusion	MMC BNF emc	
Linezolid		
Linezolid		RESTRICTED as per guidelines
Red		
tablets; infusion	MMC BNF emc	

Polymyxins		
Colistimethate Sodium   injection  		RESTRICTED as per guidelines
Colistimethate Sodium (DPI)   Colobreathe® inhalation powder    		RESTRICTED as per guidelines
MHRA Drug Safety Update (Nov-14): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage - new instructions for use		
Pristinamycin		
Pristinamycin   500mg tablets   		RESTRICTED as per BASHH guidelines for <i>Mycoplasma genitalium</i>
Rifaximin		
Rifaximin  550mg tablets    		RESTRICTED as per guidelines
Spectinomycin		
Spectinomycin  Kirin® injection  		RESTRICTED cephalosporin resistant gonorrhoea
Taurolidine		
Taurolidine citrate 4% TauroLock® 4% ampoules  		RESTRICTED as per CVC guidelines
5.1.8 Sulphonamides & Trimethoprim		
Trimethoprim		
tablets; oral suspension  		
Co-trimoxazole		
 tablets; oral suspension; infusion  		RESERVED as per guidelines
Sulfadiazine		
tablets  		RESTRICTED
5.1.9 Antituberculosis Drugs  until patient stabilised then  		
Bedaquiline		
 tablets     		RESTRICTED MDR TB only
Ethambutol Hydrochloride		
 tablets    		
Isoniazid		
 tablets; oral solution; injection    		
Prothionamide		
 tablets   		RESTRICTED MDR TB only
Pyrazinamide		
 tablets   		
Rifampicin		
 capsules; oral solution; infusion   		
Rifabutin		
 capsules  		2nd line where rifampicin not suitable
Rifater®		
 Rifampicin / Isoniazid / Pyrazinamide tablets   		
Rifinah®		
 Rifampicin / Isoniazid tablets   		
Voractiv®		
 Rifampicin / Isoniazid / Pyrazinamide / Ethambutol Hydrochloride tablets   		

Capreomycin		
injection	  	RESTRICTED MDR TB only Not stocked
Cycloserine		
capsules	 	RESTRICTED MDR TB only Not stocked
Delamanid		
 tablets	  	RESTRICTED MDR TB only
Streptomycin		
 injection	  	RESTRICTED MDR TB only Not stocked
Moxifloxacin		
tablets; injection	   	RESTRICTED
Para aminosalicylic acid (PAS)		
granules	   	RESTRICTED MDR TB only Not stocked
5.1.10 Antitubercular Drugs		
Clofazimine		
 capsules	  	RESTRICTED MDR TB only
Dapsone		
 tablets	  	RESERVED
5.1.11 Metronidazole & Tinidazole		
Metronidazole		
tablets; oral suspension; infusion; suppositories; vaginal gel	  	
Tinidazole		
tablets	 	RESTRICTED
5.1.12 Quinolones		
Ciprofloxacin		
tablets; oral suspension; infusion (see also sections 11.3.1 & 12.1.1)	 	RESERVED as per guidelines
Levofloxacin		
tablets; infusion (see also section 11.3.1)	  	RESTRICTED MDR TB only Not stocked
Moxifloxacin		
tablets; infusion	  	RESTRICTED MDR TB only
Nalidixic acid		
tablets	 	RESTRICTED Urology use in children only
Ofloxacin		
tablets (see also section 11.3.1)	 	RESTRICTED GU infections only
<p>MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate</p> <p>MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour</p> <p>MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk</p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p> <p>MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients</p>		

5.1.13 Urinary-tract Infections**Nitrofurantoin**

M/R capsules; capsules; tablets



MHRA Drug Safety Update (Apr-23): Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions

MHRA Drug Safety Update (Sep-14): Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m²**Fosfomycin**

sachets; infusion
















































**RESTRICTED**
Micro recommendation only**Methenamine Hippurate**

tablets























































































































**RESTRICTED** Urology Consultants**Urease inhibitor****Acetohydroxamic acid**

Lithostat® tablets




































































































**RESTRICTED** Urology Consultants


















































5.2 Antifungal drugs		GMMMG
5.2.1 Triazole Antifungals		
Fluconazole		
capsules; infusion; oral suspension.	 	
Isavuconazole		RESTRICTED micro / specialist use only
capsules; infusion	   	
Itraconazole		
capsules; oral solution; infusion	 	
Posaconazole		RESTRICTED micro / specialist use only
G/R tablets; oral suspension; infusion	   	
MHRA Drug Safety Update (Sep-16): Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable		
Voriconazole		RESTRICTED micro / specialist use only
tablets; oral suspension; infusion	   	
5.2.3 Polyene Antifungals		
Nystatin		
100,000 units/mL oral suspension	 	
Amphotericin (liposomal)		RESTRICTED micro / specialist use only
 <i>AmBisome</i> ® infusion (systemic use)	   	
Amphotericin		RESTRICTED micro / specialist use only
 <i>Fungizone</i> ®	   	
5.2.4 Echinocandin Antifungals		
Anidulafungin		1st line RESTRICTED micro / specialist use only
  <i>Ecalta</i> ® infusion	   	
Micafungin		RESTRICTED micro / specialist use only
  <i>Mycamine</i> ® infusion	   	
5.2.5 Other Antifungals		
Griseofulvin		2nd line following topical therapy
tablets	  	
Terbinafine		2nd line following topical therapy
tablets	 	
Flucytosine		RESTRICTED micro / Neonates only
infusion	 	
MHRA Drug Safety Update (Oct-20): Flucytosine (Ancotil): new contraindication in patients with DPD deficiency		


















5.3 Antiviral drugs		GMMMG
Casirivimab with Imdevimab Red Ronapreve® infusion PbR X NICE MMC BNF		RESTRICTED
Molnupiravir Red Lagevrio® 200mg capsules PbR X MMC BNF		RESTRICTED CMDU see COVID-19 guidance
Nirmatrelvir with Ritonavir Red Paxlovid® 150mg/100mg tablets PbR X NICE MMC BNF		RESTRICTED see COVID-19 guidance
MHRA Drug Safety Update (Nov-23): Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir		
Remdesivir Red Veklury® infusion PbR X NICE MMC BNF		RESTRICTED see COVID-19 guidance
Sotrovimab Red Veklury® infusion PbR X NICE MMC BNF		RESTRICTED see COVID-19 guidance
Tecovirimat monohydrate Red Tecovirimat SIGA® 200mg capsules PbR X MMC BNF		RESTRICTED patients hospitalised due to monkeypox
5.3.1 HIV Infection Red		BHIVA treatment guidelines
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)		CHIVA PEP 2023
Abacavir Red tablets; oral solution PbR X MMC BNF		
Bictegravir / Emtricitabine / Tenofovir Alafenamide Red Biktarvy® tablets PbR X MMC BNF		
Emtricitabine Red capsules PbR X MMC BNF		
Lamivudine Red tablets; oral solution PbR X BNF		
Tenofovir Disoproxil Red tablets; granules PbR X NICE MMC BNF		
Tenofovir Alafenamide Red Descovy® / Odefsey® / Genvoya® tablets PbR X MMC BNF		RESTRICTED patients requiring new formulation
Tenofovir Disoproxil / Efavirenz / Emtricitabine Red Atripla® tablets PbR X MMC BNF		
Tenofovir / Cobicistat / Elvitegravir / Emtricitabine Red Stribild® tablets PbR X MMC BNF		
Tenofovir / Emtricitabine Red Truvada® tablets PbR X MMC BNF		
Emtricitabine / Rilpivirine / Tenofovir Red Eviplera® tablets PbR X MMC BNF		
Zidovudine / Lamivudine Red Combivir® tablets PbR X BNF		
Didanosine Red Videx® capsules (to be DISCONTINUED Q1 2020) PbR X MMC BNF		
Stavudine Red Zerit® capsules (to be DISCONTINUED Q1 2020) PbR X BNF		



















Protease Inhibitors		BHIVA treatment guidelines
Atazanavir   capsules    		
Atazanavir / Cobicistat   Evotaz® tablets    		
Darunavir   tablets; oral suspension    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
Darunavir / Cobicistat   RezoSta® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
Darunavir / Cobicistat / Emtricitabine & Tenofovir   Symtuza® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
Fosamprenavir   Telzir® tablets    		
Fostemsavir tromethamine   Rukobia® tablets    		
Lopinavir / Ritonavir   Kaletra® tablets; oral solution   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
Ritonavir   tablets; powder for oral suspension   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
Saquinavir   tablets   		
Tipranavir   capsules    		
Non-Nucleoside Reverse Transcriptase Inhibitors (Non-NRTIs)		BHIVA treatment guidelines
Doravirine   Pifeltro® tablets    		
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate   Delstrigo® tablets    		
Efavirenz   tablets; capsules   		
Etravirine   Intelence® tablets    		
Nevirapine   tablets; oral suspension; M/R tablets    		
Rilpivirine   Edurant® tablets / Rekambys® injection     		
Other Antiretrovirals		BHIVA treatment guidelines
Cabotegravir   Vocabria® injection     		
Dolutegravir   Tivicay® tablets    		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
MHRA Drug Safety Update (Jun-18): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): increased risk of neural tube defects; DNP to women seeking to become pregnant...		

Dolutegravir / Abacavir / Lamivudine 		
Triumeq® tablets		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
Dolutegravir / Lamivudine 		
Dovato® tablets		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
Dolutegravir / Rilpivirine 		
Juluca® tablets		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
Enfuvirtide 		
Fuzeon® injection		
Maraviroc 		
Celsentri® tablets		
Raltegravir 		
tablets; chewable tablets; granules		
Pharmacokinetic enhancers of antiretrovirals		
Cobicistat 		
Tybost® tablets		
5.3.2 Herpesvirus Infection		
5.3.2.1 Herpes Simplex & Varicella-Zoster Infection		
Aciclovir tablets; oral suspension; infusion (see also section 13.10.3)		
Valaciclovir tablets		RESTRICTED Specialist use only Haematology / Renal
5.3.2.2 Cytomegalovirus (CMV) Infection		
Cidofovir 		RESERVED Specialist use only
infusion		
Foscarnet Sodium 		RESERVED Specialist use only; also for aggressive CMV retinitis
infusion		
Ganciclovir 		RESERVED Specialist use only
infusion (see also eye gel section 11.3.3)		
Letermovir 		RESERVED Specialist use only
Prevmis® tablets		
Maribavir 		RESERVED Specialist use only in line with NICE
Livtency® tablets		
Valganciclovir 		RESERVED Specialist use only
tablets; oral solution		
5.3.3 Viral Hepatitis		
5.3.3.1 Chronic hepatitis B		
Adefovir Dipivoxil 		NICE CG165
Hepsera® tablets		
Entecavir 		
Baraclude® tablets		NHSE Hepatitis C
MHRA Drug Safety Update (Jan-17): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation		
MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
Dasabuvir 		RESTRICTED Specialist use only in line with NHSE Commissioning
Exviera® tablets		

<p>Elbasvir / Grazoprevir   Zepatier® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA413</p>
<p>Glecaprevir / Pibrentasvir   Maviret® tablets      </p>	<p>RESTRICTED Specialist use only in line with NHSE and NICE TA499</p>
<p>Ombitasvir / Paritaprevir / Ritonavir   Viekirax® tablets      </p>	<p>RESTRICTED Specialist use only in line NICE / NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels</p>	
<p>Sofosbuvir   Sovaldi® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA330</p> 
<p>MHRA Drug Safety Update (Aug-15): Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone</p>	
<p>Sofosbuvir / Ledipasvir   Harvoni® tablets      </p>	<p>RESTRICTED Specialist use only in line NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (May-15): Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone</p>	
<p>Sofosbuvir / Velpatasvir   Epclusa® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA430</p>
<p>Sofosbuvir / Velpatasvir / Voxilaprevir   Vosevi® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA507</p>
<p>5.3.3.3 Hepatitis D</p>	
<p>Bulevirtide   Hepcludex® injection      </p>	<p>RESTRICTED Specialist use only in line with NICE TA896</p>
<p>5.3.4 Influenza</p>	
<p>Oseltamivir Tamiflu® capsules; oral suspension     </p>	
<p>MHRA Drug Safety Update (Sep-12): Oseltamivir (Tamiflu): changed concentration and dosing dispenser of oral suspension</p>	
<p>Zanamivir Relenza® inhalation powder     </p>	
<p>Zanamivir  Dectova® 10mg/mL infusion     </p>	<p>RESTRICTED Virology approval only</p>
<p>5.3.5 Respiratory Syncytial Virus (RSV)</p>	
<p>Palivizumab   Synagis® 100mg/mL injection     </p>	<p>RESTRICTED Specialist use only</p> 
<p>Ribavirin   capsules; tablets      </p>	<p>RESTRICTED Specialist use only</p>

5.4 Antiprotozoal drugs		GMMMG
Nitazoxanide    500mg tablets; 100mg/5mL oral suspension  MMC 		RESTRICTED Specialist use only
5.4.1 Antimalarials		
Artesunate  injection  		RESTRICTED Specialist use only
Artemether with Lumefantrine  tablets MMC  		RESTRICTED Specialist use only
Chloroquine  tablets  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
Mefloquine  tablets  		RESTRICTED Specialist use only
Primaquine  tablets  		RESTRICTED Specialist use only
Proguanil Hydrochloride  tablets  		RESTRICTED Specialist use only
Proguanil Hydrochloride / Atovaquone  Malarone® tablets  		RESTRICTED Specialist use only
Pyrimethamine  tablets MMC  		RESTRICTED Specialist use only
Pyrimethamine with Sulfadoxine  tablets  		RESTRICTED Specialist use only
Quinine Dihydrochloride   injection  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
Quinine Sulfate  tablets  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
5.4.2 Amoebicides		
Metronidazole (see also section 5.1.11)  		
Tinidazole Fasigyn® tablets  		RESERVED Specialist use only
Diloxanide Furoate tablets  		RESTRICTED Non-formulary micro. recommendation only
5.4.3 Trichomonacides		
Metronidazole (see also section 5.1.11)  		
5.4.4 Antigiardial drugs		
Metronidazole (see also section 5.1.11)  		

5.4.5 Leishmaniicides		
Paromomycin  tablets	  	RESTRICTED treatment of Cryptosporidiosis
Sodium Stibogluconate  injection	  	RESTRICTED treatment of Leishmaniicides
5.4.7 Drugs for toxoplasmosis		
Sulfadiazine  tablets	 	RESTRICTED treatment of toxoplasmosis micro. recommendation only
5.4.8 Drugs for pneumocystis pneumonia		
Atovaquone  oral suspension	 	RESTRICTED Specialist use only
Pentamidine Isethionate  injection	 	RESTRICTED Specialist use only

5.5 Anthelmintics		GMMMG
5.5.1 Drugs for Threadworms (pinworms, <i>Enterobius vermicularis</i>)		
Albendazole  tablets   		RESTRICTED Specialist use only
Mebendazole chewable tablets; oral suspension  		
5.5.2 Ascaricides		
Levamisole  tablets   		RESTRICTED Specialist use only
5.5.5 Schistosomicides (bilharziasis)		
Praziquantel  tablets   		RESTRICTED Schistosomicides / tapeworm
5.5.6 Filaricides		
Diethylcarbamazine  tablets   		RESTRICTED Specialist use only

Section 6: Endocrine System

Supported by the
formulary ([click here](#))



6.1 Drugs used in diabetes

6.1.1 Insulins

6.1.1.1 Short-acting insulins

6.1.1.2 Intermediate & long-acting insulins

Biphasic insulins

6.1.2 Antidiabetic drugs

6.1.2.1 Sulphonylureas

6.1.2.2 Biguanides

6.1.2.3 Other antidiabetic drugs

Alpha glucosidase inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Rapid acting insulin secretagogues (meglitinides)

Glucagon-like peptide-1 (GLP-1) receptor agonists

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Thiazolidinediones

6.1.4 Treatment of hypoglycaemia

6.1.5 Treatment of diabetic nephropathy and neuropathy

6.1.6 Diagnostic and monitoring agents for diabetes mellitus

6.2 Thyroid & antithyroid drugs

6.2.1 Thyroid hormones

6.2.2 Antithyroid drugs

6.3 Corticosteroids

6.3.1 Replacement therapy

6.3.2 Glucocorticoid therapy

6.4 Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens & HRT

6.4.1.2 Progestogens and progesterone receptor modulators

6.4.2 Male sex hormones & antagonists

6.5 Hypothalamic and pituitary hormones & anti-oestrogens

6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

6.5.2 Posterior pituitary hormones & antagonists

6.6 Drugs affecting bone metabolism

6.6.1 Calcitonin & parathyroid hormone

6.6.2 Bisphosphonates & other drugs affecting bone metabolism

6.7 Other endocrine drugs

6.7.1 Bromocriptine & other dopaminergic drugs

6.7.2 Drugs affecting gonadotrophins

6.7.3 Metyrapone

6.7.4 Somatomedins

Trust Guidelines










































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

















NICE Guidance



Safer insulin prescribing (KTT20)
 Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
 Type 1 diabetes in adults: diagnosis and management (NG17)
 Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
 Diabetic foot problems: prevention and management (NG19)
 Type 2 diabetes in adults: management (NG28)
 Heavy menstrual bleeding: assessment and management (NG88)
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
 Human growth hormone - adults (TA64)
 Diabetes (type 1) - insulin pump therapy (TA151)
 Osteoporosis - Primary Prevention (TA160)
 Osteoporosis - Secondary Prevention (TA161)
 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)
 Osteoporotic Fractures - denosumab (TA204)
 Bone metastases from solid tumours - denosumab (TA265)
 Type 2 diabetes - Dapagliflozin combination therapy (TA288)
 Diabetes (type 2) - canagliflozin (TA315)
 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
 Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
 Bisphosphonates for treating osteoporosis (TA464)
 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)
 Dapagliflozin with insulin for treating type 1 diabetes (TA597)
 Sotagliflozin with insulin for treating type 1 diabetes (TA622)
 Liraglutide for managing overweight and obesity (TA664)
 Dapagliflozin for treating chronic kidney disease (TA775)
 Romosozumab for treating severe osteoporosis (TA791)
 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)
 Somatrogen for treating growth disturbance in people 3 years and over (TA863)
 Tirzepatide for treating type 2 diabetes (TA924)
 Empagliflozin for treating chronic kidney disease (TA942)
 Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)













GMMMG Formulary














Formulary Homepage
 Chapter 6: Endocrine system (Complete)
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMMG Paediatric [Red/Amber/Green](#) Drug List




















6.1 Drugs used in diabetes		GMMMG
6.1.1 Insulins		
Insulins must ONLY be initiated by practitioners experienced in their use Insulins must be prescribed by BRAND NAME		
MHRA Drug Safety Update (Apr-15): High strength, fixed combination & biosimilar insulin products: minimising the risk of medication error		
		NICE NG3
		NICE NG17
		NICE NG18
		NICE NG19
		NICE NG28
6.1.1.1 Short-acting insulins		
Human		
Actrapid®		
Human Insulin	 	
apidra®		
Insulin Glulisine	 	
Fiasp®		
Insulin Aspart	  	
Humalog®		
Insulin Lispro	 	
Humulin R®		
 Human Insulin	  	
Humulin S®		
Human Insulin	 	
Insulin Lispro Sanofi®		
Insulin Lispro	  	
Lyumjev®		
 Insulin Lispro	  	
NovoRapid®		
Insulin Aspart	  	
Trurapi®		
 Insulin Aspart	  	
Animal		
Hypurin® Bovine Neutral		
Insulin Bovine	 	
Hypurin® Porcine Neutral		
Insulin Porcine	 	
6.1.1.2 Intermediate & long-acting insulins		
Human		
Humulin I® Insulin		
Isophane Insulin	 	
Insulatard®		
Isophane Insulin	 	
Animal		
Hypurin® Bovine Isophane		
Isophane Insulin	 	
Hypurin® Porcine Isophane		
Isophane Insulin	 	

Long-acting insulins		
Human		
Levemir®		
Insulin Detemir	 MMC BNF emc	
Lantus®		
Insulin Glargine	 MMC BNF emc	2nd line use in patients where normal basal insulins cause nocturnal hypoglycaemia
Abasaglar®		
Insulin Glargine biosimilar	 MMC BNF emc	
Toujeo®		
Insulin Glargine HIGH STRENGTH	 MMC BNF emc	
Tresiba®		
Insulin Degludec	 MMC BNF emc	RESTRICTED 3rd line after Levemir & Lantus Diabetes Consultant only
MHRA Drug Safety Update (Apr-13): Insulin degludec (Tresiba ▼): available in additional higher strength		
Animal		
Hypurin® Bovine Lente		
Insulin Zinc suspension	 BNF emc	
Biphasic insulins		
Human		
Humalog® Mix 25		
Biphasic Insulin Lispro	 BNF emc	
Humalog® Mix 50		
Biphasic Insulin Lispro	 BNF emc	
Humulin M3®		
Biphasic Isophane Insulin	 BNF emc	
Insuman® Comb 25		
Biphasic Isophane Insulin	 BNF emc	
NovoMix® 30		
Biphasic Insulin Aspart	 MMC BNF emc	
Animal		
Hypurin® Porcine 30/70 Mix Insulin		
Biphasic Isophane Insulin	 BNF emc	
6.1.2 Antidiabetic drugs		
6.1.2.1 Sulfonylureas		
Gliclazide		
tablets	 BNF emc	
Glipizide		
tablets	 BNF emc	RESTRICTED Not for initiation
6.1.2.2 Biguanides		
Metformin Hydrochloride		
 oral solution; tablets	 MMC BNF emc	
MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns		











6.1.2.3 Other antidiabetic drugs		NICE NG28
Alpha glucosidase inhibitors		
Acarbose		
tablets	 	
Dipeptidyl peptidase 4 (DPP 4) inhibitors		
MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis		
Alogliptin		
		
tablets	  	
Linagliptin		
		
tablets	  	
Saxagliptin		
		2nd line to improve glycaemic control in adults with metformin
tablets	  	
Sitagliptin		
		
tablets	  	
Rapid acting insulin secretagogues (meglitinides)		
Nateglinide		
tablets	  	2nd line
Repaglinide		
tablets	  	2nd line
Glucagon-like peptide-1 (GLP-1) receptor agonists		
MHRA Drug Safety Update (Jun-19): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued		
Dulaglutide		
		RESTRICTED 1st line weekly preparation Diabetes Consultants only
injection	  	
Exenatide		
		2nd line patients with poor glycaemic control
injection	   	
Bydureon®		
		3rd line after failure / inadequate response to oral therapy
Exenatide prolonged release (once weekly injection)	  	
Liraglutide (Victoza®)		
		2nd line to achieve glycaemic control with metformin or a sulphonylurea
6mg/mL pre-filled pen	   	PRESCRIBE BY BRAND NAME
Liraglutide (Saxenda®)		
		RESTRICTED in line with NICE TA664 PRESCRIBE BY BRAND NAME
6mg/mL pre-filled pen	   	
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
GLP-1 receptor agonists (continued)		
Lixisenatide		
		RESTRICTED 3rd line as per by GMMMG & NICE Diabetes Consultants only
injection	  	
Semaglutide		
		1st line weekly preparation
Ozempic® injection	  	
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
Semaglutide		
		RESTRICTED as per by GMMMG
Rybelsus® tablets	   	
Tirzepatide		
		RESTRICTED as per NICE / GMMMG T2DM pathway
Mounjaro® injection	   	



Sodium-glucose co-transporter 2 (SGLT2) inhibitors	
MHRA Drug Safety Update (Mar-20): SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness	
MHRA Drug Safety Update (Feb-19): SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)	
MHRA Drug Safety Update (Mar-17): SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)	
MHRA Drug Safety Update (Apr-16): SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis	
Canagliflozin tablets 	RESTRICTED in line with NICE Diabetes Consultants only
MHRA Drug Safety Update (Jun-16): Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations in trial in high CV risk patients	
Dapagliflozin Green tablets 	RESTRICTED in line with NICE
MHRA Drug Safety Update (Apr-16): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus	
Empagliflozin Green tablets 	RESTRICTED in line with NICE
Ertugliflozin tablets 	RESTRICTED in line with NICE Diabetes Consultants only
Sotagliflozin Zynquista® 200mg tablets 	RESTRICTED in line with NICE Diabetes Consultants only
Thiazolidinediones	
Pioglitazone tablets 	2nd line add-on with metformin or a sulphonylurea
MHRA Drug Safety Update (Aug-11): Pioglitazone: risk of bladder cancer	
6.1.4 Treatment of hypoglycaemia	
Glucagon 1mg injection 	
Glucose gel 40% oral gel 	
Diazoxide Green tablets 	Hyperinsulinaemic Hypoglycaemia
6.1.5 Treatment of diabetic nephropathy and neuropathy	
Diabetic nephropathy 	NICE NG3
Diabetic neuropathy  (see also section 4.7.3 Neuropathic pain)	NICE NG17
	NICE NG18
	NICE NG19
	NICE NG28
6.1.6 Diagnostic and monitoring agents for diabetes mellitus	
	

6.2 Thyroid & antithyroid drugs		GMMMG
6.2.1 Thyroid hormones		
Levothyroxine Sodium		
oral solution; tablets	 	
MHRA Drug Safety Update (May-21): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products		
Liothyronine Sodium		
Red Green	 	2nd line use (I.V. RESTRICTED to hypothyroid coma)
injection; tablets		
6.2.2 Antithyroid drugs		
Carbimazole		
tablets	 	
MHRA Drug Safety Update (Feb-19): Carbimazole: increased risk of congenital malformations; strengthened advice on contraception MHRA Drug Safety Update (Feb-19): Carbimazole: risk of acute pancreatitis		
Iodine (Aqueous Iodine Oral Solution)		
 Lugol's Iodine	 	
Potassium Iodide		
tablets	 	
Propylthiouracil		
Green	 	
tablets		

6.3 Corticosteroids		GMMMG
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
6.3.1 Replacement therapy		
Fludrocortisone		
tablets	 	
6.3.2 Glucocorticoid therapy		
Prednisolone		1st line: standard tablets If 1st line not tolerated 2nd line: dissolve standard tablets 3rd line: oral liquid 4th line: soluble tablets (££)
	 	
Dexamethasone		
	 	
Hydrocortisone		
	 	
MHRA Drug Safety Update (Dec-18): Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks		
Hydrocortisone M/R		RESTRICTED 2 nd line use in adrenal insufficiency
5mg tablets	  	
Hydrocortisone		RESTRICTED 2 nd line use in adrenal insufficiency
Green	 	
Alkindi® granules in capsules		
MHRA Drug Safety Update (Feb-21): Alkindi (granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules		
Betamethasone		RESTRICTED Specialist use only
	 	
Methylprednisolone		
	 	
MHRA Drug Safety Update (Oct-17): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy		
Triamcinolone		RESTRICTED Specialist use only
(see also section 10.1.2.2)	 	

6.4 Sex hormones		GMMMG
6.4.1 Female sex hormones and their modulators		
6.4.1.1 Oestrogens & HRT		
Conjugated oestrogens with progestogen		
Premique®		2nd line use oral (continuous combined HRT)
tablets	BNF emc	
Estradiol with Progestogen		
Elleste-Duet®		1st line use oral (sequential HRT)
tablets	BNF emc	
Femoston®		2nd line use oral (sequential HRT)
tablets	BNF emc	
Kliovance®		1st line use oral (continuous combined HRT)
tablets	MMC BNF emc	
Evorel Conti®		RESTRICTED (Continuous combined HRT) when oral contraindicated
patch	BNF emc	
Estradiol only		
Elleste Solo®		1st line use oral (oestrogen only HRT)
tablets	BNF emc	
Estradot®		RESTRICTED (Oestrogen only HRT) when oral contraindicated.
patch	BNF emc	
Evorel®		RESTRICTED Paed. Endocrine Consultants
patch	MMC BNF emc	
Ethinylestradiol, raloxifene & tibolone		
Ethinylestradiol		2 microgram tablets (unlicensed) for amenorrhoea
tablets	MMC BNF emc	
Raloxifene Hydrochloride		RESTRICTED Specialist Med. Consultant only
tablets	NICE MMC BNF emc	
Tibolone		3rd line use oral (continuous combined HRT)
tablets	BNF emc	
6.4.1.2 Progestogens and progesterone receptor modulators		
Dydrogesterone		
tablets	BNF emc	
Medroxyprogesterone Acetate		
<i>Depo-Provera®</i> 150mg/mL injection	BNF emc	
Medroxyprogesterone Acetate		
<i>Sayana Press®</i> 104mg/0.65 mL injection	MMC BNF emc	
Norethisterone		
tablets	BNF emc	
Progesterone		
Red (suppositories in IVF)		
pessaries; vaginal capsules; injection	MMC BNF emc	
Ulipristal Acetate		
Red		RESTRICTED Specialist use only uterine fibroids
<i>Esmya®</i> 5mg tablets	MMC BNF emc	
MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury		
MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment		
MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users		

6.4.2 Male sex hormones & antagonists	
Testosterone & Esters	
Oral	
Testosterone Green Amber	
injection & implants only	 
Transdermal preparations	
Androstanolone (aka Dihydrotestosterone (DHT))	RESTRICTED Specialist use only - 3 rd line
Andractim® 2.5% gel	MMC  
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure	
Testosterone	RESTRICTED Specialist use only
Tostran® 2% gel	MMC  
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure	
Anti-androgens	
Cyproterone Acetate Green	
tablets (see also section 8.3.4.2)	 
Finasteride Amber	
tablets	 
MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts	

6.5 Hypothalamic & pituitary hormones & anti-oestrogens		GMMMG
6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens		
Anti-oestrogens		
Clomifene Citrate		
Red		
tablets	BNF emc	
Anterior pituitary hormones (Corticotrophins)		
Tetracosactide		
Red		RESTRICTED test for adrenocortical insufficiency
injection	BNF emc	
Corticotropin releasing hormone		
Red		RESTRICTED Specialist use only
injection	BNF emc	
Anterior pituitary hormones (Gonadotrophins)		
Human Chorionic Gonadotrophin (hCG)		
Red		RESTRICTED Specialist use only
Zivafert® injection	MMC BNF emc	
Recombinant human follicle stimulating hormone (r-hFSH)		
Red		RESTRICTED Specialist use only
Ovaleap® injection	MMC BNF emc	
Anterior pituitary hormones (Growth Hormone)		
Somatropin		
Red Amber ££		RESTRICTED as per NICE
injection	PbR X NICE MMC BNF emc	
Somatogon		
Red ££		RESTRICTED as per NICE
Ngenla® injection	PbR X NICE MMC BNF emc	
Growth hormone for children		
		Amber
Growth hormone for primary and secondary hypopituitarism		
		Green
Growth hormone for adults except in proven primary and secondary hypopituitarism		
		Red
Anterior pituitary hormones (Growth Hormone receptor antagonists)		
Pegvisomant		
Red ££		RESTRICTED acromegaly on named patient basis NOT STOCKED
injection	PbR X MMC BNF blueveq emc	
Hypothalamic hormones		
Gonadorelin (GnRH; LHRH)		
Red		RESTRICTED Specialist use only
injection	BNF emc	
Protirelin (TRH)		
Red		RESTRICTED Specialist use only
injection	BNF emc	
6.5.2 Posterior pituitary hormones & antagonists		
Desmopressin		
		RESTRICTED Haematology Consultants only
injection; oral lyophilisates; nasal spray; solution; tablets (see also section 7.4.2)	MMC BNF emc	
Terlipressin Acetate		
		RESTRICTED oesophageal varices / HRS-AKI
injection	MMC BNF emc	
MHRA Drug Safety Update (Mar-23): Terlipressin: new recommendations to reduce risks of respiratory failure & septic shock in patients with type 1 hepatorenal syndrome		
Tolvaptan		
Red ££		RESTRICTED Adult. Endocrine / Renal Consultant only
tablets	PbR X NICE MMC BNF emc	
Vasopressin		
		RESTRICTED pituitary diabetes insipidus
injection	BNF emc	
Antidiuretic hormone antagonists		
Demeclocycline Hydrochloride		
Red		RESTRICTED SIADH only
capsules (see also section 5.1.3)	MMC BNF emc	

6.6 Drugs affecting bone metabolism		GMMMG
6.6.1 Calcitonin & parathyroid hormone		
Calcitonin (salmon) / Salcatonin (Miacalcic®)		RESTRICTED osteoporosis patients with acute fracture pain.
injection	MMC BNF emc	
MHRA Drug Safety Update (Aug-12): Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.		
Parathyroid hormone		RESTRICTED postmenopausal osteoporosis if failure or non-compliance with bisphosphonates
Red		
injection	PbR X MMC BNF emc	
Teriparatide (Forsteo®)		RESTRICTED as per NICE/NHSE
Red		
250 micrograms / mL injection	PbR X NICE MMC BNF emc	Paeds. see decision tables
Teriparatide (Movymia®)		RESTRICTED as per forsteo for new patients
Red		
250 micrograms / mL injection	PbR X NICE MMC BNF emc	NHS England
6.6.2 Bisphosphonates & other drugs affecting bone metabolism		
MHRA Guidance (Dec-14): Bisphosphonates: use and safety		
MHRA Drug Safety Update (Dec-15): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jun-11): Bisphosphonates: atypical femoral fractures		
MHRA Drug Safety Update (Nov-09): Bisphosphonates: osteonecrosis of the jaw		
Alendronic Acid		1st line use
tablets	NICE MMC BNF emc	
Risedronate Sodium		2nd line Osteoporosis & Paget's disease
tablets	NICE MMC BNF emc	
Strontium Ranelate		3rd line osteoporosis patients unable to take bisphosphonates
Red		
oral suspension	MMC BNF emc	
Ibandronic Acid		RESTRICTED monthly treatment when daily/weekly dosing contraindicated; NICE TA464
Red injection		
tablets; injection	NICE MMC BNF emc	
Denosumab		RESTRICTED specialist use / NICE TA204
Amber		
Prolia® injection	NICE MMC BNF emc	
MHRA Drug Safety Update (May-22): Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia		
MHRA Drug Safety Update (Aug-20): Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment		
MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk		
Denosumab		RESTRICTED specialist use / NICE TA265
Red		
Xgeva® injection	NICE MMC BNF emc	
MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for advanced malignancies involving bone: study data show new 1ry malignancies reported more frequently...		
MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation		
MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk		
Zoledronic Acid		RESTRICTED see decision tables; also NICE TA464
Red		
infusion	NICE MMC BNF emc	
Burosumab		RESTRICTED specialist use only XLH / TIO
Red		
infusion	NICE MMC BNF emc	
Romosozumab		RESTRICTED specialist use NICE TA791
Red		
Evenity® injection	NICE MMC BNF emc	

6.7 Other endocrine drugs		GMMMG
6.7.1 Bromocriptine & other dopaminergic drugs		
Bromocriptine		
1mg; 2.5mg tablets	MMC BNF emc	
Cabergoline		RESTRICTED Hyperprolactinaemia
500 microgram tablets	BNF emc	
6.7.2 Drugs affecting gonadotrophins		
Danazol		
capsules	BNF emc	
Buserelin		RESTRICTED IVF
Red		
injection (see also section 8.3.4.2)	MMC BNF emc	
Buserelin Acetate		RESTRICTED adult haem-oncology patients
Red		
Suprecur® nasal spray	MMC BNF emc	
Goserelin		
Amber Red		
implant (also section 8.3.4.2)	BNF emc	
Leuprorelin Acetate		
Amber Red		
injection (also section 8.3.4.2)	MMC BNF emc	
Triptorelin		RESTRICTED
Amber Red		
injection (also section 8.3.4.2)	MMC BNF emc	
Cetrorelix acetate		RESTRICTED IVF
Red		
injection	MMC BNF emc	
Ganirelix		RESTRICTED IVF
Red		
injection	MMC BNF emc	
Relugolix with estradiol & norethisterone acetate		RESTRICTED specialist use NICE TA832
Green		
Ryeqo® 40mg/1mg/0.5mg tablets	NICE MMC BNF emc	
Goserelin/Leuprorelin - Licensed Indications (Pre-op management prior to endometrial ablation/fibroid surgery)		Amber
Goserelin/Leuprorelin/Triptorelin - Licensed Indications (Prostate cancer for all and breast cancer for Goserelin)		Amber
Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)		Red
Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)		Red
6.7.3 Metyrapone		
Metyrapone		RESTRICTED Specialist use only
Red		
250mg capsules	BNF emc	
6.7.4 Somatomedins		
Mecasermin		RESTRICTED Specialist use only
££		
10mg/mL injection	PbR X BNF emc blueTEQ	
MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia		

Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the
formulary ([click here](#))



7.1 Drugs used in Obstetrics

7.1.1 Prostaglandins & oxytocics

7.1.1.1 Ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal & vulval conditions

7.2.1 Preparations for vaginal & vulval changes

7.2.2 Vaginal & vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone

Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary, enuresis & incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations & urological surgery

7.4.5 Drugs for erectile dysfunction

7.4.6 Drugs for premature ejaculation

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

NICE Guidance


































Long-acting reversible contraception (CG30)
Lower urinary tract symptoms (CG97)
Nocturnal enuresis - the management of bedwetting in children and young people (CG111)
Antenatal and postnatal mental health: clinical management and service guidance (CG192)
Heavy menstrual bleeding: assessment and management (NG88)
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
Caesarean birth (NG192)
Antenatal care for uncomplicated pregnancies (NG201)
Inducing labour (NG207)
Intrapartum care for healthy women and babies (NG235)
Overactive bladder - mirabegron (TA290)
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

























GMMM Formulary

Formulary Homepage
Chapter 7: Obstetrics, gynaecology & urinary tract disorders (Complete)
GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List


















7.1 Drugs used in Obstetrics		GMMMG
7.1.1 Prostaglandins & oxytocics		NICE NG207
Carbetocin Red		RESTRICTED Obs & Gynae Consultants only
<i>Pabal</i> ® injection	MMC BNF emc	
Carboprost Red		
injection	BNF emc	
Ergometrine Maleate Red		
injection	BNF emc	
Gemeprost Red		
pessaries	BNF emc	
Oxytocin Red		
injection	BNF emc	
Dinoprostone Red		RESTRICTED Obs & Gynae Consultants only
injection; pessaries; vaginal gel; vaginal tablet	MMC BNF emc	
7.1.1.1 Drugs affecting the ductus arteriosus		(see also BNFC)
Maintenance of patency		
Alprostadil Red		
<i>Prostin VR</i> ® infusion	MMC BNF emc	
Closure of the ductus arteriosus		
Indometacin Red		
injection	BNF emc	
7.1.2 Mifepristone		
Mifepristone Red		
tablets	BNF emc	
7.1.3 Myometrial relaxants		
Atosiban		
Atosiban Red		RESTRICTED Obs & Gynae Consultants only
infusion; injection	MMC BNF emc	
Beta₂ agonists		
Salbutamol Red		
injection (see also section 3.1.1.1)	BNF emc	
Terbutaline Sulfate Red		
injection (see also section 3.1.1.1)	BNF emc	





















7.2 Treatment of vaginal & vulval conditions		GMMMG
7.2.1 Preparations for vaginal & vulval changes		
Oestrogens, topical		
Estradiol		
Vagifem® 10 microgram pessaries	BNF emc	
Estriol		
0.01% cream	BNF emc	
Estradiol vaginal ring		RESTRICTED Obs & Gynae Consultants only
Estring® 7.5 microgram / 24 hours ring	BNF emc	
7.2.2 Vaginal & vulval infections		
Preparations for vaginal & vulval candidiasis		
Clotrimazole		
cream; pessaries	BNF emc	
Miconazole		
vaginal cream	BNF emc	
Preparations for other vaginal infections		
Clindamycin		
2% vaginal cream	BNF emc	
Nystatin		
vaginal cream; pessaries	BNF emc	
Metronidazole		RESTRICTED Obs & Gynae Consultants only
Zidoval® 0.75% vaginal gel	MMC BNF emc	
Boric acid		RESTRICTED specialist use only for vulvovaginal candidiasis
Red U vaginal pessary	MMC emc	

7.3 Contraceptives		GMMMG
MHRA Drug Safety Update (Mar-19): Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?		
7.3.1 Combined hormonal contraceptives		NICE CG30
MHRA Drug Safety Update (Mar-14): Combined hormonal contraceptives: risk of venous thromboembolism		
Ethinylestradiol with Desogestrel		
Munalea®		2nd line due to increased risk of VTE
tablets	 	
Mercilon®		2nd line due to increased risk of VTE
tablets	 	
Ethinylestradiol with Gestodene		
Femodene®		2nd line due to increased risk of VTE
tablets	 	
Aidulan®		2nd line due to increased risk of VTE
20microgram / 75 microgram tablets	 	
Ethinylestradiol with Levonorgestrel		NICE NG88
TriRegol®		
tablets	 	
Microgynon 30®		
tablets	 	
Ovranette®		
tablets	 	
Ethinylestradiol with Norelgestromin		
Evra®		RESTRICTED in line with GMMMG and SmPC
patch	  	
Ethinylestradiol with Norethisterone		
Loestrin 20®		
tablets	 	
Loestrin 30®		
tablets	 	
Norimin®		
tablets	 	
Ethinylestradiol with Norgestimate		
Cilest®		
tablets	 	
Mestranol with Norethisterone		
Norinyl-1®		2nd line due to increased risk of VTE
tablets	 	
7.3.2 Progestogen-only contraceptives		
7.3.2.1 Oral progestogen-only contraceptives		
Desogestrel		
Cerazette® 75 microgram tablets	 	
Levonorgestrel		
Norgeston® 35 microgram tablets	 	
Norethisterone		
Noriday® 350 microgram tablets	 	

7.3.2.2 Parenteral progestogen-only contraceptives	
Injectable preparations	
Medroxyprogesterone Acetate	
<i>Depo-Provera</i> ® 150mg/mL intramuscular injection	 
Medroxyprogesterone Acetate	
<i>Sayana Press</i> ® 160mg/mL subcutaneous injection	  
Implants	
Etonogestrel	
<i>Nexplanon</i> ® 68mg subdermal implant	  
MHRA Drug Safety Update (Feb-20): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury & implant migration MHRA Drug Safety Update (Jun-16): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung	
7.3.2.3 Intra-uterine progestogen-only device	
Levonorgestrel	
<i>Mirena</i> ® 20micrograms/24 hours IUD	 
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
Levonorgestrel	RESTRICTED Specialist use Tertiary Services only
<i>Jaydess</i> ® 13.5mg IUD	  
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
Levonorgestrel	RESTRICTED Specialist use Tertiary Services only
<i>Kyleena</i> ® 19.5mg IUD	  
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
7.3.5 Emergency contraception	
Levonorgestrel	
<i>Levonelle</i> ® 1500 microgram tablets	 
MHRA Drug Safety Update (Sep-16): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers... MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women	
Ulipristal Acetate	RESTRICTED emergency contraception (SARC)
<i>ellaOne</i> ® 30mg tablets	  
MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women	
Assisted Reproductive Technology (ART) cycles	
Progesterone	RESTRICTED ART cycles 2 nd line
<i>Utrogestan</i> ® 100mg; 200mg vaginal capsules	  

7.4 Drugs for genito-urinary disorders		GMMMG
7.4.1 Drugs for urinary retention		NICE CG97
Alpha blockers		NICE CG111
		NICE NG123
Alfuzosin Hydrochloride		
tablets	BNF emc	
Tamsulosin Hydrochloride		
capsules, tablets	MMC BNF emc	1 st line
7.4.2 Drugs for urinary, enuresis & incontinence		
Urinary incontinence		NICE NG123
Oxybutynin Hydrochloride		
oral solution; patch; tablets	NICE MMC BNF emc	1 st line in OAB
Darifenacin Hydrobromide		
tablets	NICE MMC BNF emc	1 st line in OAB
Tolterodine Tartrate		
capsules, tablets	NICE MMC BNF emc	1 st line in OAB
Solifenacin Succinate		
tablets	MMC BNF emc	2 nd line in OAB patients failed / intolerant to oxybutynin
Duloxetine		
capsules	MMC BNF emc	
Tropium Chloride		
capsules; tablets	MMC BNF emc	RESTRICTED 1 ^{RY} Care referral only
Mirabegron		
tablets	NICE MMC BNF emc	RESTRICTED in line with TA290 / Paeds 3 rd line
MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and cardiac events		
Nocturnal enuresis		
Amitriptyline		
oral solution; tablets (see also section 4.3.1)	BNF emc	
Desmopressin		
injection; nasal spray; tablets (see also section 6.5.2)	MMC BNF emc	RESTRICTED Haematology Consultants only
7.4.3 Drugs used in urological pain		
Methionine		
tablets	BNF emc	RESTRICTED resistant calcium phosphate lithiasis eau European Association of Urology
Pentosan polysulfate sodium		
capsules	NICE MMC BNF emc	RESTRICTED Urology Cons. in line with NICE
MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy		
Potassium Citrate		
tablets	BNF emc	

7.4.4 Bladder instillations & urological surgery		
Chlorhexidine 0.02% irrigation solution	 	
Dimethyl Sulfoxide  50% solution	 	
Glycine 1.5% irrigation solution	 	
Sodium Chloride 0.9% irrigation solution	 	
Sodium Citrate 3% irrigation solution	 	
Sodium Hyaluronate  Cystistat® 40mg/50mL bladder instillation	 	RESTRICTED Urology Consultants only
Sodium Hyaluronate with sodium chondroitin sulfate  iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	 	RESTRICTED Urology Consultants only

7.4.5 Drugs for erectile dysfunction		
Alprostadil Green	   	RESTRICTED Urology Consultants only
cream; injection; urethral sticks		
Aviptadil with Phentolamine Green	   	RESTRICTED Urology Consultants only
<i>Invicorp</i> ® injection		
Sildenafil Green or Red PAH	   	RESTRICTED 1 ^{RY} Care referral only
injection; oral suspension; tablets (see also section 2.5.1)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
Tadalafil Green or Red PAH	   	RESTRICTED 1 ^{RY} Care referral only
tablets (see also section 2.5.1)		
Vardenafil	   	RESTRICTED 1 ^{RY} Care referral only
tablets		
7.4.6 Drugs for premature ejaculation		
NOT STOCKED		NOT STOCKED

Section 8: Malignant disease & immunosuppression

Supported by the
formulary ([click here](#))



8.1 Cytotoxic drugs

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
 - 8.3.4.1 Breast Cancer
 - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
 - 8.3.4.3 Somatostatin analogues

8.4 Miscellaneous preparations

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

[Non-formulary Conversion Table](#)

NICE Guidance

Advanced breast cancer (CG81)
 Familial breast cancer (CG164)
 Hepatitis B (chronic) (CG165)
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
 Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)
 Early and locally advanced breast cancer: diagnosis and management (NG101)
 Lung cancer: diagnosis and management (NG122)
 Prostate cancer: diagnosis and management (NG131)
 Colorectal cancer (NG151)
 Temozolomide for malignant glioma (TA23)
 Leukaemia (lymphocytic) - fludarabine (TA29)
 Trastuzumab for advanced breast cancer (TA34)
 Paclitaxel for ovarian cancer (TA55)
 Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)
 Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)
 Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)
 Hepatitis B: Chronic (TA96) (partially updated by CG165)
 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)
 Docetaxel for prostate cancer (hormone-refractory) (TA101)
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)
 Paclitaxel for early breast cancer (TA108)
 Docetaxel for early breast cancer (TA109)
 Gemcitabine for Breast Cancer (TA116)
 Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)
 Leukaemia (lymphocytic) - fludarabine (TA119)
 Carmustine implants and temozolomide for glioma (newly diagnosed & high grade) (TA121)
 Pemetrexed for lung cancer (non small cell) (TA124)
 Multiple sclerosis - natalizumab (TA127)
 Bortezomib for relapsed multiple myeloma (TA129)
 Pemetrexed for mesothelioma (TA135)
 Rituximab for follicular non-Hodgkin's lymphoma (TA137)
 Head and neck cancer - cetuximab (TA145)
 Renal cell carcinoma - sunitinib (TA169)
 Lenalidomide - multiple myeloma (TA171)
 Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
 Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)
 Renal Cell Carcinoma (TA178)
 Sunitinib for gastrointestinal stromal tumours (TA179)
 Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)
 Cervical cancer (recurrent) - topotecan (TA183)
 Lung cancer (small cell) - topotecan (TA184)
 Soft tissue sarcoma - trabectedin (TA185)
 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)
 Gastric cancer (advanced) - capecitabine (TA191)
 Lung cancer (non-small-cell, first line) - gefitinib (TA192)
 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)
 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)
 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)
 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)
 Colorectal cancer (metastatic) - bevacizumab (TA212)
 Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)
 Renal cell carcinoma (1st line metastatic) - pazopanib (TA215)
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
 Myelodysplastic syndrome - azacitidine (TA218)
 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)
 Multiple myeloma (1st line) - bortezomib and thalidomide (TA228)
 Osteosarcoma - mifamurtide (TA235)
 Follicular lymphoma - rituximab (review TA110) (TA243)
 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)
 Melanoma (stage III or IV) - ipilimumab (TA268)
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)
 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
 Bevacizumab in combination with paclitaxel & carboplatin for 1st line treatment of advanced ovarian cancer (TA284)
 Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)
 Multiple sclerosis (relapsing) - teriflunomide (TA303)
 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)
 Multiple myeloma - bortezomib (induction therapy) (TA311)

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)
 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)
 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)
 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)
 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)
 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)
 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
 Idelalisib for treating chronic lymphocytic leukaemia (TA359)
 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
 Bortezomib for previously untreated mantle cell lymphoma (TA370)
 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)
 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
 Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
 Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
 Olaparib for ovarian, fallopian tube and peritoneal cancer (TA381)
 Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)
 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
 Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)
 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)
 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
 Bosutinib for previously treated chronic myeloid leukaemia (TA401)
 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)
 Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
 Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)
 Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
 Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
 Nivolumab for previously treated advanced renal cell carcinoma (TA417)
 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)
 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)
 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
 Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
 Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)
 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)
 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)
 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
 Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)
 Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)
 Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)
 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
 Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)
 Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)
 Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
 Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)
 Ibrutinib for treating Waldenström's macroglobulinaemia (TA491)
 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)
 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)
 Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)
 Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)
 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
 Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
 Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
 Tivozanib for treating advanced renal cell carcinoma (TA512)
 Obinutuzumab for untreated advanced follicular lymphoma (TA513)
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)
 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)
 Cabozantinib for treating medullary thyroid cancer (TA516)
 Avelumab for treating metastatic Merkel cell carcinoma (TA517)
 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)
 Midostaurin for untreated acute myeloid leukaemia (TA523)
 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)
 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)
 Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)
 Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)
 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)
 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
 Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
 Dinutuximab beta for treating neuroblastoma (TA538)
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)
 Cabozantinib for untreated advanced renal cell carcinoma (TA542)
 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)
 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
 Padeliporfin for untreated localised prostate cancer (TA546)
 Vandetanib for treating medullary thyroid cancer (TA550)
 Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)
 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
 Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)
 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)
 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)
 Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
 Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
 Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)
 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)
 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)
 Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)
 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
 Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)
 Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
 Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
 Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
 Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)
 Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)
 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
 Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)
 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)
 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
 Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)
 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)
 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemtrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)
 Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)
 Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
 Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)
 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
 Ofatumumab for treating relapsing multiple sclerosis (TA699)
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)
 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
 Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)
 Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
 Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)
 Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)
 Midostaurin for treating advanced systemic mastocytosis (TA728)
 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)
 Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)
 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)
 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
 Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)
 Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)
 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)
 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
 Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
 Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)
 Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)
 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
 Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)
 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)
 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)
 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
 Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)
 Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)
 Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)
 Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
 Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)
 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)
 Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)
 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)
 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)
 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)
 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)
 Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
 Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
 Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)
 Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)
 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)
 Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)
 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)
 Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)
 Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
 Regorafenib for previously treated metastatic colorectal cancer (TA866)
 Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia... (TA893)
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)
Ruxolitinib for treating polycythaemia vera (TA921)
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)
Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)
Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

GMMMG Formulary










































































































Formulary Homepage

































































































































































Chapter 8: Malignant disease & immunosuppression (Complete)









GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Paediatric **Red/Amber/Green** Drug List

8.1 Cytotoxic drugs		GMMMG
8.1 Cytotoxic drugs		
Dexrazoxane		
<p>Red </p> <p>infusion </p>		RESTRICTED Haematology Consultants only
Folinic Acid (as calcium folinate)		
<p>Red</p> <p>tablets; injection </p>		RESTRICTED Haematology Consultants only
Mesna		
<p>Red</p> <p>tablets; injection </p>		RESTRICTED Haematology Consultants only
Palifermin		
<p>Red</p> <p>injection </p>		RESTRICTED Haematology Consultants only
8.1.1 Alkylating drugs		
Busulfan		
<p>Red</p> <p>infusion </p>		RESTRICTED Haematology Consultants only
Bendamustine		
<p>Red </p> <p>infusion </p> <p>MHRA Drug Safety Update (Mar-21): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) MHRA Drug Safety Update (Jul-17): Bendamustine: increased mortality in recent clinical studies in off-label use; monitor for opportunistic infections, HBV reactivation</p>		RESTRICTED Haematology Consultants only
Carmustine		
<p>Red</p> <p>infusion </p>		RESTRICTED Haematology Consultants only
Chlorambucil		
<p>Red</p> <p>tablets </p>		RESTRICTED Haematology Consultants only
Cyclophosphamide		
<p>Red</p> <p>injection; tablets; oral suspension </p>		RESTRICTED Haematology Consultants only
Ifosfamide		
<p>Red</p> <p>injection </p>		RESTRICTED Haematology Consultants only
Lomustine		
<p>Red</p> <p>capsules </p>		RESTRICTED Haematology Consultants only
Melphalan		
<p>Red</p> <p>injection; tablets </p>		RESTRICTED Haematology Consultants only
Treosulfan		
<p>Red</p> <p>injection </p>		RESTRICTED Adult Haematology / Paediatric Haematology / Oncology
8.1.2 Anthracyclines & other cytotoxic antibiotics		
Bleomycin		
<p>Red</p> <p>injection </p>		RESTRICTED Haematology Consultants only
Daunorubicin		
<p>Red</p> <p>injection </p>		RESTRICTED Haematology Consultants only
Doxorubicin Hydrochloride		
<p>Red </p> <p>infusion; injection </p>		RESTRICTED Haematology Consultants only
Idarubicin		
<p>Red</p> <p>capsules; injection </p>		RESTRICTED Haematology Consultants only
Mitomycin		
<p>Red</p> <p>injection </p>		RESTRICTED Consultants only
Mitoxantrone		
<p>Red</p> <p>infusion </p>		RESTRICTED Haematology Consultants only
Pixantrone		
<p>Red </p> <p>infusion </p>		RESTRICTED Haematology Consultants only



















8.1.3 Antimetabolites		NICE CG81
		NICE NG151
Azacitidine   injection     		RESTRICTED Haematology Consultants only
Capecitabine  tablets    		
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity		
MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment		
Cladribine   infusion; injection      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury		
MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected		
Clofarabine   infusion    		RESTRICTED Haematology Consultants only
Cytarabine  injection   		RESTRICTED Haematology Consultants only
Cytarabine / Daunorubicin   Vyxeos® 100mg/44mg infusion      		RESTRICTED Haematology Consultants only
Fludarabine  injection; tablets   		RESTRICTED Haematology Consultants only
Fluorouracil  injection    		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity		
Gemcitabine  infusion    		RESTRICTED Haematology Consultants only
Mercaptopurine  oral suspension; tablets (see also section 1.5.3)  		
Methotrexate  infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3)   		
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions		
Pemetrexed   injection      		RESTRICTED Respiratory Consultants only in line with TA402
8.1.4 Vinca alkaloids & etoposide		
Etoposide  capsules; infusion  		RESTRICTED Haematology Consultants only
Vinblastine Sulfate  injection  		RESTRICTED Haematology Consultants only
Vincristine Sulfate  injection  		RESTRICTED Haematology Consultants only
8.1.5 Other antineoplastic drugs		
Acalabrutinib   infusion      		RESTRICTED Haematology Consultants only
Arsenic Trioxide   infusion      		RESTRICTED Haem. Consultants only / also in line with NICE TA526
Asciminib   Scemblis® 20mg/40mg tablets      		RESTRICTED Haem. Consultants in line with NICE TA813
Asparaginase e-coli  infusion   		RESTRICTED Haematology Consultants only

Autologous anti-CD19-transduced CD3+ cells   Tecartus® infusion      	RESTRICTED Haem. Consultants in line with NICE TA677
Axicabtagene ciloleucel   Yescarta® infusion      	RESTRICTED in line with NICE TA872
Bevacizumab   Avastin® 100mg in 4mL vial     	RESTRICTED Haematology Consultants only
Bortezomib   injection      	RESTRICTED Haematology Consultants only
Brentuximab Vedotin   infusion      	RESTRICTED Haematology Consultants only
Brexucabtagene autoleucel   Tecartus® infusion     	RESTRICTED Haem. Consultants only in line with CDF
Cabozantinib   tablets; capsules      	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Carfilzomib   infusion      	RESTRICTED Haematology Consultants only in line with NICE
Ceritinib   capsules      	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Cetuximab   infusion      	RESTRICTED Haematology Consultants only in line with NICE
Crisantaspase   injection  	RESTRICTED Haematology Consultants only
Dacarbazine  injection  	RESTRICTED Haematology Consultants only
Durvalumab   infusion      	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Entrectinib   injection      	RESTRICTED Specialist Consultant use only in line with NICE
Eribulin   injection      	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Erlotinib   tablets      	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Everolimus   tablets      	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Hydroxycarbamide  capsules; tablets (see below)  	RESTRICTED Haematology Consultants only
Ipilimumab   infusion      	RESTRICTED Dermatology Consultants only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation	
Ixazomib   capsules      	RESTRICTED Haematology Consultants only in line with NICE
Lorlatinib   Lorviqua® tablets      	RESTRICTED Respiratory Consultants only in line with NICE
Midostaurin   Rydapt® capsules      	RESTRICTED Haematology Consultants only in line with NICE
































































































<p>Nintedanib esilate   Ofev® capsules      </p>	<p>RESTRICTED Respiratory Consultants only in line with NICE</p>
<p>Nintedanib esilate   Vargatef® capsules      </p>	<p>RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED</p>
<p>Niraparib   Zejula® capsules      </p> <p>MHRA Drug Safety Update (Oct-20): Niraparib (Zejula▼): reports of severe hypertension & PRES, particularly in early treatment</p>	<p>RESTRICTED Gynaecology Consultants only in line with NICE NOT STOCKED</p>
<p>Panitumumab   infusion      </p>	<p>RESTRICTED Haematology Consultants only in line with NICE NOT STOCKED</p>
<p>Panobinostat   capsules     </p>	<p>RESTRICTED Haematology Consultants only in line with TA380</p>
<p>Pegaspargase   Oncaspar® injection     </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>Pembrolizumab   infusion      </p> <p>MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection</p>	<p>RESTRICTED Specialist use only in line with NICE / NHSE</p>
<p>Pentostatin   infusion  </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>Pertuzumab   infusion      </p>	<p>RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED</p>
<p>Procarbazine   capsules  </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>Sacituzumab govitecan   Trodelvy® infusion      </p>	<p>RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED</p>
<p>Sorafenib   tablets      </p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p>	<p>RESTRICTED Haematology Consultants only in line NICE / NHSE</p>
<p>Sotorasib   Lumykras® tablets      </p>	<p>RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781</p>
<p>Talimogene Laherparepvec   injection      </p>	<p>RESTRICTED Dermatology Consultants only in line with TA410</p>
<p>Tisagenlecleucel   Kymriah® infusion      </p>	<p>RESTRICTED in line with CDF criteria and NICE TA554 / TA567</p>
<p>Trastuzumab   infusion; injection      </p>	<p>RESTRICTED Specialist use only in line with NICE</p>
<p>Venetoclax   tablets      </p> <p>MHRA Drug Safety Update (Dec-21): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)</p>	<p>RESTRICTED Specialist use only in line with NICE / NHSE</p>
<p>Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications</p>	<p></p>
<p>Hydroxycarbamide - Sickle Cell Disease</p>	<p></p>
<p>Hydroxycarbamide - Chemotherapy</p>	<p></p>
<p>Platinum compounds</p>	
<p>Cisplatin  injection  </p>	<p>RESTRICTED Haematology Consultants only</p>

Protein kinase inhibitors		
Abemaciclib   Verzenios® tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases		
Alectinib   Alecensa® capsules      		RESTRICTED Specialist use only in line with NICE TA536 NOT STOCKED
Alpelisib   Piqray® tablets      		RESTRICTED Specialist use only in line with NICE TA816 NOT STOCKED
Axitinib   Inlyta® tablets      		RESTRICTED Haematology Consultants only in line with NICE NOT STOCKED
Bosutinib   Bosulif® tablets      		RESTRICTED Haematology Consultants only in line with TA401
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
Brigatinib   Alunbrig® tablets      		RESTRICTED Specialist use only in line with NICE
Crizotinib   Xalkori® capsules      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Dabrafenib   Tafinlar® capsules      		RESTRICTED Specialist use only in line with NICE
Dacomitinib   Vizimpro® tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Dasatinib   Sprycel® tablets; powder for oral suspension      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
Encorafenib   Braftovi® capsules      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Fedratinib   Inrebic® capsules      		RESTRICTED Haematology Consultants only
Gefitinib   tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Gemtuzumab ozogamicin   Mylotarg® injection      		RESTRICTED Haematology Consultants only
Gilteritinib fumarate   Xospata® tablets      		RESTRICTED Haematology Consultants only
Ibrutinib   Imbruvica® capsules; tablets      		RESTRICTED Haem. Consultants only / also in line with NICE
MHRA Drug Safety Update (Nov-22): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations		
MHRA Drug Safety Update (Aug-17): Ibrutinib (Imbruvica ▼): reports of ventricular tachyarrhythmia; risk of HBV B reactivation & opportunistic infections		
Idelalisib   Zydelig® tablets      		RESTRICTED Specialist use only in line with NICE TA359
MHRA Drug Safety Update (Sep-16): Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection		
Imatinib   tablets      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
Inotuzumab ozogamicin   Besponsa® 1mg solution for infusion      		RESTRICTED Haematology Consultants only
Larotrectinib sulfate   Vitravki® 20mg/mL oral solution      		RESTRICTED Consultants only in line with NICE
















Lenvatinib   <i>Kisplyx</i> ® capsules      	RESTRICTED Specialist use only in line with NICE TA498 / 858 NOT STOCKED
Lenvatinib   <i>Lenvima</i> ® capsules      	RESTRICTED Specialist use only in line with NICE TA535 / 551 NOT STOCKED
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
Loncastuximab tesirine   <i>Zynlonta</i> ® infusion      	RESTRICTED Specialist use only in line with NICE TA947
Mobocertinib   <i>Exkivity</i> ® capsules      	RESTRICTED Specialist use only
Neratinib   <i>Nerlynx</i> ® tablets      	RESTRICTED Specialist use only in line with NICE TA612 NOT STOCKED
Nilotinib   <i>Tasigna</i> ® capsules      	RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
Osimertinib   <i>Tagrisso</i> ® tablets      	RESTRICTED Specialist use only in line with NICE
Palbociclib   <i>Ibrance</i> ® capsules      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
Ponatinib   <i>Iclusig</i> ® tablets      	RESTRICTED Specialist use only in line with NICE TA451
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome	
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events	
Regorafenib   <i>Stivarga</i> ® 40mg tablets      	RESTRICTED Specialist use only in line with NICE TA488 / TA555 NOT STOCKED
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
Ribociclib   <i>Kisqali</i> ® 200mg tablets      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
Ruxolitinib   <i>Jakavi</i> ® tablets      	RESTRICTED Specialist use only in line with NICE / NHSE
Selpercatinib   <i>Retsevmo</i> ® capsules      	RESTRICTED Specialist use only in line with NICE
Selumetinib   <i>Koselugo</i> ® capsules      	RESTRICTED Specialist use only for NF1 in line with NICE HST20
Sunitinib   <i>Sutent</i> ® capsules      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
Tepotinib   <i>Tepmetko</i> ® 225mg tablets      	RESTRICTED Specialist use in line with NICE / NHSE
Tivozanib   <i>Fotivda</i> ® capsules      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
Trametinib   <i>Mekinist</i> ® tablets      	RESTRICTED Specialist use only in line with NICE TA396 NOT STOCKED
Zanubrutinib   <i>Brukinsa</i> ® 80mg hard capsules      	RESTRICTED Specialist use in line with NICE / NHSE

Topoisomerase I inhibitors		
Tretinoin  capsules  		RESTRICTED Haematology Consultants only
Taxanes		
Paclitaxel  Infusion      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error		
Cabazitaxel   Jevtana® Infusion      		RESTRICTED Haematology Consultants only

















































8.2 Drugs affecting the immune response		GMMMG
8.2.1 Antiproliferative immunosuppressants		
Azathioprine Amber tablets; oral solution; injection (see also sections 1.5.3; 10.1.3 & 13.5.3)	PbR X NICE MMC BNF emc	
Mycophenolate Mofetil Amber capsules; tablets; oral suspension; infusion MHRA Drug Safety Update (Feb-18): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients MHRA Drug Safety Update (Dec-15): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men MHRA Drug Safety Update (Jan-15): Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis	PbR X NICE MMC BNF emc	
Belatacept U ££ Nulojix® 25mg/mL injection	PbR X NICE MMC BNF emc	RESTRICTED Renal Transplant Consultants only NOT STOCKED
8.2.2 Corticosteroids & other immunosuppressants		
Antithymocyte immunoglobulin (Rabbit) ££ injection	PbR X NICE BNF emc	
Basiliximab Red ££ Simlect® injection	PbR X NICE MMC BNF emc	RESTRICTED Renal Consultants only
Ciclosporin (Deximune®) & I.V. (Sandimmun®) Amber ££ capsules; oral solution; injection	PbR X NICE MMC BNF emc	
Sirolimus Amber ££ oral solution; tablets	PbR X NICE MMC BNF emc	RESTRICTED Renal Consultants only
Tacrolimus Amber capsules; tablets; ointment; oral suspension; infusion; sachets	PbR X NICE MMC BNF emc	
Voclosporin Red ££ capsules	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist use only in line with NICE
Immunosuppressants - e.g. ciclosporin, tacrolimus, sirolimus Amber Red if no SCP		
8.2.3 Anti-lymphocyte monoclonal antibodies		
Alemtuzumab Red ££ Lemtrada® infusion MHRA Drug Safety Update (Feb-20): Alemtuzumab: updated restrictions & monitoring requirements following review of serious CV & immune-mediated reactions MHRA Drug Safety Update (May-19): Alemtuzumab and serious CV & immune-mediated adverse reactions: new restrictions to use & strengthened monitoring requirements	PbR X NICE MMC BNF emc blueiq	RESTRICTED Renal Consultants only under Patient Access Scheme
Atezolizumab Red ££ Tecentriq® infusion; solution for injection MHRA Drug Safety Update (Jun-21): Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist Consultants in line with NICE / NHSE
Avacopan Red ££ Tavneos® capsules	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist Consultants in line with NICE
Avelumab Red ££ Bavencio® infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist Consultants in line with NICE
Blinatumomab Red ££ Blincyto® infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with NICE
Burosumab Red ££ Crysvida® injection	PbR X NICE MMC BNF emc blueiq	RESTRICTED X-linked hypophosphatemia
Daratumumab Red ££ Darzalex® infusion MHRA Drug Safety Update (Aug-19): Daratumumab (Darzalex ▼): risk of reactivation of hepatitis B virus	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with NICE / NHSE
Glofitamab Red ££ Columvi® infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with NICE
Isatuximab Red ££ infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with EAMS

Mogamulizumab   Poteligeo® infusion      	RESTRICTED Haematology Consultants only in line with NICE NOT STOCKED
Obinutuzumab   Gazyvaro® infusion      	RESTRICTED Haematology Consultants only in line with NICE
Ofatumumab   Kesimpta® injection      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Aug-14): Ofatumumab ▼: reminder of risk of serious and fatal infusion reactions MHRA Drug Safety Update (Jan-14): Ofatumumab: screen for hepatitis B virus before treatment	
Pertuzumab   Perjeta® infusion      	RESTRICTED Haematology Consultants only in line with NICE
Polatuzumab vedotin   Polivy® infusion      	RESTRICTED Haematology Consultants only in line with NICE
Rituximab   injection; infusion (see also section 10.1.3)       	RESTRICTED Consultants only in line with NICE / NHSE
MHRA Drug Safety Update (Dec-13): Rituximab: screen for hepatitis B virus before treatment	
8.2.4 Other immunomodulating drugs	
Interferon alfa	
Interferon alfa-2a   Roferon-A® injection   	
Interferon alfa-2b   IntronA®   	
Peginterferon alfa-2a   Pegasys®     	RESTRICTED Gastro Consultants only
Peginterferon alfa-2b   ViraferonPeg®    	RESTRICTED Gastro Consultants only
Interferon beta	
MHRA Drug Safety Update (Oct-14): Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome	
Interferon beta-1a   injection      	RESTRICTED Specialist use only in line with NICE TA527 NOT STOCKED
Interferon beta-1b   injection      	RESTRICTED Specialist use only in line with NICE TA527 NOT STOCKED
BCG bladder instillation	
Bacillus Calmette–Guérin  OncoTICE® bladder instillation  	RESTRICTED Specialist use only
Bacillus Calmette–Guérin  BCG-medac® intravesical suspension   	RESTRICTED Specialist use only

Other Agents		
Belumosudil Rezurock® 200mg tablets 		RESTRICTED Specialist use in line with NICE
Canakinumab Ilaris® 150mg/mL injection 		RESTRICTED Specialist use in line with NHSE
Cemiplimab Libtayo® 50mg/mL injection 		RESTRICTED Specialist use in line with CDF & NICE
Dimethyl Fumarate Tecfidera® capsules 		RESTRICTED Specialist use only in line with NICE TA320
MHRA Drug Safety Update (Jan-21): Dimethyl fumarate (Tecfidera): updated advice on the risk of PML associated with mild lymphopenia MHRA Drug Safety Update (Apr-16): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy MHRA Drug Safety Update (Mar-15): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia		
Dinutuximab beta Qarziba® 4.5mg/mL injection 		RESTRICTED Specialist use in line with CDF & NICE
Diroximel Fumarate Vumerity® 231mg capsules 		RESTRICTED Specialist use in line with NICE TA794 NOT STOCKED
Fingolimod Hydrochloride Gilenya® capsules 		RESTRICTED Specialist use only in line with NICE TA254
MHRA Drug Safety Update (Jan-21): Fingolimod (Gilenya ▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis		
Glatiramer acetate injection 		RESTRICTED Specialist use only in line with NICE TA527 NOT STOCKED
Imlifidase infusion 		RESTRICTED Specialist use only in line with NICE TA809
Lenalidomide Revlimid® capsules 		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Jan-13): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions		
Mifamurtide Mepact® Intravenous infusion 		RESTRICTED Specialist use only in line with NICE TA235 NOT STOCKED
Natalizumab Tysabri® infusion 		RESTRICTED Specialist use only in line with NICE TA127 NOT STOCKED
MHRA Drug Safety Update (Apr-16): Natalizumab (Tysabri ▼): progressive multifocal leukoencephalopathy—updated advice to support early detection		
Nivolumab Opdivo® 10mg/mL infusion 		RESTRICTED Specialist use only in line with NICE
MHRA Drug Safety Update (Oct-19): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection		
Ocrelizumab Ocrevus® 30mg/mL infusion 		RESTRICTED Specialist use only in line with NICE TA533 / TA585 NOT STOCKED
Olaparib Lynparza® tablets 		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Pomalidomide capsules 		RESTRICTED Haematology only / also in line with NICE
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (May-16): Pomalidomide (Imnovid ▼): risk of hepatitis B reactivation MHRA Drug Safety Update (May-15): Pomalidomide (Imnovid ▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity		
Ponesimod Ponvory® tablets 		RESTRICTED Specialist use only in line with NICE TA767 NOT STOCKED
Rucaparib tablets 		RESTRICTED Specialist use only in line with NICE TA611 NOT STOCKED
MHRA Drug Safety Update (Sep-22): Rucaparib (Rubraca ▼): withdrawal of third-line treatment indication		

<p>Teriflunomide   tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA303 NOT STOCKED</p>
<p>Thalidomide   capsules     </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies</p>	

8.3 Sex hormones & hormone antagonists in malignant disease		GMMMG
8.3.1 Oestrogens		
Diethylstilbestrol		RESTRICTED Specialist use only
tablets	BNF emc	
8.3.2 Progestogens		
Medroxyprogesterone Acetate		RESTRICTED Specialist use only
tablets	BNF emc	
Megestrol Acetate		RESTRICTED Specialist use only
tablets	BNF emc	
8.3.3 Androgens		
Testolactone		RESTRICTED Specialist use only
tablets	BNF emc	
8.3.4 Hormone Antagonists		
8.3.4.1 Breast Cancer		
Aminoglutethimide		NICE NG101 RESTRICTED Specialist use only
tablets	BNF emc	
Anastrozole Green		RESTRICTED Specialist use only
tablets	NICE MMC BNF emc	
Exemestane Green		RESTRICTED Specialist use only
tablets	NICE MMC BNF emc	
Letrozole Green		RESTRICTED Specialist use only
tablets	NICE BNF emc	
Tamoxifen Green		RESTRICTED Specialist use only
tablets; oral solution	NICE BNF emc	
8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists		
Gonadorelin analogues		
Buserelin Red		RESTRICTED Specialist use only
injection (see also section 6.7.2)	BNF emc	
Goserelin Amber Red		RESTRICTED Specialist use only
implant (also section 6.7.2)	BNF emc	
Leuprorelin Acetate Amber Red		RESTRICTED Specialist use only
injection (also section 6.7.2)	MMC BNF emc	
Triptorelin Amber Red		RESTRICTED Specialist use only
injection (also section 6.7.2)	MMC BNF emc	
Goserelin/Leuprorelin - Licensed Indications (pre-op management prior to endometrial ablation/fibroid surgery)		Amber
Goserelin/Leuprorelin/Triptorelin - Licensed Indications (prostate cancer (all), breast cancer (goserelin))		Amber
Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)		Red
Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)		Red

Anti-androgens		
Bicalutamide Green tablets  		RESTRICTED Specialist use only
Cyproterone Acetate Amber tablets (see also section 6.4.2) MHRA Drug Safety Update (Jun-20): Cyproterone acetate: new advice to minimise risk of meningioma MHRA Drug Safety Update (Apr-20): Cyproterone acetate: restrictions in use of due to risk of meningioma  		RESTRICTED Specialist use only
Darolutamide Red ££ 300mg tablets      		RESTRICTED Specialist use only in line with NICE
Flutamide tablets  		RESTRICTED Specialist use only
Enzalutamide Red ££ tablets      		RESTRICTED Specialist use only NOT STOCKED
Abiraterone Red ££ Zytiga® tablets      		RESTRICTED Specialist use only NOT STOCKED
Gonadotrophin-releasing hormone antagonists		
Degarelix Amber Firmagon® 80mg; 120mg injection    		RESTRICTED Specialist use only in line with NICE
Other		
Radium-223 dichloride Red ££ Xofigo® 1,100 kBq/mL injection      		RESTRICTED Specialist use only in line with NICE
MHRA Drug Safety Update (Sep-18): Xofigo ▼: new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial MHRA Drug Safety Update (Dec-17): ▼ Xofigo: Increased risk of death and fractures in RCT with abiraterone acetate & prednisolone/prednisone		
8.3.4.3 Somatostatin analogues		
Lanreotide Red ££ injection    		RESTRICTED Consultant only - acromegaly
Octreotide Red ££ injection    		RESTRICTED 3 rd line use Gastro. Consultant only
Lutetium (¹⁷⁷Lu) oxodotretotide Red ££ Lutathera® injection      		RESTRICTED Specialist use only in line with NICE NOT STOCKED

8.4 Miscellaneous preparations



Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 10.4 & 13.14)



RESTRICTED
2nd line rescue therapy



Trifluridine / Tipiracil hydrochloride



tablets



RESTRICTED Specialist use only in line with NICE
NOT STOCKED

Section 9: Nutrition & blood

Supported by the
formulary ([click here](#))



9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells

9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

9.3 Intravenous nutrition

9.4 Oral nutrition

- 9.4.1 Nutrition in special diets

9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

9.7 Bitters & tonics

9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

Trust Guidelines




























































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

























































































































NICE Guidance


































Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
 Nutrition support in adults (CG32)
 Coeliac disease: recognition, assessment and management (NG20)
 Chronic kidney disease: assessment and management (NG203)
 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
 Migalastat for treating Fabry disease (HST4)
 Eliglustat for treating type 1 Gaucher disease (HST5)
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
 Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
 Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)
 Hyperparathyroidsism - cinacalcet (TA117)
 Thrombocytopenic purpura - romiplostim (TA221)
 Thrombocytopenic purpura - eltrombopag (TA293)
 Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)
 Etelcalcetide for treating secondary hyperparathyroidism (TA448)
 Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
 Patiromer for treating hyperkalaemia (TA623)
 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)
 Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)
 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
 Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
 Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
 Avalglucosidase alfa for treating Pompe disease (TA821)
 Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
 Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)









GMMMG Formulary

Formulary Homepage
 Chapter 9: Nutrition & Blood (Complete)
 GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
 GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

9.1 Anaemias and some other blood disorders		GMMMG
9.1.1 Iron deficiency anaemias		
9.1.1.1 Oral iron		
Ferrous Sulfate		1st line use
tablets	 	STANDARD PREPARATIONS ONLY
Ferrous Fumarate		
tablets; oral solution	 	
Ferric Maltol		
capsules	  	
Sodium Feredetate		LIQUID PREPARATIONS ONLY
oral solution	 	
Iron & folic acid		
Ferrous Sulfate		
M/R tablets	 	
Ferrous Fumarate		
capsules; tablets	 	
9.1.1.2 Parenteral iron		
Ferric Carboxymaltose		RESTRICTED
 Ferinject® injection	  	
MHRA Drug Safety Update (Nov-20): Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures		
Ferric Derisomaltose		RESTRICTED
 Monofer® injection	  	
MHRA: Monofer and Diafer name change (Nov-20) MHRA Drug Safety Update (Sep-13): Intravenous iron and serious hypersensitivity reactions		
Iron Sucrose		RESTRICTED
 Venofer® injection	  	
9.1.2 Drugs used in megaloblastic anaemias		
MHRA Drug Safety Update (Dec-23): Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions		
Hydroxocobalamin		1st line use
Intramuscular injection; sachets	  	
Cyanocobalamin		See BSH guidance
 50microgram; 1mg tablets	  	
9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias		
Erythropoietins		
MHRA Drug Safety Update (Jan-18): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)		
Darbepoetin alfa		RESTRICTED Renal Consultants only
 injection	    	
Epoetin Alfa		RESTRICTED Renal Consultants only
 injection	   	
Epoetin Beta		RESTRICTED Renal Consultants only
 injection	   	
MHRA Drug Safety Update (May-15): Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded		
Sickle-cell disease		
Hydroxycarbamide		RESTRICTED Haematology Consultants only
 oral solution; capsules	 	
Voxelotor		RESTRICTED Haematology Consultants only in line with EAMS / NHSE SSC2339
  Oxbryta® 500mg tablets	    	

Iron overload		
Deferasirox   tablets    	RESTRICTED Haematology Consultants only	
Deferiprone   tablets    	RESTRICTED Haematology Consultants only	
Desferrioxamine Mesilate   injection   	RESTRICTED Haematology Consultants only	
Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI)		
Roxadustat   Evrenzo® tablets      	RESTRICTED Specialist use only in line with NICE	
Paroxysmal nocturnal haemoglobinuria & atypical haemolytic uraemic syndrome		
Eculizumab   infusion       	RESTRICTED Haematology Consultants only	
Ravulizumab   infusion      	RESTRICTED Specialist use only in line with NICE	
9.1.4 Drugs used in autoimmune thrombocytopenic purpura		
Anagrelide   capsules   	RESTRICTED Haematology Consultants only	
Avatrombopag   Doptelet® tablets      	RESTRICTED Specialist use only in line with NICE	
Caplacizumab   Cablivi® injection      	RESTRICTED Specialist use only in line with NICE NOT STOCKED	
Eltrombopag   Revolade® tablets      	RESTRICTED Haematology Consultants only	
MHRA Drug Safety Update (Jul-18): Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results		
Fostamatinib   Tavesse® tablets      	RESTRICTED Specialist use only	
Lusutrombopag   Mulpleo® tablets      	RESTRICTED Specialist use only	
Romiplostim   Nplate® injection      	RESTRICTED Haematology Consultants only	
9.1.6 Drugs used in neutropenia		
Filgrastim   injection    	RESTRICTED Haematology Consultants only	
MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
Lenograstim   injection   	RESTRICTED Haematology Consultants only	
Pegfilgrastim   injection    	RESTRICTED Haematology Consultants only	
MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
9.1.7 Drugs used to mobilise stem cells		
Plerixafor   injection      	RESTRICTED - initiation on advice of Haematology Consultant only	

9.2 Fluids and electrolytes		GMMMG
9.2.1 Oral preparations for fluid & electrolyte imbalance		
9.2.1.1 Oral potassium		
Potassium Chloride		
Sando-K® effervescent tablets; Kay-Cee-L® syrup	 	
Potassium removal		
Calcium Polystyrene Sulfonate		
Calcium Resonium® powder; enema (unlicensed)	 	
Sodium Zirconium Cyclosilicate		
Red	   	
Lokelma® powder sachets		
9.2.1.2 Oral sodium and water		
Sodium Chloride (Slow Sodium®)		
600mg M/R tablets	 	
Oral Rehydration Therapy (ORT)		
Oral Rehydration Salts (ORS)		
oral powder	 	
9.2.1.3 Oral bicarbonate		
Sodium Bicarbonate		
500mg capsules; 8.4% (1mmol/mL) oral solution	 	
Sodium Hydrogen Carbonate		
Nephrotrans® 50mg gastro-resistant capsules	  	RESTRICTED 2 nd line patients with severe GI side effects
9.2.2 Parenteral preparations for fluid & electrolyte imbalance		
9.2.2.1 Electrolytes & water		
Intravenous sodium		
Sodium Chloride		
infusion; injection	 	
Sodium chloride with other ingredients		
Sodium Chloride & Glucose		
infusion	 	
Sodium Chloride, Calcium Chloride & Potassium Chloride (Ringer's solution)		
infusion	 	
Sodium Chloride, Calcium Chloride, Potassium Chloride & Sodium Lactate		
infusion	 	
Intravenous glucose		
Glucose		
infusion	 	
MHRA Drug Safety Update (May-23): Glucose solutions: recommendations to minimise the risks associated with the accidental use instead of saline solutions in arterial lines		
MHRA Drug Safety Update (Jul-12): Glucose solutions: false blood glucose readings when used to flush arterial lines		
Intravenous potassium		
Potassium Chloride and Glucose		
infusion	 	
Potassium Chloride and Sodium Chloride		
infusion	 	
Potassium Chloride, Sodium Chloride & Glucose		
infusion	 	




Bicarbonate and lactate	
Sodium Bicarbonate	
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	 
Water	
Water for Injections	
injection	 
9.2.2.2 Plasma & plasma substitutes	
Dextran	
<i>Dextran 40</i> - 10% in sodium chloride 0.9% infusion	
Dextrose Acid Citrate ACDA	
solution	
Gelatin	
<i>Gelofusine</i> ® infusion	 













































9.3 Intravenous nutrition






























































Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)













NICE CG32

9.4 Oral nutrition		
Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)		NICE CG32
9.4.1 Nutrition in special diets		
Sapropterin dihydrochloride   <i>Kuvan</i> ® 100mg soluble tablets     	RESTRICTED Tetrahydrobiopterin deficiency 	
LaBiNIC® probiotic drops  <i>LaBiNIC</i> ® probiotic drops   	RESTRICTED prevention of NEC	

9.5 Minerals		GMMMG
9.5.1 Calcium and magnesium		
9.5.1.1 Calcium supplements		
Oral preparations		
Calcium Carbonate Green		
<i>Cacit</i> ® effervescent tablets; <i>Calcichew</i> ® chewable tablets	 	
Calcium Carbonate & Calcium Lactate Gluconate Green		
<i>Sandocal</i> ® 1000 effervescent tablets	 	
Parenteral preparations		
Calcium Gluconate		
10% injection	 	
MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia		
Calcium Chloride		
10% injection	 	
MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia		
with vitamin D		
see section 9.6.4	 	
with risedronate sodium & colecalciferol		
see section 6.6.2	 	
9.5.1.2 Hypercalcaemia & hypercalciuria		
Cinacalcet Red 2 nd HPT Amber 1 st HPT ££		RESTRICTED as per NICE TA117
tablets	    	
Etelcalcetide Red ££		RESTRICTED as per NICE TA448
injection	     	
9.5.1.3 Magnesium		
Magnesium Aspartate Dihydrate		NICE ESUOM4
<i>Magnaspartate</i> ® sachets	  	1st line use
Magnesium Glycerophosphate		
chewable tablets; capsules; oral solution; tablets	  	
Magnesium Sulfate		
injection; infusion	 	
MHRA Drug Safety Update (May-19): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy		
9.5.2 Phosphorus		
9.5.2.1 Phosphate supplements		
Phosphate supplements (<i>Phosphate-Sandoz</i>®)		Effervescent tabs
effervescent tablets	 	
Phosphates (<i>Polyfusor</i>®) Red		I.V. preparation
infusion	 	
9.5.2.2 Phosphate-binding agents		
Aluminium Hydroxide Green		NICE NG203
capsules	 	
Calcium Carbonate Green		
tablets (see also section 9.5.1.1)	 	
Calcium Acetate Green		
tablets	  	
Calcium Acetate / Magnesium Carbonate Green		RESTRICTED Renal Consultants only
<i>Osvaren</i> ® 435mg/235mg tablets	  	

<p>Lanthanum   chewable tablets; oral powder   </p>	<p>RESTRICTED Renal Consultants only</p>
<p>Patiromer Calcium   Veltassa® oral powder    </p>	<p>RESTRICTED Consultants only in line with NICE TA623</p>
<p>Sevelamer Carbonate   tablets     </p>	<p>RESTRICTED Renal Consultants only</p>
<p>Sucroferric Oxyhydroxide   chewable tablets   </p>	<p>RESTRICTED Renal Consultants only - 3rd line</p>
<p>9.5.3 Fluoride</p>	
<p>Sodium Fluoride tablets, paediatric drops, dental rinse  </p>	
<p>9.5.4 Zinc</p>	
<p>Zinc Sulfate Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules  </p>	

9.6 Vitamins		GMMMG
9.6.1 Vitamin A		
Vitamin A		
150,000units/mL drops	 	
Vitamin A Palmitate		
100,000units/2mL injection	 	
Vitamins A & D		
capsules	 	
9.6.2 Vitamin B group		
Pyridoxine Hydrochloride		
tablets	 	
Thiamine		
tablets	 	
Vitamin B Compound		
	 	
Vitamin B Compound Strong		
tablets	 	
Vitamins B & C		
<i>Pabrinex</i> ® Intramuscular (IM) & Intravenous (IV) injection	 	
9.6.3 Vitamin C (Ascorbic acid)		
Ascorbic acid		
tablets	 	
9.6.4 Vitamin D		
Alfacalcidol		
Green		
capsules; injection; oral drops	 	
Calcitriol		
capsules; oral solution	 	
Vitamin D and calcium		
Colecalciferol		1st line use
Calcichew D3® Forte tablets / Adcal D3® chewable tablets	MMC  	
Calcium & Ergocalciferol		
calcium 97mg/vitamin D 400units	 	
Colecalciferol		
<i>Cacif</i> ® D3 effervescent granules; 800 IU capsules	MMC  	
9.6.5 Vitamin E (Tocopherols)		
Alpha Tocopheryl Acetate (Vitamin E)		
500mg/5mL liquid	 	
Alpha Tocopheryl Acetate (Vitamin E)		
75 unit capsules	 	








































































9.6.6 Vitamin K		
Phytomenadione		
<i>Konakion® MM & Konakion® MM Paediatric</i> injection	  	
Menadiol Sodium Phosphate		
oral solution; tablets	  	
9.6.7 Multivitamin preparations		
Vitamins B,C		RESTRICTED
<i>Renavit®</i> tablets	  	
Vitamins A,D,E,K		RESTRICTED Paediatric CF patients
<i>Paravit-CF®</i> capsules; liquid	  	

9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use

9.8 Metabolic disorders		GMMMG
9.8.1 Drugs used in metabolic disorders		
Serine deficiency		
L-Serine		RESTRICTED Specialist use only
(Nutricia L-Serine) powder	MMC	
Wilson's Disease		
Penicillamine 		
tablets (see also section 10.1.3)		
Trientine Dihydrochloride 		3rd line use
capsules		
Carnitine Deficiency		
Levocarnitine 		RESTRICTED Specialist use only
injection; oral solution		
Fabry's disease		
Agalsidase alfa 		RESTRICTED Specialist use only NOT STOCKED
Replagal® infusion		
MigALastat 		RESTRICTED Specialist use only (NICE HST4)
Galafold® capsules		
Mucopolysaccharidosis		
Elosulfase alfa 		RESTRICTED Specialist use only (NICE HST19)
Vimizim® infusion		
Galsulfase 		RESTRICTED Specialist use only NOT STOCKED
Naglazyme® infusion		
Idursulfase 		RESTRICTED Specialist use only
Elaprase® infusion		
Laronidase 		RESTRICTED Specialist use only NOT STOCKED
Aldurazyme® infusion		
Vestronidase alfa 		RESTRICTED Specialist use only
Mepsevii® infusion		
Nephropathic cystinosis		
Cystagon® (Mercaptamine) 		RESTRICTED Specialist use only
capsules (NB: prescribe as CYSTAGON®)		
Pompe disease		
Avalglucosidase alfa 		RESTRICTED Specialist use only (NICE TA821)
Nexviadyme® infusion		
Tyrosinemia type I		
Nitisinone 		RESTRICTED Specialist use only
capsules; oral suspension		
Urea cycle disorders		
BIMDG		
Arginine 		RESTRICTED Specialist use only
infusion; oral solution		
Carglumic acid 		RESTRICTED Specialist use only
dispersible tablets		
Citrulline 		RESTRICTED Specialist use only
powder		
Glycerol Phenylbutyrate 		RESTRICTED Specialist use only
Ravicti® 1.1g/mL oral liquid		

Sodium Phenylbutyrate   tablets; injection; oral liquid; granules (discontinued)	   	RESTRICTED Specialist use only
Homocystinuria		
Betaine   tablets; oral powder	  	RESTRICTED Specialist use only
Sodium Benzoate injection; oral solution; tablets; powder	  	RESTRICTED Specialist use only
Uridine	  	RESTRICTED Specialist use only
Other metabolic disorders		
Asfotase alfa   <i>Strensiq</i> ® injection	     	RESTRICTED Specialist use only (NICE HST23)
Cerliponase alfa   <i>Brineura</i> ® 150mg solution for infusion	     	RESTRICTED Specialist use only (NICE HST12)
Eliglustat   <i>Cerdelga</i> ® 84mg capsules	     	RESTRICTED Specialist use only (NICE HST5)
MigLUstat   100mg capsules	   	RESTRICTED Specialist use only
Sebelipase alfa   <i>Kanuma</i> ® 2mg/mL solution for infusion	    	RESTRICTED Specialist use only (NICE)
Sodium dichloroacetate    50 mg/mL powder for reconstitution for oral solution (200 mL)	  	RESTRICTED Specialist use only Primary lactic acidosis / PDHC deficiency
Velaglycerase alfa   <i>VPRIV</i> ® 400 units vial	   	RESTRICTED Specialist use only
9.8.2 Acute porphyrias		
Haem Arginate   infusion	  	

Section 10: Musculoskeletal & Joint Diseases

Supported by the
formulary ([click here](#))



10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process
 - Gold
 - Penicillamine
 - Antimalarials
 - Drugs affecting the immune response
 - Cytokine modulators
- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
 - Nocturnal leg cramps
- 10.2.3 Drugs used in neuromuscular disorders

10.3 Drugs for the relief of soft-tissue inflammation

- 10.3.1 Enzymes
- 10.3.2 Rubefacients & other topical antirheumatics

10.4 Miscellaneous preparations

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)








































































































NICE Guidance
















Biosimilar Medicines (KTT15)
 Rheumatoid arthritis in adults: management (NG100)
 Osteoarthritis in over 16s: diagnosis and management (NG226)
 Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)
 Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)
 Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)
 Hyperuricaemia - febuxostat (TA164)
 Psoriasis - ustekinumab (TA180)
 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)
 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)
 Psoriatic arthritis - golimumab (TA220)
 Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)
 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)
 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)
 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
 Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)
 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)
 Apremilast for treating active psoriatic arthritis (TA433)
 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
 Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
 Baricitinib for moderate to severe rheumatoid arthritis (TA466)
 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)
 Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
 Sarilumab for moderate to severe rheumatoid arthritis (TA485)
 Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)
 Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)
 Tocilizumab for treating giant cell arteritis (TA518)
 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)
 Nusinersen for treating spinal muscular atrophy (TA588)
 Upadacitinib for treating severe rheumatoid arthritis (TA665)
 Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
 Anakinra for treating Still's disease (TA685)
 Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)
 Ixekizumab for treating axial spondyloarthritis in adults (TA718)
 Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)
 Tofacitinib for treating juvenile idiopathic arthritis (TA735)
 Upadacitinib for treating moderate rheumatoid arthritis (TA744)
 Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)
 Risdiplam for treating spinal muscular atrophy (TA755)
 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)
 Upadacitinib for treating active ankylosing spondylitis (TA829)
 Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
 Bimekizumab for treating axial spondyloarthritis (TA918)
 Tofacitinib for treating active ankylosing spondylitis (TA920)

















GMMMG Formulary




















































Formulary Homepage
 Chapter 10: Musculoskeletal & Joint Diseases (Complete)
 GMMMG Adult [Red/Amber/Green](#); DNP and [Grey](#) Drug List
 GMMMG Paediatric [Red/Amber/Green](#) Drug List









10.1 Drugs used in rheumatic diseases & gout		GMMMG
10.1 Drugs used in rheumatic diseases & gout		NICE CG177
10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs)		NICE NG100
MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks		
MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment		
MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks		
Ibuprofen (oral)		1 st line use
200mg; 400mg; 600mg tablets; 5% gel	MMC BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk		
Ibuprofen (IV)		short-term symptomatic treatment of acute moderate pain
200mg in 50mL solution for infusion	MMC BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk		
Naproxen		
250mg; 500mg tablets	BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
Celecoxib		RESTRICTED - osteoarthritis in line with NICE NG226
100mg; 200mg capsules	MMC BNF emc	
MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks		
Diclofenac Sodium		RESTRICTED - acute post-operative pain (injection)
50mg tablets; suppositories; injection	MMC BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription		
MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings		
Flurbiprofen		
50mg tablets	BNF emc	
Mefenamic Acid		
250mg; 500mg tablets	BNF emc	
Meloxicam		
7.5mg; 15mg tablets	BNF emc	
Sulindac		
100mg; 200mg tablets	MMC BNF emc	
Etodolac		RESTRICTED Consultant Anaesthetist use only
600mg tablets	MMC BNF emc	
Phenylbutazone		RESTRICTED Specialist use only, ankylosing spondylitis
100mg; 200mg tablets	BNF emc	
10.1.2 Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
10.1.2.1 Systemic corticosteroids		NICE NG100
Prednisolone		
	BNF emc	
10.1.2.2 Local corticosteroid injections		NICE NG100
Hydrocortisone Acetate		
25mg/mL injection	BNF emc	
Methylprednisolone Acetate		
40mg/mL injection	BNF emc	
Triamcinolone Acetonide		
10mg/mL; 40mg/mL injection	BNF emc	
Triamcinolone Hexacetonide		RESTRICTED Paediatric Rheumatology Consultants only
20mg/mL injection	MMC BNF emc	

10.1.3 Drugs that suppress the rheumatic disease process		
Gold		NICE NG100
Auranofin 		RESTRICTED Rheumatology Consultants only
tablets	 	
Sodium Aurothiomalate 		RESTRICTED Rheumatology Consultants only
injection	 	
Penicillamine		
Penicillamine 		RESTRICTED Rheumatology Consultants only
tablets	 	
Antimalarials		
Hydroxychloroquine 		RESTRICTED Rheumatology Consultants only
tablets	  	
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions		
MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
Mepacrine hydrochloride 		RESTRICTED Rheumatology Consultants only
100mg tablets	  	
Drugs affecting the immune response		NICE NG100
Azathioprine 		RESTRICTED Rheumatology Consultants only
tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 & 13.5.3)	  	
Ciclosporin 		RESTRICTED Consultants only
capsules; oral solution; injection (see also sections 8.2.2 & 13.5.3)	   	
Leflunomide 		RESTRICTED Rheumatology Consultants only
tablets	  	
Methotrexate  oral  parenteral		RESTRICTED Consultants only
tablets; injections (see also sections 1.5.3, 8.1.3 & 13.5.3)	  	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions		
MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose		
Cytokine modulators		
Abatacept  		RESTRICTED Rheum. Consultants only in line with NICE / NHSE
injection; infusion	      	
Adalimumab  		RESTRICTED Consultants only in line with NICE
injection (see also sections 1.5.3, 11.4.2 & 13.5.3)	     	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
Anakinra  		RESTRICTED Consultants only in line with NICE / NHSE
injection	      	
Apremilast  		RESTRICTED 3 rd / 4 th line as per NICE/GMMMG
10mg; 20mg; 30mg tablets	    	
Baricitinib  		RESTRICTED Rheumatology Consultants only in line with NICE
2mg; 4mg tablets	      	
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
MHRA Drug Safety Update (Aug-20): Baricitinib (Olmiant▼): increased risk of diverticulitis, particularly in patients with risk factors		
MHRA Drug Safety Update (Mar-20): Baricitinib (Olmiant▼): risk of venous thromboembolism		
Belimumab  		RESTRICTED Consultants only
infusion	     	
MHRA Drug Safety Update (Apr-19): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials		
Bimekizumab  		RESTRICTED in line with NICE
injection (see also section 13.5.3)	     	
Certolizumab  		RESTRICTED Rheumatology Consultants in line with NICE
injection (see also section 13.5.3)	    	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		

Etanercept  injection  MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	RESTRICTED Consultants only; in line with NICE
Filgotinib  tablets  MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality	RESTRICTED Consultants only in line with NICE
Golimumab  injection  MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	RESTRICTED Consultants only in line with NICE
Guselkumab  100mg/mL injection 	RESTRICTED in line with NICE
Infliximab  <i>Remicade®</i> infusion; <i>Remsima®</i> infusion  MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	RESTRICTED Consultants only MMC Remsima
Ixekizumab  80mg/1mL injection (see also section 13.5.3) 	RESTRICTED Consultants only in line with NICE
Rituximab  injection; infusion (see also section 8.2.3) 	RESTRICTED Consultants only in line with NICE / NHSE
Sarilumab  <i>Kevzara®</i> 150mg/1.14mL injection 	RESTRICTED Rheumatology Consultants only in line with NICE
Secukinumab  <i>Cosentyx®</i> 150mg/1mL injection (see also section 13.5.3) 	RESTRICTED Rheumatology Consultants only in line with NICE
Tocilizumab  infusion  MHRA Drug Safety Update (Jul-19): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation	RESTRICTED Consultants only in line with NICE
Tofacitinib  <i>Xeljanz®</i> 5mg; 10mg tablets (see also section 1.5.3)  MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing	RESTRICTED Consultants only in line with NICE
Upadacitinib  MR tablet (see also sections 1.5.3 & 13.5.3) 	RESTRICTED Consultants only in line with NICE
Ustekinumab  injection; infusion (see also section 13.5.3)  MHRA Drug Safety Update (Jan-15): Ustekinumab (Stelara): risk of exfoliative dermatitis	RESTRICTED Dermatology TA340 / Gastro 3 rd line Crohn's

10.1.4 Gout and cytotoxic induced hyperuricaemia		
Acute attacks of gout		
Colchicine		
tablets	 	
Long-term control of gout		
Allopurinol		1st line use
tablets	 	
Febuxostat		RESTRICTED Rheumatology Consultants only
		
tablets	   	
MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease		
MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease		
MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity		
Hyperuricaemia associated with cytotoxic drugs		
Rasburicase		RESTRICTED Haematology Consultants only
 		
Fasturtec® infusion	    	
10.1.5 Other drugs for rheumatic diseases		NICE CG177
		NICE TA477
		NICE TA508

10.2 Drugs used in neuromuscular disorders		GMMMG
10.2.1 Drugs that enhance neuromuscular transmission		
Anticholinesterases		
Pyridostigmine Bromide		1st line use
tablets	 	
Neostigmine		
tablets; injection	 	
Edrophonium Chloride		RESTRICTED diagnosis of myasthenia gravis Licensed product discontinued
injection	 	
10.2.2 Skeletal muscle relaxants		
Baclofen		1st line use
10mg tablets; 5mg/mL oral solution	 	
Dantrolene Sodium		
25mg; 100mg capsules; Ryanodex 250mg/20mL vial	 	
Diazepam		
tablets; liquid; injection; rectal tube (see also sections 4.1.2, 4.8 & 15.1.4.1)	 	
Tizanidine		RESTRICTED Consultant Neurologist only
Amber 2mg; 4mg tablets	 	
Nocturnal leg cramps		
Quinine Sulfate		
tablets (see also section 5.4.1)	 	
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
MHRA Drug Safety Update (Jun-10): Quinine: not to be used routinely for nocturnal leg cramps		
10.2.3 Drugs used in neuromuscular disorders		
Ataluren		Specialist use only in line with NICE HST22
Red  oral suspension sachets	     	
Atidarsagene autotemcel		Specialist use only in line with NICE HST18
Red  Libmeldy® infusion	     	
Nusinersen		Specialist use only in line with NICE TA588 / NHSE Named patient access
Red  injection	     	
MHRA Drug Safety Update (Sep-18): Nusinersen (Spinraza ▼): reports of communicating hydrocephalus; discuss symptoms with patients & carers - investigate urgently		
Onasemnogene abeparvovec		RESTRICTED Paediatric Neurology Consultants only NICE / NHSE
Red  Zolgensma® infusion	     	
Risdiplam		Specialist use only in line with NICE TA755
Red  oral solution	     	

10.3 Drugs for the relief of soft-tissue inflammation		
10.3.1 Enzymes		
Hyaluronidase Red	 	RESTRICTED extravasation
injection		
10.3.2 Rubefacients & other topical antirheumatics		
Piroxicam	 	
0.5% gel		
Capsaicin DNP	  	Patch restricted to peripheral neuropathic pain specialists at TGH
cream, patch		

10.4 Miscellaneous preparations



Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 13.14)



RESTRICTED
2nd line rescue therapy



Section 11: Eye

Supported by the
formulary ([click here](#))



11.3 Anti-infective eye preparations

11.3.1 Antibacterials

11.3.3 Antivirals

11.4 Corticosteroid & other anti-inflammatory preparations

11.4.1 Corticosteroids

11.4.2 Other anti-inflammatory preparations

11.5 Mydriatics & cycloplegics

11.6 Treatment of glaucoma

11.7 Local anaesthetics

11.8 Miscellaneous ophthalmic preparations

11.8.1 Tear deficiency, ocular lubricants & astringents

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment

11.8.3 Other preparations

Trust Guidelines























































































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)











NICE Guidance



































































Glaucoma: diagnosis and management (NG81)
 Macular degeneration (age related) ranibizimab & pegaptanib (TA155)
 Macular oedema (retinal vein occlusion) - dexamethasone (TA229)
 Macular oedema (diabetic) - ranibizumab (TA274)
 Macular oedema (retinal vein occlusion) - ranibizumab (TA283)
 Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)
 Vitreomacular traction - ocriplasmin (TA297)
 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)
 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)
 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)
 Aflibercept for treating diabetic macular oedema (TA346)
 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)
 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
 Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
 Aflibercept for treating choroidal neovascularisation (TA486)
 Cenegermin for treating neurotrophic keratitis (TA532)
 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
 Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
 Brolucizumab for treating wet age-related macular degeneration (TA672)
 Faricimab for treating diabetic macular oedema (TA799)
 Faricimab for treating wet age-related macular degeneration (TA800)
 Brolucizumab for treating diabetic macular oedema (TA820)
 Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)












GMMMG Formulary











































Formulary Homepage
 Chapter 11: Eye (Complete)
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

11.3 Anti-infective eye preparations		GMMMG
11.3.1 Antibacterials		
Chloramphenicol		
0.5% eye drops, 1% eye ointment	 	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
Fusidic Acid (ophthalmic)		
1% eye drops	 	
Amikacin (ophthalmic)  	 	RESTRICTED microbial keratitis. Consultant Ophthalmologist only
2.5% eye drops	 	NOT STOCKED
Amphotericin		
0.15% eye drops	 	RESTRICTED Consultant Ophthalmologist only
Azithromycin (ophthalmic)		
	 	RESTRICTED Consultant Ophthalmologist only
Azyter® 1.5% eye drops	  	
Ceftazidime (ophthalmic)		
	 	RESTRICTED Consultant Ophthalmologist only
5% eye drops	 	NOT STOCKED
Cefuroxime (ophthalmic)		
 	 	RESTRICTED Consultant Ophthalmologist only
5% eye drops	 	
Cefuroxime (intracameral injection)		
	 	RESTRICTED Consultant Ophthalmologist only
Ximaract® 50mg in 5mL intracameral injection	  	
Chlorhexidine (ophthalmic)		
 	 	RESTRICTED acanthamoeba keratitis. Consultant only
0.02% eye drops	 	
Ciprofloxacin (ophthalmic)		
	 	RESTRICTED microbial keratitis. Consultant Ophthalmologist only
0.3% eye drops	 	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
Erythromycin (ophthalmic)		
	 	RESTRICTED superficial eye infections
0.5% eye ointment	 	
Gentamicin (ophthalmic)		
 	 	RESTRICTED Consultant Ophthalmologist only
1.5% eye drops (Use with cefuroxime eye drops)	 	
Levofloxacin (ophthalmic)		
	 	RESTRICTED Consultant only corneal ulcers/ keratitis
0.5% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
Natamycin		
	 	RESTRICTED fungal keratitis, conjunctivitis, fungal blepharitis
5% eye drops	 	
Ofloxacin		
	 	RESTRICTED Consultant Ophthalmologist only
0.3% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
Penicillin (ophthalmic)		
 	 	RESTRICTED microbial keratitis. Consultant Ophthalmologist only
2,500 units/mL eye drops	 	
Polyhexamethylene Biguanide (PHMB)		
 	 	NOT STOCKED
0.02% eye drops	 	

<p>Polymyxin B Sulfate</p> <p>eye ointment</p>  	<p>RESTRICTED gram negative bacteria, including pseudomonas</p>
<p>Propamide Isetionate</p> <p>Green</p> <p>0.1% eye drops</p>  	<p>RESTRICTED Consultant Ophthalmologist only</p>
<p>Vancomycin (ophthalmic)</p> <p>U</p> <p>5% eye drops</p>  	<p>RESTRICTED gram positives, including MRSA but not VRE NOT STOCKED</p>
<p>11.3.3 Antivirals</p>	
<p>Ganciclovir</p> <p>Green</p> <p>0.15% eye gel</p>  	
<p>Trifluorothymidine</p> <p>U Red</p> <p>1% eye drops</p>  	

11.4 Corticosteroid & other anti-inflammatory preparations		GMMMG
11.4.1 Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
Betamethasone 0.1% eye drops & ointment	 	
Dexamethasone 0.1% eye drops & minims	 	
Dexamethasone (intravitreal implant)   Ozurdex® 700micrograms intravitreal implant	    	RESTRICTED as per NICE TA229; TA460 & TA824
Fluocinolone Acetonide   Iluvien® 190micrograms intravitreal implant	    	RESTRICTED as per NICE TA301 & TA590
Prednisolone 0.5% & 1% eye drops; 0.5% minims	 	
Fluorometholone  0.1% eye drops	 	
Hydrocortisone sodium phosphate Softacort® 3.35 mg/mL PF single use eye drops	  	
Triamcinolone Acetonide   Kenalog® 40mg/mL injectable suspension	  	RESTRICTED intralesional injection in skin grafts
Triamcinolone Acetonide  Triesence® 40mg/mL injectable suspension	  	RESTRICTED uveitis; sympathetic ophthalmia
Triamcinolone Acetonide  Intracinol® 40mg/mL ophthalmic suspension	  	RESTRICTED opacification of the vitreous humour
Corticosteroids preparations with antibiotics		
Betamethasone / Neomycin Sulphate 0.1% / 0.5% eye drops (Betnesol-N®)	 	
Dexamethasone / Neomycin Sulphate / Polymyxin B Sulphate 1 mg/mL : 3500 IU/mL : 6000 IU/mL (Maxitrol® eye drops & ointment)	 	
11.4.2 Other anti-inflammatory preparations		
Sodium Cromoglicate 2% eye drops	 	
Adalimumab   Amgevita® injection (see also sections 1.5.3, 10.1.3 & 13.5.3)	    	RESTRICTED Consultant Ophthalmologist only Non-infectious Uveitis
Antazoline with Xylometazoline 0.5% eye drops	 	
Azelastine 0.05% eye drops	 	RESTRICTED allergic conjunctivitis, children only
Ketotifen hydrogen fumarate Ketofall® 0.25mg/mL PF eye drops	 	
Lodoxamide 0.1% eye drops	 	RESTRICTED allergic conjunctivitis
Olopatadine 1mg/mL eye drops	  	RESTRICTED Seasonal allergic conjunctivitis
Potassium Ascorbate  10% eye drops	 	RESTRICTED management of chemical burns to the cornea

11.5 Mydriatics & cycloplegics		GMMMG
Antimuscarinics		
Atropine Sulphate		
1% minims	 	
Cyclopentolate Hydrochloride		
1% eye drops, 0.5% & 1% minims	 	
Tropicamide		
0.5% & 1% eye drops, 0.5% & 1% minims	 	
Sympathomimetics		
Phenylephrine Hydrochloride		10% contraindicated in children & the elderly
2.5% & 10% minims	 	
Sympathomimetics with tropicamide		
Phenylephrine Hydrochloride with Tropicamide		RESTRICTED Pre-operative mydriasis in cataract patients
Mydriaser [®] 5.4mg / 280micrograms ophthalmic insert	  	

11.6 Treatment of glaucoma		GMMMG
Beta-blockers		NICE NG81
Timolol		
0.25% & 0.5% eye drops	 	
Timolol once-daily		
0.25% eye drops, <i>Tiopex</i> ® 0.1% gel, 0.5% long-acting ophthalmic gel	 	
Betaxolol		
0.25% & 0.5% eye drops, 0.25% minims	 	
Levobunolol Hydrochloride		
0.5% eye drops	 	
Prostaglandin analogues and prostamides		
Bimatoprost		
100 microgram/mL eye drops	  	
Latanoprost		
50 microgram/mL eye drops	 	
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
Latanoprost (preservative free)		
50 microgram/mL preservative free eye drops	  	
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
Travoprost		
40 microgram/mL eye drops	  	
Prostaglandin analogues (combination products)		
Latanoprost / Timolol		
50microgram/mL / 5mg/mL eye drops; preservative free eye drops	  	
Sympathomimetics		
Brimonidine Tartrate		
0.2% eye drops	  	
Apraclonidine		
Green or Red		RESTRICTED to delay laser treatment / surgery in uncontrolled glaucoma
0.5%; 1% eye drops	 	
Carbonic anhydrase inhibitors & systemic drugs		
Acetazolamide		
Green		
250mg tablets; <i>Diamox SR</i> ® 250mg capsules	 	
Brinzolamide		
10mg/mL eye drops	 	
Brinzolamide / Brimonidine		
<i>Simbrinza</i> ® 2% eye drops	  	RESTRICTED glaucoma patients in whom monotherapy provides insufficient IOP reduction
Dorzolamide		
2% eye drops; also preservative free	 	
Dorzolamide / Timolol		
<i>Cosopt</i> ® 2% eye drops; also preservative free	 	
Miotics		
Pilocarpine		
1%, 2% & 4% eye drops, 2% minims	 	
Pilocarpine		
4% ophthalmic gel	 	

11.7 Local anaesthetics



Ocular Local anaesthetics

Lidocaine (Lignocaine) and Fluorescein (minims)

4% / 0.25% eye drops



Oxybuprocaine (minims)

0.4% eye drops



Proxymetacaine (minims)

0.5% eye drops



























































































Tetracaine (Amethocaine) (minims)

1% & 2% eye drops



11.8 Miscellaneous ophthalmic preparations		GMMMG
Other preparations		
Botulinum toxin type A		RESTRICTED Consultant Ophthalmologist only blepharospasm & strabismus
Xeomin® injection	MMC BNF emc	
Ciclosporin (eye)		RESTRICTED Consultant Ophthalmologist only
U 2% eye drops	BNF emc	
Ciclosporin (Ikervis®)		RESTRICTED Consultant Ophthalmologist only in line with NICE TA369
Green 1mg/mL eye drops	NICE MMC BNF emc	
Ciclosporin (Verkazia®)		RESTRICTED Paediatrics for vernal keratoconjunctivitis / severe allergic eye disease
Green 1mg/mL eye drops	MMC BNF emc	
Mercaptamine		RESTRICTED Specialist use only NHSE
Red FF Cystadrops® eye drops	PbR x MMC BNF blueiteq emc	NHS England
Sodium Chloride		
U Red 5% eye drops	BNF emc	
Allogeneic Serum eye drops		RESTRICTED Consultant Ophthalmologist only
U Red eye drops (minims) (from NHS Blood & Transplant Service) (not a medicine)	MMC blueiteq	NHS England
11.8.1 Tear deficiency, ocular lubricants & astringents		
Acetylcysteine		
U Ilube® 5% eye drops	BNF emc	
Alteplase		RESTRICTED Consultant Ophthalmologist only
25microgram in 0.1mL intravitreal injection	MMC BNF emc	
Carbomers		
Viscotears® 0.2% eye drops	MMC BNF emc	
Carmellose Sodium		
Celluvisc® 0.5% eye drops	BNF emc	
Cationorm®		
preservative free eye drops	MMC BNF emc	
Hydroxyethylcellulose		
Minims® Artificial Tears preservative free eye drops	BNF emc	
Hypromellose		
0.3% eye drops	MMC BNF emc	
Liquid Paraffin		
Lacri-Lube® ointment	BNF emc	
Poly (carboxymethylglucose sulfate)		RESTRICTED Consultant Ophthalmologist only NOT STOCKED
Cacicol® eye drops (0.33mL)	MMC BNF emc	
Polyvinyl Alcohol		
Liquifilm Tears® 1.4% eye drops	MMC BNF emc	
Sodium Chloride (minims)		
0.9% eye drops	BNF emc	
Sodium Hyaluronate		
Hyo-Forte® 0.2% eye drops	MMC BNF emc	

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment		
Ocular diagnostic preparations		
Fluorescein Sodium		
1% & 2% preservative free eye drops	 	
Fluorescein Sodium 		RESTRICTED Specialist use only fundus fluorescein angiography
100mg/mL injection	  	
Indocyanine green (ICG) 		RESTRICTED Specialist use only
Verdye® 5mg/mL injection	  	
Ocular peri-operative drugs		
Acetylcholine Chloride		
1% intraocular irrigation	 	RESTRICTED Consultant Ophthalmologist only
Apraclonidine		
lopidine® 0.5% eye drops; 1% preservative free eye drops	 	RESTRICTED Consultant Ophthalmologist only
Bromfenac		
Yellox® 0.9 mg/mL eye drops	  	RESTRICTED Consultant only for pseudophakic CMO
Ketorolac Trometamol 		
Acular® 0.5% eye drops	 	RESTRICTED Consultant Ophthalmologist only
Nepafenac		
Nevanac® 1 mg/mL eye drops	  	RESTRICTED. 1 st line post cataract surgery in diabetics. 2 nd line CMO
Povidone-Iodine		
5% eye drops	  	RESTRICTED Consultant Ophthalmologist only
Heavy Silicone oil		
Densiron® 68 - 10mL syringe	 	RESTRICTED intraocular tamponade of inferior retinal breaks
Subfoveal choroidal neovascularisation		
Aflibercept  		
Eylea® 40mg in 1mL injection	    	RESTRICTED Consultant Ophthalmologist only
Bevacizumab   		
Avastin® 100mg in 4mL vial	    	RESTRICTED Consultant Ophthalmologist only
Brolucizumab  		
Beovu® 120mg in 1mL injection	    	RESTRICTED Consultant Ophthalmologist only
MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals		
Faricimab  		
Vabysmo® 120mg/mL injection	    	RESTRICTED Consultant Ophthalmologist in line with NICE
Ranibizumab  		
Lucentis® / Ongavia® 10mg/mL injection	    	RESTRICTED Consultant Ophthalmologist only 
Verteporfin  		
Visudyne® 15mg vial	   	RESTRICTED Consultant Ophthalmologist only
Vitreomacular traction		
Ocriplasmin  		
Jetrea® 0.5 mg/0.2mL injection	    	RESTRICTED Consultant Ophthalmologist only
11.8.3 Other preparations		
Voretigene		
Voretigene neparvec  		
Luxturna® 2mL vial	    	RESTRICTED Consultant Ophthalmologist in line with NICE
Insulin eye drops		
Insulin (soluble) eye drops  		
Humulin S® in Systane® lubricant eye drops		RESTRICTED Consultant Ophthalmologist

Section 12: Ear, nose & oropharynx

Supported by the
formulary ([click here](#))



12.1 Drugs acting on the ear

- 12.1.1 Otitis externa
- 12.1.3 Removal of ear wax

12.2 Drugs acting on the nose

- 12.2.1 Drugs used in nasal allergy
- 12.2.2 Topical nasal decongestants
- 12.2.3 Nasal preparations for infection

12.3 Drugs acting on the oropharynx

- 12.3.1 Drugs for oral ulceration & inflammation
- 12.3.2 Oropharyngeal anti-infective drugs
- 12.3.4 Mouthwashes, gargles & dentifrices
- 12.3.5 Treatment of dry mouth

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)
Sore throat (acute): antimicrobial prescribing (NG84)
Otitis media (acute): antimicrobial prescribing (NG91)
Tinnitus: assessment and management (NG155)
Otitis media with effusion in under 12s (NG233)
Allergic rhinitis (CKS)

GMMM Formulary

Formulary Homepage
Chapter 12: Ear, nose & oropharynx (Complete)
GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List
GMMM Paediatric [Red/Amber/Green](#) Drug List

12.1 Drugs acting on the ear



12.1.1 Otitis externa

Astringent preparations

Aluminium Acetate

ear drops



Anti-inflammatory preparations

Betamethasone Sodium Phosphate

Betnesol® 0.1% ear drops



Prednisolone Sodium Phosphate

Predsol® 0.5% ear drops



Anti-inflammatory with antibacterial preparations

Dexamethasone / Neomycin Sulphate

Otomize® 0.1% / 3250u per mL ear spray



Dexamethasone / Framycetin Sulphate / Gramicidin

Sofradex® 0.05% / 0.5% / 0.005% ear/eye drops



Flumetasone Pivalate / Clioquinol

Locorten-Vioform® 0.02% / 1% ear drops



Hydrocortisone / Gentamicin

1% / 0.3% ear drops



Hydrocortisone / Neomycin Sulfate / Polymyxin B Sulphate

Otosporin® 1% : 3400u/mL : 10,000u/mL ear drops



Analgesic / Anti-inflammatory / local anaesthetic preparations

Phenazone with Lidocaine

Otigo® 40mg/g / 10mg/g ear drops



RESTRICTED
paeds in line with NICE NG91

Anti-infective preparations

Ciprofloxacin

Green

Cetralax® 0.2% ear drops



MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects

Clotrimazole

1% ear drops



12.1.3 Removal of ear wax

Chlorobutanol / Arachis oil

Cerumol® ear drops



Olive oil ear drops

DNP

ear drops























Sodium Bicarbonate

DNP

5% ear drops



12.2 Drugs acting on the nose		GMMMG
12.2.1 Drugs used in nasal allergy		
Antihistamines		
Azelastine Hydrochloride		
140micrograms nasal spray	NICE BNF emc	
Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
Beclometasone Dipropionate		1 st line use
50micrograms nasal spray	BNF emc	
Betamethasone Sodium Phosphate		
0.1% nose drops	BNF emc	
Mometasone Furoate		1 st line use nasal polyps
50micrograms nasal spray	MMC BNF emc	
Fluticasone Furoate		
Avamys® 27.5micrograms nasal spray	MMC BNF emc	
Fluticasone Propionate / Azelastine Hydrochloride		RESTRICTED 3 rd line use
Green Dymista® 50micrograms / 137micrograms nasal spray	NICE MMC BNF emc	
Cromoglicate		
Sodium Cromoglicate		
4% nasal spray	BNF emc	
12.2.2 Topical nasal decongestants		
Sympathomimetics		
Ephedrine Hydrochloride		1 st line use
0.5%; 1% nasal drops	BNF emc	
Sodium Chloride		
0.9% nasal drops	BNF emc	
Xylometazoline Hydrochloride		
0.1% nasal drops	BNF emc	
Antimuscarinics		
Ipratropium Bromide		Rhinorrhoea associated with allergic & non-allergic rhinitis
0.03% nasal spray	BNF emc	
12.2.3 Nasal preparations for infection		
Chlorhexidine Dihydrochloride / Neomycin		1 st line use staphylococcal infections
Naseptin® 0.1% / 0.5% nasal cream	MMC BNF emc	
Mupirocin		RESTRICTED MRSA / post nasal cautery
2% nasal ointment	MMC BNF emc	

12.3 Drugs acting on the oropharynx		GMMMG
12.3.1 Drugs for oral ulceration & inflammation		
Local Analgesics		
Benzylamine Hydrochloride Green	 BNF  emc	
0.15% oral rinse; 0.15% spray		
Carmellose Sodium	 BNF  emc	
30g protective paste		
Corticosteroids		
Hydrocortisone	 BNF  emc	
muco-adhesive buccal tablets		
12.3.2 Oropharyngeal anti-infective drugs		
Oropharyngeal fungal infections		
Miconazole DNP	 BNF  emc	
2% oral gel		
MHRA Drug Safety Update (Sep-17): Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin		
Nystatin DNP	 BNF  emc	
100,000 units/mL oral suspension		
12.3.4 Mouthwashes, gargles & dentifrices		
Chlorhexidine Gluconate	 BNF  emc	
0.2% mouthwash; 1% dental gel		
12.3.5 Treatment of dry mouth		
Local treatment		
AS Saliva Orthana®	 BNF  emc	
spray; lozenges		
BioXtra®	 BNF  emc	
oral gel		
Systemic treatment		
Pilocarpine	 BNF  emc	RESTRICTED Consultant use only following irradiation for head & neck cancer
5mg tablets		
Treatment of Dental Caries		
Silver Diamine Fluoride (SDF) 38%	 BNF  emc	
liquid	MMC	

Section 13: Skin

Supported by the
formulary (click here)



13.2 Emollient & barrier preparations

13.2.1 Emollients

13.2.2 Barrier preparations

13.3 Topical local anaesthetics & antipruritics

13.4 Topical corticosteroids

13.5 Preparations for eczema & psoriasis

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response

Cytokine Modulators

13.6 Acne & Rosacea

13.6.1 Topical preparations for acne

13.6.2 Oral preparations for acne

13.7 Preparations for warts & calluses

13.8 Sunscreens & camouflagers

13.8.1 Sunscreen preparations

13.9 Shampoos & other preparations for scalp/hair conditions

13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.2 Antifungal preparations

13.10.3 Antiviral preparations

13.10.4 Parasitocidal preparations

13.10.5 Preparations for minor cuts & abrasions

13.11 Skin cleansers, antiseptics & desloughing agents

13.11.1 Alcohols & saline

13.11.2 Chlorhexidine salts

13.11.4 Iodine

13.11.6 Oxidisers & dyes

13.11.7 Desloughing agents

13.12 Antiperspirants

13.13 Topical circulatory preparations

13.14 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

NICE Guidance

Biosimilar Medicines (KTT15)
 Atopic eczema in children (CG57)
 Psoriasis: assessment and management (CG153)
 Pressure Ulcers (CG179)
 Pubic lice CKS (2011)
 Scabies CKS (2011)
 Acne vulgaris CKS (2014)
 Head lice CKS (2015)
 Surgical site infections: prevention and treatment (NG125)
 Atopic dermatitis (eczema) - topical steroids (TA81)
 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)
 Psoriasis - efalizumab and etanercept (TA103) EMA (efalizumab)
 Psoriasis - infliximab (TA134)
 Psoriasis - adalimumab (TA146)
 Alitretinoin for the treatment of severe chronic hand eczema (TA177)
 Psoriasis - ustekinumab (TA180)
 Melanoma (stage III or IV) - ipilimumab (TA268)
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)
 Secukinumab for treating moderate to severe plaque psoriasis (TA350)
 Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
 Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)
 Apremilast for treating active psoriatic arthritis (TA433)
 Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
 Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
 Brodalumab for treating moderate to severe plaque psoriasis (TA511)
 Guselkumab for treating moderate to severe plaque psoriasis (TA521)
 Dupilumab for treating moderate to severe atopic dermatitis (TA534)
 Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
 Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
 Risankizumab for treating moderate to severe plaque psoriasis (TA596)
 Baricitinib for treating moderate to severe atopic dermatitis (TA681)
 Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)
 Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
 Bimekizumab for treating active psoriatic arthritis (TA916)
 Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

GMMMG Formulary

Formulary Homepage
 Chapter 13: Skin (Complete)
 GMMMG Adult Red/Amber/Green; DNP and Grey Drug List
 GMMMG Paediatric Red/Amber/Green Drug List

13.2 Emollient & barrier preparations		GMMMG
13.2.1 Emollients		
Non-Proprietary emollient preparations		
MHRA Drug Safety Update (Aug-20): Emollients and risk of severe and fatal burns: new resources available MHRA Drug Safety Update (Jul-20): Safe use of emollient skin creams to treat dry skin conditions MHRA Drug Safety Update (Dec-18): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients MHRA Patient Info Leaflet (Jul-20): Skin creams - risk of fire and burns		
Aqueous cream BP		
cream	 	
Emulsifying ointment BP		
ointment	 	
Liquid & white soft paraffin		
ointment	 	
Paraffin, white soft BP		
white petroleum jelly	 	
Paraffin, yellow soft BP		
yellow petroleum jelly	 	
Proprietary emollient preparations		
Diprobase®		
cream; ointment	 	
Doublebase®		
gel	 	
Hydromol®		
cream; ointment	  	
Oilatum®		
	 	
Preparations containing urea		
Balneum® Plus		
	 	
With antimicrobials		
Dermol® & Dermol® 500		
	  	RESTRICTED patients unable to tolerate 1 st / 2 nd line antimicrobial washes
13.2.1.1 Emollient bath and shower preparations DNP		
Emollient bath and shower preparations without antimicrobials		
When used for the management of eczema in children or adults. This recommendation does not apply to the use of standard emollients when used in the bath or shower as a soap substitute		DNP
With antimicrobials		
Dermol® 600		
Grey Green		
bath emollient	 	
Oilatum® Plus		
bath emollient	 	2nd line MRSA decolonisation therapy
13.2.2 Barrier preparations		
Proprietary barrier preparations		
Metanium®		
ointment	 	2nd line only at parental request
Sudocrem®		
cream	 	2nd line only at parental request

13.3 Topical local anaesthetics & antipruritics

GMMMG








































13.3 Topical local anaesthetics & antipruritics**Crotamiton**












































































cream; lotion





























**Mepyramine Maleate**




















2% w/w cream



















13.4 Topical corticosteroids		GMMMG
Corticosteroid only preparations		NICE TA81
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
HYDROCORTISONE		Potency
Canesten HC®		Mild
hydrocortisone 1% plus clotrimazole 1% cream	 	
Daktacort®		Mild
hydrocortisone 1%, miconazole nitrate 2% cream; ointment	 	
Eurax-Hydrocortisone®		Mild
hydrocortisone 0.25%, crotamiton 10% cream	 	
Fucidin H®		Mild
hydrocortisone 1%, fusidic acid 1% cream	 	
BETAMETHASONE ESTERS		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Betamethasone valerate		Moderate
0.025% ointment, cream	 	
Betnovate-RD®		Moderate
Betamethasone valerate 0.025% cream; ointment	 	
CLOBETASONE BUTYRATE		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Eumovate®		Moderate
0.05% cream; ointment	 	
BETAMETHASONE ESTERS		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Betamethasone valerate		Potent
0.1% ointment; cream; lotion; scalp lotion	 	
Betnovate®		Potent
0.1% cream; ointment; scalp application; lotion	 	
Betamethasone valerate / Clioquinol		Potent
0.1% / 3% ointment; cream	 	
Betamethasone valerate / Neomycin sulfate		Potent
0.1% / 0.5% cream; ointment	 	
Diprosalic®		Potent
Betamethasone dipropionate 0.05%, salicylic acid 3% ointment	 	
Fucibet®		Potent
Betamethasone valerate 0.1% plus fusidic acid 2% cream	 	
Betnovate®		Potent
ointment 25% in coal tar	 	DERMATOLOGY ONLY
CLOBETASOL PROPIONATE		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Dermovate®		Very potent
clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	 	
Dermovate NN®		Very potent
clobetasol propionate 0.05% / neomycin / nystatin cream	 	
Etrivex®		Very potent
clobetasol propionate 500micrograms/g shampoo	  	RESTRICTED - 1 st Care referral
DIFLUCORTOLONE VALERATE		Potency
Diflucortolone valerate 		Very potent
0.3% oily cream	  	RESTRICTED Consultant Gynaecologist












13.5 Preparations for eczema & psoriasis		GMMMG
13.5.1 Preparations for eczema		
Alitretinoin   10mg; 30mg capsules     		RESTRICTED Dermatology Consultants only
MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women		
13.5.2 Preparations for psoriasis		
Topical preparations for psoriasis		NICE CG153
Calcipotriol Dovonex® ointment; with Betamethasone (<i>Dovobet</i> ® 0.05% ointment)  		RESTRICTED Dermatology Consultants only
Dithranol   (unlicensed preps) Dithocream® 0.1% & 0.25% cream  		RESTRICTED Dermatology Consultants only
Salicylic acid Zinc & Salicylic acid paste BP (<i>Lassar's Paste</i>)  		RESTRICTED Dermatology Consultants only
Tacalcitol Curatoderm® lotion; ointment  		RESTRICTED Dermatology Consultants only
Tars		
Coal tar paste BP paste  		RESTRICTED Dermatology Consultants only
Coccolis® scalp ointment  		RESTRICTED Dermatology Consultants only
Oral retinoids for psoriasis		
Acitretin  10mg; 25mg capsules  		RESTRICTED Dermatology Consultants only
Dimethyl Fumarate Dimethyl Fumarate   30mg; 120mg tablets      		RESTRICTED 3 rd /4 th line as per NICE/GMMMG Referral to SRFT
13.5.3 Drugs affecting the immune response		
Abrocitinib   Cibingo® 50mg; 100mg; 200mg tablets      		RESTRICTED Dermatology Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality		
Azathioprine  25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3)  		RESTRICTED Dermatology Consultants only
Ciclosporin  25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2)    		RESTRICTED Dermatology Consultants only
Methotrexate  2.5mg tablets (see also sections 8.1.3 & 10.1.3)   		RESTRICTED Dermatology Consultants only
Pimecrolimus  1% cream    		RESTRICTED Dermatology Consultants only
Sirolimus  Hyfor® 0.2% gel   		RESTRICTED Dermatology Consultants only
Tacrolimus (specially made by SRFT)  0.03%; 0.1% ointment     		RESTRICTED Dermatology Consultants only
Upadacitinib   Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3)      		RESTRICTED Dermatology Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality		

Cytokine Modulators		(see also section 10.1.3)
Adalimumab   injection (see also sections 1.5.3, 10.1.3 & 11.4.2)	     	RESTRICTED Dermatology Consultants only
Apremilast   10mg; 20mg; 30mg tablets	    	RESTRICTED 3 rd /4 th line as per NICE/GMMMG Referral to SRFT
Bimekizumab   <i>Bimzelx</i> ® injection (see also section 10.1.3)	     	RESTRICTED in line with NICE
Brodalumab   <i>Kyntheum</i> ® 140mg/mL injection	    	RESTRICTED Dermatology only in line with NICE
Certolizumab   <i>Cimzia</i> ® 200mg injection (see also section 10.1.3)	    	RESTRICTED Dermatology only in line with NICE
Dupilumab   <i>Dupixent</i> ® 150mg/mL injection (see also section 3.4.2)	     	RESTRICTED Dermatology only in line with NICE
Etanercept   injection (see also section 10.1.3)	     	RESTRICTED Dermatology Consultants only
Guselkumab   100mg/mL injection	    	RESTRICTED in line with NICE
Infliximab   100mg injection (see section 10.1.3)	     	RESTRICTED Dermatology only in line with NICE
Ixekizumab   80mg/1mL injection (see also section 10.1.3)	    	RESTRICTED Dermatology only in line with NICE
Risankizumab   75mg; 150mg injection	     	RESTRICTED Specialist use only in line with NICE
Secukinumab   150mg/1mL injection	     	RESTRICTED Dermatology only in line with NICE
Tildrakizumab   100mg injection	    	RESTRICTED Dermatology only in line with NICE NOT STOCKED
Ustekinumab   injection (see section 10.1.3)	     	RESTRICTED Dermatology NICE TA180 & 455 / Gastro 3 rd line Crohn's

13.6 Acne & Rosacea		GMMMG
13.6.1 Topical preparations for acne		NICE CKS: Acne
For mild to moderate acne, use topical benzyl peroxide or a topical retinoid 1st line. Topical antibiotic should be reserved for patients who have not responded to other topical preparations.		
Benzyl peroxide & azelaic acid		
Benzoyl Peroxide DNP	 	1 st line
4% cream; 5% gel		
Azelaic acid	 	2 nd line
Skinoren® 20% cream		
Topical antibacterials for acne		
Clindamycin	 	2 nd / 3 rd line
Dalacin T® 1% topical lotion		
Erythromycin	 	2 nd / 3 rd line
Zineryt® 40mg/mL erythromycin; zinc acetate 12mg/mL lotion		
Topical retinoids & related preparations for acne		
Adapalene	 	1 st line
Differin® 0.1% cream; 0.1% gel		
Topical retinoids with antibacterial		
Isotretinoin with Erythromycin	 	RESTRICTED Dermatology Consultants only
Isotrexin® 500micrograms/1g : 20mg/1g gel		
13.6.2 Oral preparations for acne		NICE CKS: Acne
Oral antibiotics should be reserved for moderate to severe acne or where topical preparations have failed. Please refer to Chapter 5.		
Lymecycline	  	RESTRICTED GP referral only
408mg capsules (see also section 5.1.3)		
Hormone treatment for acne		
Co-cyprindiol	 	RESTRICTED GP referral only
Cyproterone acetate 2mg / ethinylestradiol 35micrograms tablets		
Oral retinoid for acne		
Isotretinoin Red	 	RESTRICTED Dermatology Consultants only
5mg; 10mg; 20mg; 40mg capsules		
<p>MHRA Drug Safety Update (Oct-23): Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight on initiation of treatment in under 18s</p> <p>MHRA Drug Safety Update (Apr-23): Isotretinoin (Roaccutane ▼): new safety measures, including additional oversight on initiation of treatment in under 18s</p> <p>MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼, and acitretin ▼): temporary monitoring advice during COVID-19 pandemic</p> <p>MHRA Drug Safety Update (Nov-20): Isotretinoin (Roaccutane ▼): contribute to expert review</p> <p>MHRA Drug Safety Update (Aug-20): Isotretinoin (Roaccutane ▼): reminder of important risks and precautions</p> <p>MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women</p> <p>MHRA Drug Safety Update (Oct-17): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido</p> <p>MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders</p>		

13.7 Preparations for warts & calluses		GMMMG
13.7 Preparations for warts & calluses		
Salicylic acid DNP ointment; liquid	 	
Silver Nitrate pencil	 	RESTRICTED Dermatology Consultants only
Silver Nitrate 75% applicator	  	RESTRICTED ENT - nasal cauterly
Anogenital warts		
Podophyllotoxin 0.15% cream	 	1st line
Imiquimod Green 5% cream	  	RESTRICTED GUM Consultant only

13.8 Sunscreens & camouflagers		GMMMG
13.8.1 Sunscreen preparations		
Photodamage		
Methyl-5-Aminolevulinate		RESTRICTED Dermatology Consultants & Vulval Intraepithelial Neoplasia (VIN) only
 160mg/g cream 		
Diclofenac Sodium		RESTRICTED Dermatology Consultants
Solaraze® 3% gel 		
Fluorouracil / Salicylic acid		RESTRICTED Dermatology Consultants as per MMC
Actikerall® 0.5% / 10% cutaneous solution 		

13.9 Shampoos & other preparations for scalp / hair conditions		GMMMG
Shampoos		
Ketoconazole		RESTRICTED persistent / severe seborrhoeic dermatitis / dandruff
<i>Nizoral</i> ® 2% shampoo	 	
Capasal ®		RESTRICTED Dermatology Consultants only
coal tar 1%, coconut oil 1% &, salicylic acid 0.5% shampoo	 	
Ceanel Concentrate ®		RESTRICTED Dermatology Consultants only
cetrimide 10%, undecenoic acid 1% & phenylethyl alcohol 7.5% shampoo	 	
Other scalp preparations		
Polytar ®		
40mg/mL coal tar scalp shampoo	 	
Hirsutism		
Eflornithine		RESTRICTED Dermatology Consultants only
<i>Vaniqa</i> ® 11.5% cream	  	

13.10 Anti-infective skin preparations



13.10.1 Antibacterial preparations

Topical antibacterials should generally be avoided for the treatment of infections

13.10.1.1 Antibacterial preparations only used topically

Mupirocin

2% cream; ointment

MMC

Fusidic acid

2% cream; ointment

RESTRICTED
superficial impetigo

Metronidazole

0.75% topical gel; cream

RESTRICTED
topical treatment of rosacea

Silver Sulfadiazine

1% w/w cream

RESTRICTED
Treatment/prophylaxis of burns

13.10.2 Antifungal preparations

Amorolfine

5% nail lacquer

MMC

1st line
antifungal for nail infections

Benzoic acid ointment, compound, BP

benzoic acid 6% / salicylic acid 3% / in emulsifying ointment

1st line
treatment of ringworm

Clotrimazole

1% cream

1st line
fungal skin infections

Miconazole

2% cream

2nd line
fungal skin infections

Terbinafine

1% cream

2nd line
fungal skin infections

13.10.3 Antiviral preparations

Aciclovir

5% cream

1st line

13.10.4 Parasitocidal preparations

NICE CKS: Head lice

NICE CKS: Pubic lice

NICE CKS: Scabies

Ivermectin

tablets

MMC

Malathion

0.5% aqueous solution

Permethrin

1% crème rinse; 5% dermal cream

MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition...

13.10.5 Preparations for minor cuts & abrasions

Proflavine cream, BPC

0.1% cream

Brulidine

0.15% w/w cream

RESTRICTED
Theatres only

Preparations for boils

Magnesium Sulfate

















paste, BP











Skin tissue adhesive

Histoacryl®

0.5mL skin adhesive

RESTRICTED
Theatres only

13.11 Skin cleansers, antiseptics & desloughing agents		GMMMG
13.11.1 Alcohols & saline		
Isopropyl Alcohol 70%	 	
Sodium Chloride	 	
0.9% irrigation solution		
13.11.2 Chlorhexidine salts		
Chlorhexidine Gluconate	 	
13.11.4 Iodine		
Alcoholic Iodine solution BP	 	
Iodine weak solution	 	
Povidone-Iodine	 	
13.11.6 Oxidisers & dyes		
Hydrogen Peroxide solution, BP	 	RESTRICTED Specialist use only
3% solution; 6% solution		
Potassium Permanganate	 	RESTRICTED Specialist use only
400mg tablets for cutaneous solution		
National Patient Safety Alert (Apr-22): Inadvertent oral administration of potassium permanganate		
13.11.7 Desloughing agents		
CONTACT THE TISSUE VIABILITY TEAM on x64042		

13.12 Antiperspirants		
Aluminium salts		
Aluminium Chloride Hexahydrate		
20% solution	 	
Glycopyrronium Bromide		
Glycopyrronium Bromide		
Robinul®	  	
Glycopyrrolate		
	  	RESTRICTED Diabetes Consultants only (gustatory sweating)
0.5% cream		

13.13 Topical circulatory preparations








Topical circulatory preparations

Hirudoid®

0.3% cream; 0.3% gel



13.14 Miscellaneous preparations		GMMMG
8-Methoxypsoralen  10mg tablets MMC emc		RESTRICTED Dermatology Consultants only
Fumaric Acid Esters  Fumaderm® tablets MMC emc		RESTRICTED Dermatology Consultants only
Glucarpidase   Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4) PBR X MMC BNF emc		RESTRICTED 2 nd line rescue therapy NHS England
Hyaluronic acid / Lidocaine  Juvederm® / Belotero® injection MMC emc		RESTRICTED vocal cord paralysis
Non-Formulary Items		
Ingenol Mebutate Picato® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities) MMC BNF emc		WITHDRAWN
MHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy MHRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato▼): increased incidence of skin tumours seen in some clinical studies		

Section 14: Immunological products & vaccines

Supported by the
formulary ([click here](#))



14.4 Vaccines & antisera

- Bacillus Calmette-Guérin (BCG) vaccines
- Botulism antitoxin
- COVID-19 vaccine
- Diphtheria vaccines (children under 10yrs old)
- Diphtheria vaccines (children over 10yrs old & adults)
- Haemophilus type B conjugate vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papilloma virus vaccine
- Influenza vaccine
- Measles, Mumps & Rubella (MMR) vaccine
- Meningococcal vaccines
- Pneumococcal vaccines
- Poliomyelitis vaccines
- Rabies vaccines
- Tetanus vaccines
- Typhoid vaccines
- Varicella-zoster vaccines

14.5 Immunoglobulins

- 14.5.1 Normal immunoglobulin
- 14.5.2 Disease-specific immunoglobulins
- 14.5.3 Anti-D (Rh₀) immunoglobulin

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin
Immunoglobulin follow up form
Immunoglobulin Prescribing and Administration Guidelines
Immunoglobulin Prescribing Flow Chart
Immunoglobulin request form
National Demand Programme for Immunoglobulin - Clinical Info
[Non-formulary Conversion Table](#)

NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

GMMM Formulary

Formulary Homepage
Chapter 14: Immunological products & vaccines **(ON HOLD)**
GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List
GMMM Paediatric **Red/Amber/Green** Drug List

Other Links

National Immunoglobulin Database
DH: Clinical guidelines for immunoglobulin use (2nd edition update)
Immunoglobulin handbook (HPA)

14.4 Vaccines & antisera

MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed

Bacillus Calmette-Guérin (BCG) vaccines

Bacillus Calmette-Guérin (BCG) vaccine

injection



BCG vaccine diagnostic agent (Tuberculin purified protein derivative (PPD))

injection



Botulism antitoxin

Botulism antitoxin

injection



RESTRICTED
Emergencies only

COVID-19 vaccine

UK HSA: The Green book Ch14a

Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)

12 years of age and older

Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)



pending availability of XBB1.5

Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)

12 years of age and older

Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)



Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)

5 to 11 year olds

Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)



AstraZeneca COVID-19 vaccine

DISCONTINUED

Vaxzevria® injection



Moderna Biotech COVID-19 vaccine

DISCONTINUED

Spikevax® injection



Novavax COVID-19 vaccine

PAUSED by JCVI

Nuvaxovid® injection



MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023

MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023

MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023

MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022

MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022

MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022

MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022

MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022

MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022

MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022

MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022

MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022

MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022

MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022

MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022

MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021

MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021

MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021

MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021

MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021

MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021

MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021

MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021

MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021

MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice

MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19

Diphtheria vaccines (children under 10yrs old)

PediaceI®

injection



Infanrix-IPV+Hib®

injection



Infanrix-IPV®
















injection



Repevax®

injection



Diphtheria vaccines (children over 10yrs old & adults)		
Revaxis®		
injection	 	
Haemophilus type B conjugate vaccine		
Haemophilus Influenzae B vaccine		
Hiberix® injection	 	
Haemophilus Influenzae B & Meningitis C vaccine		
Menitorix® injection	 	
Hepatitis A vaccine		
Hepatitis A vaccine single component		
Havrix Monodose®; Havrix Junior Monodose®; Vaqta® Paediatric injection	 	
Hepatitis B vaccine		
Hepatitis B single component		
Engerix B®; Engerix B® Paediatric injection	 	
Hepatitis B single component		
HBvaxPRO®; HBvaxPRO® Paediatric injection	 	
Human papilloma virus (HPV) vaccine		
Human Papilloma Virus (HPV) quadrivalent vaccine		RESTRICTED
Gardasil® injection	  	Paediatric Immunology Consultant

Influenza vaccine		
Influenza vaccine		
injection, intranasal	 	
Measles, Mumps & Rubella (MMR) vaccine		
Measles, Mumps & Rubella vaccine		
injection	 	
Meningococcal vaccines		
Meningococcal Polysaccharide A, C, W135 & Y vaccine		
injection	 	
Meningococcal group B vaccine		RESTRICTED childhood immunisation schedule & high risk patients
Bexsero® injection	  	
Meningococcal group C vaccine		
injection	 	
Pneumococcal vaccines		
Pneumococcal Polysaccharide vaccine		
injection	 	
Poliomyelitis vaccines		
Poliomyelitis vaccine inactivated		
	 	
Rabies vaccines		
Rabies vaccine inactivated		RESTRICTED Not Stocked
Rabipur® injection	 	
Tetanus vaccines		
Tetanus vaccine adsorbed		
injection	 	
Typhoid vaccines		
Typhoid polysaccharide vaccine		
Typhim Vi® injection	 	
Varicella-zoster vaccines		
Varicella-Zoster live attenuated vaccine		
Varivax® injection	 	

14.5 Immunoglobulins		IVIG Request Form
14.5.1 Normal immunoglobulin Red (for ITP & home treatment programmes)		
<i>For intramuscular use</i>		
Normal immunoglobulin injection Red ££		RESTRICTED Specialist use only IVIG Request Form
injection	PbR X BNF emc	
<i>For subcutaneous use</i>		
Normal immunoglobulin injection Red ££		RESTRICTED Specialist use only IVIG Request Form
injection	PbR X MMC BNF emc	
<i>For intravenous use</i>		
Human normal immunoglobulin Red ££		RESTRICTED Specialist use only IVIG Request Form
injection	PbR X MMC BNF emc	
14.5.2 Disease-specific immunoglobulins		
<i>Hepatitis B immunoglobulin</i>		
Hepatitis B immunoglobulin		RESTRICTED Not Stocked
injection	BNF emc	
<i>Tetanus immunoglobulin</i>		
Tetanus immunoglobulin		
injection	BNF emc	
<i>Varicella-Zoster immunoglobulin</i>		
Varicella-Zoster immunoglobulin Green		RESTRICTED Not Stocked
injection	BNF emc	
<i>Cytomegalovirus (CMV) immunoglobulin</i>		
Human normal immunoglobulin (CMV)		RESTRICTED Specialist use only
injection	MMC BNF emc	
14.5.3 Anti-D (Rh₀) immunoglobulin		
Anti-D (Rh₀) immunoglobulin Red		
injection	NICE MMC BNF emc	

Section 15: Anaesthesia

Supported by the
formulary ([click here](#))



15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
 - 15.1.4.1 Benzodiazepines
 - 15.1.4.2 Non-opioid analgesics
 - 15.1.4.3 Opioid analgesics
 - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs
 - Non-depolarising neuromuscular blocking drugs
 - Depolarising neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
 - Anticholinesterases
 - Other drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

15.2 Local anaesthesia

- Local Anaesthetic Toxicity
- Other agents

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
Paediatric Anaesthesia Website
Children's Pain Management Website
PICU Emergency Drugs Calculator
[Non-formulary Conversion Table](#)

NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

GMMMG Formulary

Formulary Homepage
Chapter 15: Anaesthesia (**ON HOLD**)
GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List
GMMMG Paediatric **Red/Amber/Green** Drug List

15.1 General anaesthesia

15.1.1 Intravenous anaesthetics

Etomidate

injection



Ketamine

Red

injection



Propofol

injection; infusion



Thiopental Sodium

injection



15.1.2 Inhalational anaesthetics

Volatile liquid anaesthetics

Desflurane

anaesthetic agent



RESTRICTED
Theatres only

Isoflurane

anaesthetic agent



Methoxyflurane

Penthrox® inhalation vapour



RESTRICTED
ED only

Sevoflurane

anaesthetic agent



Nitrous oxide

Nitrous Oxide



Nitrous Oxide 50% & Oxygen 50%

Entonox®



15.1.3 Antimuscarinic drugs

Atropine Sulfate

600microgram/1mL injection



Adults 600microgram/1mL
I.M. or I.V.

Glycopyrronium Bromide

200micrograms/1mL; 600micrograms/3mL injection



Adults 200-400microgram I.V.

Hyoscine Hydrobromide

400microgram/mL injection



15.1.4 Sedative & analgesic post-operative drugs

15.1.4.1 Benzodiazepines

Diazepam

tablets; liquid; injection; rectal tube (see also sections 4.1.2 & 4.8.2)



NICE CG112

Lorazepam

tablets; injection (see also sections 4.1.2 & 4.8.2)



Midazolam

Green

oromucosal solution; injection; infusion (see also section 4.8.2)



Temazepam

tablets; oral solution (see also section 4.1.1)



15.1.4.2 Non-opioid analgesics

Ketorolac Trometamol

injection






















































Parecoxib

injection




























RESTRICTED
Theatres only - acute postop. pain

15.1.4.3 Opioid analgesics		
Alfentanil		
 injection	 	
Fentanyl		
 injection (see also section 4.7.2)	 	
Remifentanyl		RESTRICTED Specialist use only
 injection	  	
15.1.4.4 Other drugs for sedation		
Dexmedetomidine		RESTRICTED Specialist use only
infusion	  	
15.1.5 Neuromuscular blocking drugs		
Non-depolarising neuromuscular blocking drugs		
Atracurium Besilate		
injection	 	
Cisatracurium		RESTRICTED Consultant only
injection	  	
Mivacurium		
injection	 	
Rocuronium Bromide		
injection	 	
Vecuronium Bromide		
injection	 	
Depolarising neuromuscular blocking drugs		
Suxamethonium Chloride		
injection	 	
15.1.6 Drugs for reversal of neuromuscular blockade		
Anticholinesterases		
Neostigmine Metilsulfate		
injection	 	
Neostigmine Metilsulfate with Glycopyrronium Bromide		
injection	 	
Other drugs for reversal of neuromuscular blockade		
Sugammadex		RESTRICTED - Consultant (Emergency) use in Theatres only Complete Trust incident & audit forms
<i>Bridion</i> ® injection	  	
15.1.7 Antagonists for central & respiratory depression		
Doxapram Hydrochloride		
injection (see also section 3.5.1)	 	
Flumazenil		
injection	 	
Naloxone Hydrochloride		
injection	 	
15.1.8 Drugs for malignant hyperthermia		
Dantrolene Sodium		
injection	 	
MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals		

15.2 Local anaesthesia	AAGBI SAFETY GUIDELINE
15.2 Local anaesthesia	
Lidocaine Hydrochloride	
Lidocaine	
0.5%, 1% & 2% injection	 
with adrenaline	
Lidocaine with Adrenaline	
1%, 2% injection	 
for surface anaesthesia	
Lidocaine with Chlorhexidine	
<i>Instillagel</i> ® 2% gel	 
Lidocaine with Phenylephrine	
<i>Co-phenylcaine</i> ® 5% / 0.5% spray	  
Lidocaine with Prilocaine	
<i>EMLA</i> ® 5% cream	 
Lidocaine	
4% topical solution	 
Lidocaine	
<i>Laryngojet</i> ® 4% (160mg/4mL) jet spray	 
Lidocaine	
5% ointment	 
Lidocaine	
<i>Xylocaine</i> ® 10% spray	 
Lidocaine	
Green DNP	
<i>Versatis</i> ® 700mg medicated plaster	  
Bupivacaine Hydrochloride	
Bupivacaine Hydrochloride	
0.25% Infusion (500mL)	 
Bupivacaine Hydrochloride with Glucose	
<i>Marcain Heavy</i> ® 0.5% Injection	 
with adrenaline	
Bupivacaine and Adrenaline	
0.25% with 1:200,000 injection	 
Bupivacaine and Adrenaline	
0.5% with 1:200,000 injection	 
with other ingredients	
Bupivacaine and Fentanyl	
 0.125% with 1mg/500mL infusion	 
Bupivacaine and Sodium Chloride	
0.08% in 0.9%	 
Bupivacaine Hydrochloride with Glucose	
20mg with 320mg/4mL spinal injection	 
Levobupivacaine	
Levobupivacaine	
<i>Chirocaine</i> ® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL	  
Levobupivacaine with Fentanyl	
 0.1% with 2microgram/mL epidural	 

RESTRICTED
Consultant / specialist pain team only

Prilocaine Hydrochloride		
Prilocaine Hydrochloride		
<i>Citanest</i> ® 1% injection	 	
Prilocaine Hydrochloride		
<i>Prilotekal</i> ® 2% injection	  	
Prilocaine with Felypressin		
<i>Octapressin</i> ® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)	 	
Ropivacaine Hydrochloride		
Ropivacaine		For Consultant use on CDU (elective CS), Theatre 1 (ortho) & wards 1 & 2 (following surgery in Th. 1)
injection; infusion	  	
Tetracaine (Amethocaine)		
Tetracaine		RESTRICTED children under 1yr by specific doctor request or /V team
4% gel	  	
Local Anaesthetic Toxicity		AAGBI SAFETY GUIDELINE
Intralipid 20%		
20% injection	 	
Other agents		
Cocaine		
 5% solution	 	
Ethyl Chloride		
<i>Cryogesic</i> ® spray	  	
Mepivacaine Hydrochloride		
3% injection	 	
Neomycin Sulfate / Fluocinolone Acetonide / Lidocaine Hydrochloride		RESTRICTED Paediatrics. Intra-urethral steroid ointment
<i>Nefluan</i> ® 10g gel	 	

Section 16: Miscellaneous

Supported by the
formulary ([click here](#))



16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids
- 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
[Non-formulary Conversion Table](#)

NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

GMMMG Formulary

Formulary Homepage
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List
GMMMG Paediatric [Red/Amber/Green](#) Drug List

16.1 Organ Perfusion fluids		
16.1.1 Cardiac perfusion fluids		
Aspartate / Glutamate Solution U 100mL	MMC	
Bretschneiders Histidine-Tryptophan-Ketoglutarate (HTK) U Custodiol Cardioplegia® solution (1000mL)	MMC	emc⊕
Cardioplegia in Ringer's Solution U 1000mL	MMC	
Cardioplegic ULTH Formula A U 500mL	MMC	
Cardioplegic ULTH Formula B U 500mL	MMC	
Sterile Concentrate for Cardioplegia Infusion 20mL	MMC	emc⊕
16.1.2 Kidney / Pancreas / Liver perfusion fluids		
Cold Storage Solution (UW Solution) Belzer UW® (1000mL)	MMC	emc⊕
Kidney Perfusion Fluid Soltran® (1000mL)	MMC	emc⊕
Lung Perfusion Solution Perfadex® (1000mL)	MMC	emc⊕
Machine Perfusion Solution Belzer MPS® UW machine perfusion solution (1000mL)	MMC	emc⊕
16.1.3 Contrast Agents		
Gadobutrol Gadovist® (1.0mmol/mL) injection	MMC	emc⊕
Gadoteric acid Dotarem® (0.5mmol/mL) injection	MMC	emc⊕
Gadoxetic acid Primovist® (0.25mmol/mL) injection	MMC	emc⊕
Perflutren Luminity® (150microlitres/mL) lipid microspheres for injection	MMC	emc⊕
Sulphur Hexafluoride SonoVue® (8microlitre/mL) injection	MMC	emc⊕